0001428336-19-000026.txt : 20191205 0001428336-19-000026.hdr.sgml : 20191205 20191205161655 ACCESSION NUMBER: 0001428336-19-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20191031 FILED AS OF DATE: 20191205 DATE AS OF CHANGE: 20191205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 191270586 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 10-Q 1 hqy-2019x10x3110q.htm 10-Q Document
false--01-31Q32020000142833620.1024.3663.640.100.1044.5344.5373.6182.3982.3912500010210000.00010.00019000000009000000006244600070832000624460007083200015686000607800002133400039854000P5YP5Y00.00010.00011000000001000000000000P4YP4Y0.37840.36530.37090.35980.02790.02430.02520.0221P6Y3MP5Y2M1DP5Y1M2DP4Y11M12D 0001428336 2019-02-01 2019-10-31 0001428336 2019-12-02 0001428336 2019-01-31 0001428336 2019-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-02-01 2019-10-31 0001428336 2018-02-01 2018-10-31 0001428336 2018-08-01 2018-10-31 0001428336 2019-08-01 2019-10-31 0001428336 us-gaap:ServiceMember 2019-02-01 2019-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-02-01 2018-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-02-01 2019-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-08-01 2018-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-08-01 2019-10-31 0001428336 us-gaap:ServiceMember 2019-08-01 2019-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-02-01 2018-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-08-01 2019-10-31 0001428336 us-gaap:ServiceMember 2018-02-01 2018-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-08-01 2018-10-31 0001428336 us-gaap:ServiceMember 2018-08-01 2018-10-31 0001428336 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2019-07-31 0001428336 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-02-01 2018-10-31 0001428336 us-gaap:CommonStockMember 2018-02-01 2018-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-08-01 2019-10-31 0001428336 us-gaap:CommonStockMember 2018-01-31 0001428336 us-gaap:RetainedEarningsMember 2018-07-31 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:RetainedEarningsMember 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0001428336 us-gaap:CommonStockMember 2018-07-31 0001428336 us-gaap:CommonStockMember 2019-08-01 2019-10-31 0001428336 us-gaap:RetainedEarningsMember 2018-02-01 2018-10-31 0001428336 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-31 0001428336 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-08-01 2018-10-31 0001428336 us-gaap:RetainedEarningsMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001428336 us-gaap:CommonStockMember 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2019-10-31 0001428336 us-gaap:CommonStockMember 2019-10-31 0001428336 us-gaap:CommonStockMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001428336 us-gaap:CommonStockMember 2018-08-01 2018-10-31 0001428336 us-gaap:CommonStockMember 2019-02-01 2019-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001428336 us-gaap:RetainedEarningsMember 2018-08-01 2018-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0001428336 2018-07-31 0001428336 us-gaap:CommonStockMember 2019-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2018-01-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-08-01 2019-10-31 0001428336 us-gaap:RetainedEarningsMember 2019-02-01 2019-10-31 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-02-01 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-02-01 2018-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2018-02-01 2018-10-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-02-01 2019-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-02-01 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-30 0001428336 hqy:WageWorksInc.Member 2019-08-29 0001428336 srt:MinimumMember 2019-02-01 2019-10-31 0001428336 hqy:LimitedPartnershipForEarlyStageCompaniesInHealthcareIndustryMember 2019-10-31 0001428336 srt:MinimumMember 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-30 0001428336 hqy:TechnologyBasedFinancialHealthcareProductsLimitedPartnershipMember 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-30 2019-08-30 0001428336 us-gaap:AccountingStandardsUpdate201602Member 2019-02-01 0001428336 srt:MaximumMember 2019-02-01 2019-10-31 0001428336 srt:MaximumMember 2019-10-31 0001428336 hqy:WageWorksInc.Member hqy:EquityAwardsAssumedAttributableToPreAcquisitionServiceMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:EquityAwardsExchangedForCashAttributableToPreAcquisitionServiceMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:CommonStockMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-01 2019-10-31 0001428336 hqy:WageWorksInc.Member 2018-02-01 2018-10-31 0001428336 hqy:WageWorksInc.Member 2018-08-01 2018-10-31 0001428336 hqy:WageWorksInc.Member 2019-02-01 2019-10-31 0001428336 hqy:WageWorksInc.Member hqy:TermLoanFacilityMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:CustomerRelationshipsMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:DevelopedTechnologyRightsMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:IdentifiedIntangibleAssetsSubjectToAmortizationMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:TrademarksAndTradeNamesMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2019-08-30 2019-08-30 0001428336 us-gaap:LeaseholdImprovementsMember 2019-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-10-31 0001428336 us-gaap:LeaseholdImprovementsMember 2019-10-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-10-31 0001428336 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-31 0001428336 us-gaap:TradeNamesMember 2019-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-10-31 0001428336 us-gaap:TradeNamesMember 2019-10-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-01-31 0001428336 us-gaap:InProcessResearchAndDevelopmentMember 2019-10-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2019-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-10-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2019-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-01-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-10-31 0001428336 2018-02-01 2019-01-31 0001428336 2018-06-22 2018-06-22 0001428336 hqy:OfficeLeaseMember 2019-01-31 0001428336 hqy:OtherAgreementsMember 2019-01-31 0001428336 2018-09-06 2018-09-06 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 hqy:DebtCovenantPeriodFourMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 hqy:DebtCovenantPeriodOneMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 hqy:DebtCovenantPeriodFourMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 hqy:DebtCovenantPeriodTwoMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 hqy:DebtCovenantPeriodThreeMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 2015-09-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2019-08-30 2019-08-30 0001428336 us-gaap:PerformanceSharesMember 2018-08-01 2018-10-31 0001428336 us-gaap:RestrictedStockMember 2018-08-01 2018-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-02-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-02-01 2019-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-08-01 2018-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2018-02-01 2018-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-02-01 2019-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2019-08-01 2019-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-08-01 2019-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2019-08-01 2019-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-02-01 2019-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-08-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-08-01 2019-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-08-01 2019-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2018-02-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-02-01 2019-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-02-01 2018-10-31 0001428336 us-gaap:RestrictedStockMember 2019-02-01 2019-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2018-08-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-02-01 2018-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2018-08-01 2018-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2019-02-01 2019-10-31 0001428336 us-gaap:RestrictedStockMember 2018-02-01 2018-10-31 0001428336 us-gaap:PerformanceSharesMember 2019-08-01 2019-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-02-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-08-01 2018-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-08-01 2019-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2019-02-01 2019-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-08-01 2018-10-31 0001428336 us-gaap:RestrictedStockMember 2019-08-01 2019-10-31 0001428336 us-gaap:PerformanceSharesMember 2019-02-01 2019-10-31 0001428336 us-gaap:PerformanceSharesMember 2018-02-01 2018-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-10-31 0001428336 hqy:WageWorksInc.Member hqy:PreAcquisitionRestrictedStockUnitsRSUsMember 2019-08-30 2019-08-30 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 hqy:IncentivePlanMember 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:PostAcquisitionEquityAwardsMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 hqy:WageWorksInc.Member us-gaap:RestrictedStockUnitsRSUMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:EquityAwardsMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:PostAcquisitionRestrictedStockUnitsRSUsMember 2019-08-30 2019-08-30 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 hqy:MergerIntegrationMember 2019-08-01 2019-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-08-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-08-01 2019-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-02-01 2018-10-31 0001428336 hqy:SalesandMarketingMember 2018-02-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-02-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-08-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-02-01 2018-10-31 0001428336 hqy:SalesandMarketingMember 2019-08-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-08-01 2018-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-08-01 2019-10-31 0001428336 us-gaap:CostOfSalesMember 2018-08-01 2018-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-02-01 2019-10-31 0001428336 us-gaap:CostOfSalesMember 2019-02-01 2019-10-31 0001428336 hqy:MergerIntegrationMember 2018-02-01 2018-10-31 0001428336 hqy:MergerIntegrationMember 2018-08-01 2018-10-31 0001428336 hqy:SalesandMarketingMember 2018-08-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-08-01 2018-10-31 0001428336 us-gaap:CostOfSalesMember 2019-08-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-02-01 2019-10-31 0001428336 hqy:SalesandMarketingMember 2019-02-01 2019-10-31 0001428336 us-gaap:CostOfSalesMember 2018-02-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-02-01 2018-10-31 0001428336 hqy:MergerIntegrationMember 2019-02-01 2019-10-31 0001428336 srt:MinimumMember 2018-02-01 2018-10-31 0001428336 srt:MaximumMember 2018-02-01 2018-10-31 hqy:lawsuit xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-36568
 
 
 
HEALTHEQUITY, INC.
 
 
 
(Exact name of registrant as specified in its charter)
Delaware
 
7389
 
52-2383166
(State or other jurisdiction of
incorporation or organization)
 
(Primary Standard Industrial
Classification Code Number)
 
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(Address of principal executive offices) (Zip code)

(801) 727-1000
(Registrant's telephone Number, including Area Code)
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
HQY
The NASDAQ Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
 
 
Emerging growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of December 2, 2019, there were 70,879,268 shares of the registrant's common stock outstanding.
 



HealthEquity, Inc. and subsidiaries
Form 10-Q quarterly report

Table of contents
 
 
Page
Part I. FINANCIAL INFORMATION
 
Item 1.
 
 
 
 
 
 
Item 2.
Item 3.
Item 4.
Part II. OTHER INFORMATION
 
Item 1.
Item 1A.
Item 6.
 
 



-2-


Part I. Financial information
Item 1. Financial statements

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in thousands, except par value)
October 31, 2019


January 31, 2019

 
(unaudited)

 
 
Assets



Current assets



Cash and cash equivalents
$
174,557


$
361,475

Accounts receivable, net of allowance for doubtful accounts as of October 31, 2019 and January 31, 2019 of $1,021 and $125, respectively
66,647


25,668

Other current assets
29,119


7,534

Total current assets
270,323


394,677

Property and equipment, net
35,199


8,223

Operating lease right-of-use assets
88,515

 

Intangible assets, net
796,228


79,666

Goodwill
1,335,187


4,651

Deferred tax asset


1,677

Other assets
34,469


21,122

Total assets
$
2,559,921


$
510,016

Liabilities and stockholders’ equity



Current liabilities



Accounts payable
$
7,966


$
3,520

Accrued compensation
37,559


16,981

Accrued liabilities
54,305


8,552

Current portion of long-term debt
31,250

 

Operating lease liabilities
10,780

 

Total current liabilities
141,860


29,053

Long-term debt, net of issuance costs
1,196,016

 

Operating lease liabilities, non-current
73,052

 

Deferred tax liability
128,642


916

Other long-term liabilities
2,590


2,968

Total liabilities
1,542,160


32,937

Commitments and contingencies (see note 7)



Stockholders’ equity



Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively



Common stock, $0.0001 par value, 900,000 shares authorized, 70,832 and 62,446 shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively
7


6

Additional paid-in capital
806,050


305,223

Accumulated earnings
211,704


171,850

Total stockholders’ equity
1,017,761


477,079

Total liabilities and stockholders’ equity
$
2,559,921


$
510,016

See accompanying notes to condensed consolidated financial statements.


-3-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and
comprehensive income (loss) (unaudited)

(in thousands, except per share data)
Three months ended October 31,
 

Nine months ended October 31,
 
2019


2018


2019


2018

Revenue:



 
 
 
 
Service revenue
$
87,620

 
$
25,041

 
$
140,710

 
$
74,797

Custodial revenue
46,972

 
31,564

 
132,538

 
90,713

Interchange revenue
22,526

 
13,890

 
57,545

 
45,956

Total revenue
157,118

 
70,495

 
330,793

 
211,466

Cost of revenue:
 
 
 
 

 
 
Service costs
52,278

 
17,562

 
92,672

 
52,808

Custodial costs
4,384

 
3,551

 
12,716

 
10,492

Interchange costs
4,421

 
3,565

 
13,177

 
11,418

Total cost of revenue
61,083

 
24,678

 
118,565

 
74,718

Gross profit
96,035

 
45,817

 
212,228

 
136,748

Operating expenses:
 
 
 
 
 
 
 
Sales and marketing
12,654

 
7,502

 
30,015

 
21,605

Technology and development
23,511

 
8,678

 
46,061

 
25,055

General and administrative
19,222

 
9,161

 
37,193

 
24,561

Amortization of acquired intangible assets
13,051

 
1,490

 
16,036

 
4,438

Merger integration
17,675

 

 
20,459

 

Total operating expenses
86,113

 
26,831

 
149,764

 
75,659

Income from operations
9,922

 
18,986

 
62,464

 
61,089

Other expense:
 
 
 
 
 
 
 
Interest expense
(10,225
)
 
(68
)
 
(10,355
)
 
(204
)
Other expense, net
(30,949
)
 
(1,487
)
 
(8,347
)
 
(1,427
)
Income (loss) before income taxes
(31,252
)
 
17,431

 
43,762

 
59,458

Income tax provision (benefit)
(9,918
)
 
1,745

 
3,908

 
(1,322
)
Net income (loss) and comprehensive income (loss)
$
(21,334
)

$
15,686


$
39,854


$
60,780

Net income (loss) per share:



 
 
 
 
Basic
$
(0.30
)
 
$
0.25

 
$
0.61

 
$
0.98

Diluted
$
(0.30
)
 
$
0.25

 
$
0.59

 
$
0.96

Weighted-average number of shares used in computing net income (loss) per share:
 
 
 
 
 
 
 
Basic
70,524

 
62,088

 
65,727

 
61,718

Diluted
70,524

 
63,923

 
67,150

 
63,628

See accompanying notes to condensed consolidated financial statements.

-4-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of stockholders’ equity (unaudited)

(in thousands)
Three months ended October 31,
 
 
Nine months ended October 31,
 
2019

 
2018

 
2019

 
2018

Total stockholders' equity, beginning balances
$
1,017,031

 
$
432,619

 
$
477,079

 
$
346,274

 
 
 
 
 
 
 
 
Common stock:
 
 
 
 
 
 
 
Beginning balance
7

 
6

 
6

 
6

Issuance of common stock upon exercise of stock options, and for restricted stock

 

 

 

Issuance of common stock

 

 
1

 

Ending balance
7

 
6

 
7

 
6

Additional paid-in capital:
 
 
 
 
 
 
 
Beginning balance
783,986

 
289,568

 
305,223

 
261,237

Issuance of common stock upon exercise of stock options, and for restricted stock
712

 
2,762

 
7,363

 
21,366

Other issuance of common stock
3,776

 

 
462,270

 

Stock-based compensation
17,576

 
5,734

 
31,194

 
15,461

Ending balance
806,050

 
298,064

 
806,050

 
298,064

Accumulated comprehensive loss:
 
 
 
 
 
 
 
Beginning balance

 

 

 
(269
)
Cumulative effect from adoption of ASU 2016-01

 

 

 
269

Ending balance

 

 

 

Accumulated earnings:
 
 
 
 
 
 
 
Beginning balance
233,038

 
143,045

 
171,850

 
85,300

Net income (loss)
(21,334
)
 
15,686

 
39,854

 
60,780

Cumulative effect from adoption of ASC 606

 

 

 
13,007

Cumulative effect from adoption of ASU 2016-01

 

 

 
(356
)
Ending balance
$
211,704

 
$
158,731

 
$
211,704

 
$
158,731

 
 
 
 
 
 
 
 
Total stockholders' equity, ending balances
$
1,017,761

 
$
456,801

 
$
1,017,761

 
$
456,801

See accompanying notes to condensed consolidated financial statements.


-5-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)


Nine months ended October 31,
 
(in thousands)
2019


2018

Cash flows from operating activities:



Net income
$
39,854


$
60,780

Adjustments to reconcile net income to net cash provided by operating activities:



Depreciation and amortization
28,791


13,498

(Gains) losses on marketable equity securities and other
(25,303
)

895

Deferred taxes
690


394

Stock-based compensation
31,194


15,461

Changes in operating assets and liabilities:





Accounts receivable
(2,817
)

(2,863
)
Other assets
(4,937
)

(4,568
)
Operating lease right-of-use assets
3,340

 

Accounts payable
524


(1,087
)
Accrued compensation
(8,012
)

(2,617
)
Accrued liabilities and other current liabilities
13,655


451

Operating lease liabilities, non-current
(2,859
)
 

Other long-term liabilities
(50
)

441

Net cash provided by operating activities
74,070


80,785

Cash flows from investing activities:



Acquisitions, net of cash acquired
(1,630,066
)
 

Purchases of intangible member assets
(9,070
)

(1,195
)
Purchases of marketable equity securities and other
(53,845
)

(574
)
Purchases of property and equipment
(5,180
)

(3,467
)
Purchases of software and capitalized software development costs
(17,232
)

(7,352
)
Net cash used in investing activities
(1,715,393
)

(12,588
)
Cash flows from financing activities:



Proceeds from long-term debt
1,250,000

 

Payment of debt issuance costs
(30,504
)
 

Settlement of client-held funds obligation
(230,928
)
 

Proceeds from follow-on equity offering, net of payment for offering costs
458,495

 

Proceeds from exercise of common stock options
7,342


21,338

Net cash provided by financing activities
1,454,405


21,338

Increase (decrease) in cash and cash equivalents
(186,918
)

89,535

Beginning cash and cash equivalents
361,475


199,472

Ending cash and cash equivalents
$
174,557


$
289,007

Supplemental cash flow data:
 
 
 
Interest expense paid in cash
$
249

 
$
162

Income taxes paid in cash, net of refunds received
9,127

 
628

Supplemental disclosures of non-cash investing and financing activities:



Equity-based acquisition consideration
$
3,776

 
$

Purchases of property and equipment included in accounts payable or accrued liabilities at period end
168


6

Purchases of software and capitalized software development costs included in accounts payable or accrued liabilities at period end
316


156

Purchases of intangible member assets accrued during the period
(151
)
 

Exercise of common stock options receivable
21


28

See accompanying notes to condensed consolidated financial statements.

-6-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)


Note 1. Summary of business and significant accounting policies
Business
HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. HealthEquity, Inc. is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Acquisition of WageWorks, Inc.
On August 30, 2019, HealthEquity, Inc. closed the acquisition of WageWorks, Inc. (“WageWorks”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), for $51.35 per share in cash, or approximately $2.0 billion to WageWorks stockholders (the “Acquisition”). 
As a result of the Acquisition, HealthEquity, Inc. gained access to more of the HSA market by expanding its direct distribution to employers and benefits advisors as a single source provider of HSAs and other CDBs, including flexible spending accounts, health reimbursement arrangements, COBRA administration, commuter and other benefits.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, HealthEquity Retirement Services, LLC, and, after the closing of the Acquisition on August 30, 2019, WageWorks, Inc. and its subsidiaries MyFlexMobile, Inc., WageWorks India, Inc. and WageWorks Services, LLP (collectively referred to as the "Company").
Prior to the closing of the Acquisition, the Company held a 4% ownership interest in WageWorks. The Company measured the investment at fair value, and all gains on the investment were recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). In connection with the closing of the Acquisition on August 30, 2019, the Company's investment in WageWorks was canceled, and WageWorks became a wholly owned subsidiary of the Company.
The Company has a 22% ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately $0.2 million as of October 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 1% ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at $0.5 million as of October 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
Acquisitions of businesses, including the Acquisition of WageWorks, are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.
Basis of presentation
The accompanying condensed consolidated financial statements as of October 31, 2019 and for the three and nine months ended October 31, 2019 and 2018 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended January 31, 2019. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.

-7-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 1. Summary of business and significant accounting policies (continued)

Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies, other than the additions of the policies described below for leases, investments in equity securities, and client-held funds, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019.
Leases. The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
The Company has entered into various operating leases consisting of office space, data storage facilities, and other leases with remaining lease terms of approximately less than 1 year to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.
Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019.
Investments in equity securities. Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and were classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). As a result of the Acquisition on August 30, 2019, the Company's marketable equity security investment in WageWorks was canceled.
Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as other assets on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).
Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in other assets on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).
The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding

-8-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 1. Summary of business and significant accounting policies (continued)

charge through other expense, net in the condensed consolidated statements of operations and comprehensive income (loss).
Client-held funds. Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”, respectively) and commuter accounts. These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's condensed consolidated balance sheets.
Prior to the closing of the Acquisition, Wageworks included all Client-held funds with its corporate cash assets on its balance sheet, with an offsetting Client-held funds obligation. As of the closing of the Acquisition on August 30, 2019, WageWorks held approximately $682 million of Client-held funds, of which $238 million was combined with its corporate cash within WageWorks' corporate bank accounts; therefore, the Company determined that this $238 million of Client-held funds were assets of the Company, while the approximately $444 million of remaining Client-held funds were not assets of the Company. Prior to October 31, 2019, the Company segregated $231 million of Client-held funds from its corporate bank accounts. Accordingly, as of October 31, 2019, $7 million of Client-held funds remained combined within the Company's corporate bank accounts and therefore remained on the Company's condensed consolidated balance sheets in cash and cash equivalents, with an offsetting liability included in accrued liabilities.
Recent adopted accounting pronouncements
In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (codified as "ASC 842"), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.
The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of $40.6 million and ROU assets of $38.0 million, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and nine-month period ended October 31, 2019.
In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This ASU permits the capitalization of implementation costs incurred in a software hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. The Company elected to early adopt the new standard as of October 31, 2019 using the prospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
Recent issued accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.

-9-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 1. Summary of business and significant accounting policies (continued)

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.
In August 2018, FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
Note 2. Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
(in thousands, except per share data)
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
 
2019

 
2018

 
2019

 
2018

Numerator (basic and diluted):
 
 
 
 
 
 
 
 
Net income (loss)
 
$
(21,334
)
 
$
15,686

 
$
39,854

 
$
60,780

Denominator (basic):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
70,524

 
62,088

 
65,727

 
61,718

Denominator (diluted):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
70,524

 
62,088

 
65,727

 
61,718

Weighted-average dilutive effect of stock options and restricted stock units
 

 
1,835

 
1,423

 
1,910

Diluted weighted-average common shares outstanding
 
70,524

 
63,923

 
67,150

 
63,628

Net income (loss) per share:
 
 
 
 
 
 
 
 
Basic
 
$
(0.30
)
 
$
0.25

 
$
0.61

 
$
0.98

Diluted
 
$
(0.30
)
 
$
0.25

 
$
0.59

 
$
0.96


For the three months ended October 31, 2019 and 2018, approximately 3.2 million and 36,000 shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.
For the nine months ended October 31, 2019 and 2018, approximately 0.3 million and 0.1 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.

-10-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 3. Business combination
Acquisition of WageWorks
Overview and total consideration paid
On August 30, 2019, the Company closed the Acquisition of WageWorks for $51.35 per share in cash, or approximately $2.0 billion to WageWorks stockholders. The Company financed the transaction through a combination of $816.9 million cash on hand plus net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.5 million, under a term loan facility (see Note 8—Indebtedness).
Pursuant to the Merger Agreement, the Company replaced certain outstanding restricted stock units originally granted by WageWorks with the Company’s equivalent awards. The outstanding WageWorks vested and unvested stock options, and certain unvested restricted stock units, were settled in cash as specified in the Merger Agreement. The portion of the fair value of partially vested awards associated with pre-acquisition service of WageWorks award recipients represented a component of the total consideration, as presented below.
The Acquisition was accounted for under the acquisition method of accounting for business combinations. Under this accounting method, the total consideration paid was:
(in millions)
 
 
Aggregate fair value of WageWorks stock acquired
 
$
2,018.8

Fair value of previously owned investment in WageWorks stock
 
81.4

Fair value of equity awards exchanged for cash attributable to pre-Acquisition service
 
18.1

Fair value of equity awards replaced attributable to pre-Acquisition service
 
3.8

Total consideration paid
 
$
2,122.1


Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the Acquisition date. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants to value acquired intangible assets. The initial allocation of the consideration paid is based on a preliminary valuation and is subject to potential adjustment during the measurement period (up to one year from the Acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
Preliminary allocation of consideration
(in millions)
 
Estimated fair value

Cash and cash equivalents
 
$
406.8

Other current assets
 
56.5

Property, plant, and equipment
 
26.6

Operating lease right-of-use assets
 
42.5

Intangible assets
 
715.3

Goodwill
 
1,330.5

Other assets
 
5.9

Client-held funds obligation
 
(237.5
)
Other current liabilities
 
(69.1
)
Other long-term liabilities
 
(26.7
)
Deferred tax liability
 
(128.7
)
Total consideration paid
 
$
2,122.1



-11-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 3. Business combination (continued)


The Acquisition resulted in $1.3 billion of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational and financial benefits expected from the Acquisition, including custodial and interchange revenue synergies based on current contractual relationships, as well as operational cost synergies resulting from increased scale in service delivery and elimination of duplicative management functions and other back-office operational efficiencies. The goodwill created in the Acquisition is not expected to be deductible for tax purposes.
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
(in millions)
 
Fair value

 
Weighted-average remaining amortization period (years)
Customer relationships (1)
 
$
598.5

 
15.0
Developed technology (1)
 
96.9

 
4.5
Trade names & trademarks (1)
 
12.3

 
3.0
Identified intangible assets subject to amortization
 
707.7

 
13.4
In-process software development costs
 
3.8

 
n/a
Total acquired intangible assets
 
$
711.5

 
 
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.
In connection with the transaction, for the three and nine months ended October 31, 2019, the Company incurred approximately $32.9 million and $40.7 million, respectively, of acquisition costs, which are recorded as other expense, net. For the three months ended October 31, 2019, WageWorks contributed revenue of approximately $72.1 million.  For the three months ended October 31, 2019, operating expenses related to WageWorks were approximately $39.9 million.
Pro forma information
The unaudited pro forma results presented below include the effects of the Acquisition as if it had been consummated as of February 1, 2018, with adjustments to give effect to pro forma events that are directly attributable to the Acquisition, which include adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation.
The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings that may result from the integration of WageWorks. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the Acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations. The estimated pro forma revenue and net income (loss) includes the alignment of accounting policies, the effect of fair value adjustments related to the Acquisition, associated tax effects and the impact of the borrowings to finance the Acquisition and related expenses.
(in thousands)
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
 
2019

 
2018

 
2019

 
2018

Revenue
 
$
194,450

 
$
186,022

 
$
598,815

 
$
573,520

Net income (loss)
 
$
(3,286
)
 
$
(21,145
)
 
$
34,559

 
$
9,120








-12-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 4. Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consist of the following:
Property and equipment
Property and equipment consisted of the following as of October 31, 2019 and January 31, 2019:
(in thousands)
 
October 31, 2019

 
January 31, 2019

Leasehold improvements
 
$
19,404

 
$
3,583

Furniture and fixtures
 
6,889

 
4,476

Computer equipment
 
22,890

 
9,242

Property and equipment, gross
 
49,183

 
17,301

Accumulated depreciation
 
(13,984
)
 
(9,078
)
Property and equipment, net
 
$
35,199

 
$
8,223


Depreciation expense for the three months ended October 31, 2019 and 2018 was $3.6 million and $0.9 million, respectively, and $5.4 million and $2.6 million for the nine months ended October 31, 2019 and 2018, respectively.
Other expense, net
Other expense, net, consisted of the following:
 
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Interest income
 
$
2,046

 
$
358

 
$
5,273

 
$
919

Gain on marketable equity securities
 
285

 

 
27,570

 

Acquisition costs
 
(32,932
)
 
(849
)
 
(40,712
)
 
(1,074
)
Other expense
 
(348
)
 
(996
)
 
(478
)
 
(1,272
)
Total other expense, net
 
$
(30,949
)
 
$
(1,487
)
 
$
(8,347
)
 
$
(1,427
)

Note 5. Leases
The Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of approximately less than 1 year to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.
Amortization and interest expense related to finance leases were not material during the three and nine months ended October 31, 2019.
The components of operating lease costs, lease term and discount rate are as follows:
 
 
Three months ended

 
Nine months ended

(in thousands, except for term and percentages)
 
October 31, 2019

 
October 31, 2019

Operating lease cost
 
$
3,354

 
$
5,515

Sublease income
 
(249
)
 
(249
)
Net operating lease cost
 
$
3,105

 
$
5,266

 
 
 
 
 
 
 
 
 
As of October 31, 2019

Weighted average remaining lease term
 
9.36 years

Weighted average discount rate
 
4.37
%


-13-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 5. Leases (continued)

Maturities of operating lease liabilities as of October 31, 2019 were as follows:
Fiscal year ending January 31, (in thousands)
 
Operating leases

Remaining 2020
 
$
375

2021
 
14,340

2022
 
14,135

2023
 
10,595

2024
 
8,287

Thereafter
 
55,389

Total lease payments
 
103,121

Less imputed interest
 
(19,289
)
Present value of lease liabilities
 
$
83,832

 
 
 
Current
 
$
10,780

Non-current
 
73,052

Total lease liabilities
 
$
83,832


As of October 31, 2019, the Company had additional operating leases for office space that have not yet commenced with aggregate undiscounted lease payments of $80.2 million. These operating leases will commence in fiscal year 2021 with a lease term of approximately 11 years.
Supplemental cash flow information related to the Company's operating leases was as follows:
 
 
Three months ended

 
Nine months ended

(in thousands)
 
October 31, 2019

 
October 31, 2019

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
Operating cash flows from operating leases
 
$
2,746

 
$
4,575

ROU assets obtained in exchange for new operating lease obligations
 
$
34,196

 
$
34,394



-14-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 6. Intangible assets and goodwill
Intangible assets
During the three months ended October 31, 2019, the Company recorded $711.5 million of acquired identified intangible assets as a result of the Acquisition of WageWorks. For further information about these acquired identified intangible assets, see Note 3—Business Combination.
During the nine months ended October 31, 2019, the Company acquired the rights to act as a custodian of HSA portfolios for $7.7 million. The Company has determined the acquired intangible HSA assets to have a useful life of 15 years. The assets are being amortized using the straight-line amortization method, which has been determined to be appropriate to reflect the pattern over which the economic benefits of existing assets are realized.
During the three months ended October 31, 2019 and 2018, the Company capitalized software development costs of $7.0 million and $2.2 million, respectively, and $14.7 million and $6.4 million, respectively, for the nine months ended October 31, 2019 and 2018, related to significant enhancements and upgrades to its technology-enabled services platforms.
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2019 and January 31, 2019:
(in thousands)
 
October 31, 2019

 
January 31, 2019

Amortizable intangible assets:
 
 
 
 
Software and software development costs
 
$
66,633

 
$
44,835

Acquired HSA portfolios
 
92,770

 
85,110

Acquired customer relationships
 
601,382

 
2,882

Acquired developed technology
 
96,924

 

Acquired trade names
 
12,300

 

Amortizable intangible assets, gross
 
870,009

 
132,827

Accumulated amortization
 
(77,017
)
 
(53,161
)
Total amortizable intangible assets, net
 
792,992

 
79,666

Acquired in-process software development costs
 
3,236

 

Total intangible assets, net
 
$
796,228

 
$
79,666


During the three months ended October 31, 2019 and 2018, the Company expensed a total of $6.2 million and $3.4 million, respectively, and $13.8 million and $10.0 million for the nine months ended October 31, 2019 and 2018, respectively, in software development costs primarily related to the post-implementation and operation stages of its technology platforms.
Amortization expense for the three months ended October 31, 2019 and 2018 was $15.7 million and $3.7 million, respectively, and $23.6 million and $10.9 million, respectively, for the nine months ended October 31, 2019 and 2018.
Goodwill
During the three months ended October 31, 2019, the Company recorded $1.3 billion of goodwill from the Acquisition of WageWorks. For further information about the resulting goodwill, see Note 3—Business Combination.
There were no other changes to the goodwill carrying value during the three and nine months ended October 31, 2019 and 2018.
Note 7. Commitments and contingencies
Commitments
In addition to the indebtedness described in Note 8 below, the Company’s principal commitments consist of operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments.

-15-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 7. Commitments and contingencies (continued)


Future minimum lease payments under non-cancelable operating leases, excluding the contractual sublease income of $6.0 million, which is expected to be received through February 2023, and other agreements, are as follows:
Year ending January 31, (in thousands)
 
Operating leases

 
Other agreements

 
Total

2020
 
$
375

 
$
2,524

 
$
2,899

2021
 
14,340

 
10,325

 
24,665

2022
 
15,692

 
7,182

 
22,874

2023
 
12,191

 
4,602

 
16,793

2024
 
9,922

 
1,212

 
11,134

Thereafter
 
67,717

 
403

 
68,120

Total
 
$
120,237

 
$
26,248

 
$
146,485


Rent expense was $3.4 million and $5.5 million for the three and nine months ended October 31, 2019, respectively. Sublease income was $0.2 million for the three months ended October 31, 2019.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
WageWorks is pursuing affirmative claims against the Office of Personnel Management ("OPM") to obtain payment for services provided by WageWorks between March 1, 2016 and August 31, 2016 pursuant to its contract with OPM. In connection with WageWorks' claims against OPM, OPM has also claimed that an erroneous statement in a certificate signed by a former executive officer constituted a violation of the False Claims Act and moved to dismiss part of WageWorks' claim against OPM as a result. As with all legal proceedings, no assurance can be provided as to the outcome of these matters or if WageWorks or OPM will be successful.
On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks, its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleges claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering.
On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages and fees and costs.
Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint.
WageWorks voluntarily contacted the San Francisco office of the SEC Division of Enforcement regarding the restatement of WageWorks' financial statements and related independent investigation. WageWorks is providing information and documents to the SEC and continues to cooperate with the SEC’s investigation into these matters.

-16-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 7. Commitments and contingencies (continued)


The U.S. Attorney’s Office for the Northern District of California also opened an investigation. WageWorks has provided documents and information to the U.S. Attorney’s Office and continues to cooperate with any inquiries by the U.S. Attorney’s Office regarding the matter.
Beginning on July 30, 2019, putative class action suits were filed in the U.S. District Court Courts for the Southern District of New York, the District of Delaware, and the Northern District of California asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks and the former members of its board of directors. The complaints generally allege disclosure violations in the proxy statement issued by WageWorks in connection with the stockholder vote on the proposed merger with the Company. After WageWorks issued certain supplemental disclosures, these actions were voluntarily dismissed, but WageWorks may still be required to pay attorneys fees to the plaintiffs' lawyers.
WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense of its former directors and officers in the legal proceedings described above.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. While it is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, the Company believes, based on current knowledge, that such litigation, proceedings and claims will not have a material impact on the Company’s financial position, results of operations and cash flows for the period.
The Company maintains liability insurance coverage that is intended to cover the legal matters described above; however, it is possible that claims may be denied by our insurance carriers or could exceed the amount of our applicable insurance coverage, we may be required by our insurance carriers to contribute to the payment of claims, and our insurance coverage may not continue to be available to us on acceptable terms or in sufficient amounts.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
Note 8. Indebtedness
As of October 31, 2019, long-term debt consisted of the following:
(in millions)
 
October 31, 2019

Term loan facility
 
$
1,250

Less: unamortized loan issuance costs
 
(23
)
Long-term debt, net of issuance costs
 
$
1,227


On September 30, 2015, the Company entered into a credit facility that provided for a secured revolving credit facility in the aggregate principal amount of $100.0 million for a term of five years. Upon closing of the Acquisition on August 30, 2019, the credit facility was terminated. At the time of termination, no amounts were drawn and the Company was in compliance with all covenants.
In connection with the closing of the Acquisition, on August 30, 2019, the Company entered into a credit facility (the "Credit Agreement”) that provided for:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion, the proceeds of which were used to finance the Acquisition, to refinance substantially all outstanding indebtedness of HealthEquity and WageWorks and to pay related fees and expenses; and

-17-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 8. Indebtedness (continued)

(ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of October 31, 2019.
Borrowings under the Credit Facilities will bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The loans made under the Term Loan Facility are required to be repaid as described in the following table:
Fiscal year ending January 31, (in millions)
 
Principal payments

Remaining 2020
 
$
8

2021
 
39

2022
 
63

2023
 
70

2024
 
101

Thereafter
 
969

Total principal payments
 
$
1,250


The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.25 to 1.00, which steps down to (x) 5.00 to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) 4.50 to 1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of October 31, 2019.
The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of HealthEquity and the guarantors, in each case, subject to certain customary exceptions.
Note 9. Income taxes
The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three and nine months ended October 31, 2019, the Company recorded an income tax benefit of $9.9 million and income tax expense of $3.9 million, respectively. This resulted in an effective income tax
benefit rate of 31.7% and an income tax expense rate of 8.9% for the three and nine months ended October 31, 2019, respectively, compared with an effective income tax expense rate of 10.0% and an effective income tax benefit rate of 2.2% for the three and nine months ended October 31, 2018, respectively. For the three and nine months ended October 31, 2019 and 2018, the net impact of discrete tax items caused a percentage point benefit of

-18-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 9. Income taxes (continued)

1.1 and 8.7 and a percentage point benefit of 11.2 and 24.1, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes in the condensed consolidated statements of operations and comprehensive income (loss).
As of October 31, 2019 and January 31, 2019, the Company’s total gross unrecognized tax benefit was $8.1 million and $1.7 million, respectively. Certain unrecognized tax benefits have been netted against their related tax assets. As of October 31, 2019, an unrecognized tax benefit of $0.4 million was recorded. As of January 31, 2019, no unrecognized tax benefits had been recorded. If recognized, $7.4 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of October 31, 2019.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.
Note 10. Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:


Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Cost of revenue

$
1,415

 
$
788

 
$
3,285

 
$
2,008

Sales and marketing

1,304

 
990

 
3,469

 
2,586

Technology and development

2,171

 
1,386

 
5,600

 
3,677

General and administrative

3,332

 
2,570

 
9,486

 
7,190

Merger integration
 
1,220

 

 
1,220

 

Other expense, net
 
13,714

 

 
13,714

 

Total stock-based compensation expense

$
23,156

 
$
5,734

 
$
36,774

 
$
15,461


The following table shows stock-based compensation by award type:


Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Stock options

$
1,631

 
$
1,917

 
$
5,140

 
$
5,664

Performance stock options


 
178

 

 
503

Restricted stock units

14,099

 
1,956

 
20,718

 
5,543

Performance restricted stock units

1,422

 
793

 
3,467

 
1,843

Restricted stock awards

164

 
172

 
491

 
399

Performance restricted stock awards

260

 
718

 
1,378

 
1,509

Total non-cash stock-based compensation expense
 
17,576

 
5,734

 
31,194

 
15,461

Acquisition awards exchanged for cash
 
5,580

 

 
5,580

 

Total stock-based compensation expense

$
23,156

 
$
5,734

 
$
36,774

 
$
15,461


Stock award plans
Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock. As described below, in connection with the Acquisition, the shares of common stock available for issuance under the Incentive Plan were increased by 5.3 million shares.

-19-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 10. Stock-based compensation (continued)

In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors.
WageWorks Incentive Plan. At the closing of the Acquisition, and in accordance with the Merger Agreement, certain RSUs with respect to WageWorks common stock, granted under WageWorks, Inc. 2010 Equity Incentive Plan (the "WageWorks Incentive Plan"), were replaced by the Company and converted into RSUs with respect to 523,318 shares of common stock of the Company.
In connection with the Acquisition, an additional 5,255,027 shares of the Company, representing the remaining number of shares of common stock of WageWorks that were available for issuance under the WageWorks Incentive Plan immediately prior to the Acquisition, became available for issuance under the Incentive Plan. The additional shares may be utilized for equity-based awards to be granted under the Incentive Plan, provided that (i) the period during which such shares are available under the Incentive Plan may not be extended beyond the period during which they would have been available under the WageWorks Incentive Plan, absent the Acquisition, and (ii) such equity-based awards may not be granted to individuals who were employees, directors or consultants of HealthEquity or its affiliates at the time the Acquisition was consummated.
Stock options
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.
Valuation assumptions. The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.
Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.
The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:
  

Three months ended October 31,
 
 
Nine months ended October 31,
 
  

2019
 
2018

 
2019

 
2018

Expected dividend yield

*

%
 
%
 
%
Expected stock price volatility

*

37.09
%
 
35.98% - 36.53%

 
37.09% - 37.84%

Risk-free interest rate

*

2.79
%
 
2.21% - 2.43%

 
2.52% - 2.79%

Expected life of options

*

6.25 years

 
4.95 - 5.09 years

 
5.17 - 6.25 years


* No stock options were granted during the three months ended October 31, 2019.
The Company historically used the "simplified" method to estimate the expected life of an option as determined under Staff Accounting Bulletin No. 110 due to limited option exercise history as a public company. Commencing February 1, 2019, the Company began estimating the expected life of an option using its own historical option exercise and termination data. Expected volatility is determined using weighted average volatility of the Company's

-20-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 10. Stock-based compensation (continued)

historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations.
A summary of stock option activity is as follows:
  

Outstanding stock options
 
(in thousands, except for exercise prices and term)

Number of
options


Range of
exercise
prices

Weighted-
average
exercise
price


Weighted-
average
contractual
term
(in years)

Aggregate
intrinsic
value

Outstanding as of January 31, 2019

2,444


$0.10 - 82.39

$
27.37


6.74

$
85,971

Granted

108


$63.64 - 73.61

$
73.27





Exercised

(314
)

$0.10 - 44.53

$
23.42





Forfeited

(36
)

$24.36 - 44.53

$
30.15





Outstanding as of October 31, 2019

2,202


$0.10 - 82.39

$
30.14


6.13

$
61,562

Vested and expected to vest as of October 31, 2019

2,202




$
30.14


6.13

$
61,562

Exercisable as of October 31, 2019

1,501




$
22.91


5.50

$
51,131


The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.
As of October 31, 2019, the weighted-average vesting period of non-vested awards expected to vest is approximately 1.5 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately $8.8 million.
Restricted stock units and restricted stock awards
The Company grants RSUs and RSAs to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
Acquisition of WageWorks. As described above, at the closing of the Acquisition, and in accordance with the Merger Agreement, 523,318 service-based RSUs with respect to WageWorks common stock were replaced by the Company and converted into RSUs with respect to common stock of the Company. These replaced awards are included in the granted amounts in the summary of RSU and RSA activity below.
The awards replaced by the Company in the Acquisition were measured at the Acquisition date based on the estimated fair value of $29.7 million. A portion of that fair value, $3.8 million, which represented the pre-Acquisition service provided by team members to WageWorks, was included in the total consideration paid as part of the Acquisition. As of the closing of the Acquisition, the remaining portion of the fair value of those awards was $25.9 million, representing post-Acquisition share-based compensation expense, $8.1 million of which was recognized during the three months ended October 31, 2019 as acquisition-related costs, and the remainder of which will be recognized in the ordinary course as these team members provide service over the remaining vesting periods.
Additionally, at the closing of the Acquisition, and in accordance with the Merger Agreement, the Company exchanged for cash certain WageWorks equity awards measured at the Acquisition date based on the estimated fair value of $23.6 million. A portion of that fair value, $18.1 million, which represented the pre-Acquisition service provided by team members to WageWorks, was included in the total consideration paid as part of the Acquisition. As of the closing of the Acquisition, the remaining portion of the fair value of the awards exchanged for cash

-21-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 10. Stock-based compensation (continued)

was $5.6 million, representing post-Acquisition share-based compensation expense that was recognized during the three months ended October 31, 2019.
Performance restricted stock units and awards. In March 2017, the Company awarded 146,964 performance-based RSUs ("PRSUs"). Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2020. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 150% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.
In March 2018, the Company awarded 227,760 performance-based RSAs ("PRSAs"). Vesting of the PRSAs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2021. The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred at the grant date. The Company believes it is probable that the PRSAs will vest at least in part. The vesting of the PRSAs will ultimately range from 0% to 200% based on the level of achievement of the performance goals. The PRSAs were issued at the 200% level of achievement. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.
In March 2019, the Company awarded 129,963 PRSUs. Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2022. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 200% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.
A summary of the RSU and RSA activity is as follows:


RSUs and PRSUs
 

RSAs and PRSAs
 
(in thousands, except weighted-average grant date fair value)

Shares


Weighted-average grant date fair value


Shares


Weighted-average grant date fair value

Outstanding as of January 31, 2019

647


$
55.18


256


$
61.93

Granted

1,124


64.61





Released

(320
)

58.01


(11
)

62.75

Forfeited

(83
)

56.02


(10
)

61.72

Outstanding as of October 31, 2019

1,368


$
62.22


235


$
61.91


For the nine months ended October 31, 2019, the aggregate intrinsic value of RSUs and RSAs released was $19.9 million and $0.8 million, respectively. For the nine months ended October 31, 2018, the aggregate intrinsic value of RSUs released was $5.5 million.
Total unrecorded stock-based compensation expense as of October 31, 2019 associated with RSUs and PRSUs was $67.1 million, which is expected to be recognized over a weighted-average period of 2.6 years. Total unrecorded stock-based compensation expense as of October 31, 2019 associated with RSAs and PRSAs was $4.3 million, which is expected to be recognized over a weighted-average period of 1.6 years.



-22-


HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)

Note 11. Fair value
Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of October 31, 2019 due to the short-term nature of these instruments. 

-23-


Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning the anticipated synergies and other benefits of our Acquisition of WageWorks, health savings accounts and other tax advantaged consumer-directed benefits, tax and other regulatory changes, market opportunity, our future financial and operating results, investment and acquisition strategy, sales and marketing strategy, management’s plans, beliefs and objectives for future operations, technology and development, economic and industry trends or trend analysis, expectations about seasonality, opportunity for portfolio purchases and other acquisitions, operating expenses, anticipated income tax rates, capital expenditures, cash flows and liquidity. These statements are based on the beliefs and assumptions of our management based on information currently available to us. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk factors” included in this Quarterly Report on Form 10-Q, and in our other reports filed with the SEC. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such events.

Overview
We are a leader and an innovator in the high-growth category of technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions. Consumers use our platforms to manage their tax-advantaged health savings accounts (“HSAs”) and other consumer-directed benefits (“CDBs”) offered by employers, including flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit information, access remote and telemedicine benefits, earn wellness incentives, and receive investment advice to grow their tax-advantaged healthcare savings.
The core of our offerings is the HSA, a financial account through which consumers spend and save long-term for healthcare expenses on a tax-advantaged basis. As of October 31, 2019, we administered 5.0 million HSAs, with balances totaling $10.5 billion, which we call HSA Assets. Also, as of October 31, 2019, we administered 7.5 million complementary CDBs. We refer to the sum of HSAs and CDBs on our platforms as Total Accounts, of which we had 12.5 million as of October 31, 2019.
We reach consumers primarily through relationships with their employers, whom we call Clients. We reach Clients primarily through a sales force that calls on Clients directly, relationships with benefits brokers and advisors, and integrated partnerships with a network of health plans, benefits administrators and retirement plan recordkeepers, which we call Network Partners.
We have grown our share of the growing HSA market from 4% in 2010 to 17% in 2019, including by 3% as a result of the Acquisition of WageWorks. Today we are the largest HSA provider by accounts, second largest by assets, and, we believe, the largest provider of other CDBs. We seek to differentiate ourselves through our proprietary technology, product breadth, ecosystem connectivity and service-driven culture. Our proprietary technology is designed to help consumers optimize the value of their HSAs and other CDBs, as they gain confidence and skill in their management of financial responsibility for lifetime healthcare.
Our ability to engage consumers is enhanced by our platforms’ capacity to securely share data bidirectionally with others in the health, benefits and retirement ecosystems, whom we call Ecosystem Partners. Our commuter

-24-


benefits offering also leverages connectivity to an ecosystem of mass transit, ride hailing and parking providers. These strengths reflect our “DEEP Purple” culture of remarkable service to customers and teammates, achieved by driving excellence, ethics, and process into everything we do.
We earn revenue primarily from three sources: service, custodial and interchange. We earn service revenue mainly from fees paid by Clients on a recurring per-account per-month basis. We earn custodial revenue mainly from HSA Assets held at our members’ direction in federally insured cash deposits, insurance contracts or mutual funds, and from investment of CDB Client pre-funding amounts. We earn interchange revenue mainly from fees paid by merchants on payments that our members make using our physical payment cards and virtual platforms. See “Key components of our results of operations” for additional information on our sources of revenue.
Acquisition of WageWorks
On August 30, 2019, we completed the Acquisition of WageWorks and paid approximately $2.0 billion in cash to WageWorks stockholders, financed through net borrowings of approximately $1.22 billion under a new term loan facility and approximately $816.9 million of cash on hand.
The Acquisition is expected to increase the number of our employer opportunities, the conversion of these opportunities to Clients, and value of the Clients in generating members, HSA Assets and complementary CDBs. WageWorks’ strength of selling to employers directly and through health benefits brokers and advisors complements our distribution through Network Partners. Together these channels produce 79% of new HSAs according to Devenir. With WageWorks’ CDB capabilities, we can provide employers with a single partner for both HSAs and other CDBs, which is preferred by the vast majority of employers, according to research conducted for us by Aite Group. For Clients who partner with us in this way, we believe we can produce more value by encouraging both CDB participants to contribute to HSAs and HSA-only members to take advantage of tax savings by increasing their account balances in other CDBs. Accordingly, we believe that current Clients represent a significant opportunity.
The Acquisition has significantly increased the number of our Total Accounts, HSA Assets, Client-held funds, Adjusted EBITDA, total revenue, total cost of revenue, operating expenses, and other financial results, and we expect that it will continue to do so.
Key factors affecting our performance
We believe that our future performance will be driven by a number of factors, including those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See the section entitled “Risk factors” included in this Quarterly Report on Form 10-Q and our other reports filed with the SEC.
WageWorks integration
On August 30, 2019, we completed the Acquisition of WageWorks. We are now pursuing a multi-year integration effort that we expect will produce long-term cost savings and revenue synergies. We have identified near-term opportunities, estimated to be approximately $50 million in annualized ongoing net synergies to be achieved by the end of fiscal 2021. Furthermore, we anticipate generating revenue synergies over the longer-term as our combined distribution channels and existing client base take advantage of the broader platform and service offerings and as we continue to drive Member engagement. We estimate non-recurring costs to achieve these synergies of approximately $80 million to $100 million realized within 24 to 36 months of the closing of the Acquisition, resulting from investment in technology platforms, back-office systems and platform integration, as well as rationalization of cost of operations.
Structural change in U.S. health insurance
We derive revenue primarily from healthcare-related saving and spending by consumers in the U.S., which are driven by changes in the broader healthcare industry, including the structure of health insurance. The average premium for employer-sponsored health insurance has risen by 22% since 2014 and 54% since 2009, resulting in increased participation in HSA-qualified health plans and HSAs and increased consumer cost-sharing in health insurance more generally. We believe that continued growth in healthcare costs and related factors will spur continued growth in HSA-qualified health plans and HSAs and may encourage policy changes making HSAs or similar vehicles available to new populations such as individuals in Medicare. However, the timing and impact of these and other developments in U.S. healthcare are uncertain. Moreover, changes in healthcare policy, such as "Medicare for all" plans, could materially and adversely affect our business in ways that are difficult to predict.


-25-


Trends in U.S. tax law
Tax law has a profound impact on our business. Our offerings to members, Clients and Network Partners consist primarily of services enabled, mandated or advantaged by provisions of U.S. tax law and regulations. We believe that the present direction of U.S. tax policy is favorable to our business, as evidenced for example by recent regulatory action and bipartisan policy proposals to expand the availability of HSAs. However, changes in tax policy are speculative, and may affect our business in ways that are difficult to predict.
Our client base
Our business model is based on a B2B2C distribution strategy, meaning that we attract Clients and Network Partners to reach consumers to increase the number of our members with HSA accounts and complementary CDBs. We believe our current Clients represent a significant opportunity for us, as fewer than 5% presently partner with us for both HSAs and our complementary CDB offerings.
Broad distribution footprint
We believe we have a diverse distribution footprint to attract new Clients and Network Partners. Our sales force calls on enterprise, commercial and regional employers in industries across the U.S., as well as potential Network Partners from among health plans, benefits administrators and retirement plan record keepers. Together these channels produce 79% of new HSAs according to Devenir.
Product breadth
We are the largest custodian and administrator of HSAs (by number of accounts), as well as a market-share leader in each of the major categories of complementary CDBs, including FSAs and HSAs, COBRA and commuter benefits administration. Our Clients and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs. With WageWorks’ CDB capabilities, we can provide employers with a single partner for both HSAs and complementary CDBs, which is preferred by the vast majority of employers, according to research conducted for us by Aite Group. We believe that the combination of HSA and complementary CDB offerings significantly strengthens our value proposition to employers, health benefits brokers and consultants, and Network Partners as a leading single-source provider,
Our proprietary technology platform
We believe that innovations incorporated in our technology that enable consumers to make healthcare saving and spending decisions and maximize the value of their tax-advantaged benefits differentiate us from our competitors and drive our growth. We plan to build on these innovations by combining our HSA platform with WageWorks' complementary CDB offerings, giving us a full suite of CDB products, and adding to our solutions set and leadership position within the HSA sector. We intend to continue to invest in our technology development to enhance our platform’s capabilities and infrastructure. For example, we are making significant investments in our platform’s architecture and related platform infrastructure to improve our transaction processing capabilities and support continued account and transaction growth, as well as in data-driven personalized engagement to help our members spend less, save more and build wealth for retirement.
Our “DEEP Purple” service culture
The successful healthcare consumer needs education and guidance delivered by people as well as technology. We believe that our "DEEP Purple" culture which we define as Driving Excellence, Ethics, and Process while providing remarkable service, is a significant factor in our ability to attract and retain customers and to address nimbly, opportunities in the rapidly changing healthcare sector. We make significant efforts to promote and foster DEEP Purple within our workforce. We invest in and intend to continue to invest in human capital through technology-enabled training, career development and advancement opportunities.
Interest rates
As a non-bank custodian, we contract with federally insured banks, credit unions, and insurance company partners, whom we collectively call Depository Partners, to hold custodial cash assets on behalf of our members. We earn a material portion of our total revenue from interest rates offered to us by these partners (approximately 40% in the nine months ended October 31, 2019). The lengths of our agreements with Depository Partners range from zero to five years and may have fixed or variable interest rate terms. The terms of new and renewing agreements may be impacted by the then-prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members. We believe that diversification of Depository Partners, varied contract terms and other factors reduce our exposure to short-term fluctuations in prevailing

-26-


interest rates and mitigate the short-term impact of sustained increases or declines in prevailing interest rates on our custodial revenue. Over longer periods, sustained shifts in prevailing interest rates affect the amount of custodial revenue we can realize on custodial assets and the interest retained by our members.
Our competition and industry
Our direct competitors are HSA custodians and other CDB providers. Many of these are state or federally chartered banks and other financial institutions for which we believe technology-based healthcare services are not a core business. Certain of our direct competitors have chosen to exit the market despite increased demand for these services. This has created, and we believe will continue to create, opportunities for us to leverage our technology platform and capabilities to increase our market share. However, some of our direct competitors (including well-known mutual fund companies such as Fidelity and health insurers such as United Health Group's Optum) are in a position, should they choose, to devote more resources to the development, sale and support of their products and services than we have at our disposal. In addition, numerous indirect competitors, including benefits administration technology and service providers, partner with banks and other HSA custodians to compete with us. Our Network Partners may also choose to offer competitive services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
Regulatory environment
Federal law and regulations, including the Affordable Care Act, the Internal Revenue Code, the Employee Retirement Income Security Act and Department of Labor regulations, and public health regulations that govern the provision of health insurance and provide the tax advantages associated with our products, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as the Health Insurance Portability and Accountability Act, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, or the Advisers Act, the USA PATRIOT Act, anti-money laundering laws, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. For example, our subsidiary HealthEquity Trust Company is regulated by the Wyoming Division of Banking, and several states are considering, or have already passed, new privacy regulations that can affect our business. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.
Our acquisition strategy
We have a successful history of acquiring HSA portfolios from competitors who have chosen to exit the industry and complementary assets and businesses that strengthen our platform. We seek to continue this growth strategy and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate and integrate acquisitions. We intend to continue to thoughtfully pursue acquisitions of complementary assets and businesses that we believe will strengthen our platform.

-27-


Key financial and operating metrics
Our management regularly reviews a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
Total Accounts
The following table sets forth our HSAs, CDBs, and Total Accounts as of and for the periods indicated:
(in thousands, except percentages)

October 31, 2019


October 31, 2018


% Change


January 31, 2019

HSAs

5,031


3,677


37
%

3,994

Average HSAs - Year-to-date

4,296


3,540


21
%

3,608

Average HSAs - Quarter-to-date

4,743


3,642


30
%

3,813

New HSAs - Year-to-date

1,113


338


229
%

679

New HSAs - Quarter-to-date

898


119


655
%

341

Active HSAs

4,115


2,972


38
%

3,241

HSAs with investments

197


153


29
%

163

CDBs
 
7,504

 
598

 
1,155
%
 
572

Total Accounts
 
12,535

 
4,275

 
193
%
 
4,566

Average Total Accounts - Year-to-date
 
6,482

 
4,125

 
57
%
 
4,194

Average Total Accounts - Quarter-to-date
 
9,970

 
4,239

 
135
%
 
4,402

The number of our HSAs and CDBs are key metrics because our revenue is driven by the amount we earn from them. The number of our HSAs increased by approximately 1.4 million, or 37%, from October 31, 2018 to October 31, 2019, primarily driven by the Acquisition of WageWorks and other HSA portfolio acquisitions, which contributed approximately 757,000 HSAs. The remainder of the increase was due to further penetration into existing Network Partners and the addition of new Network Partners. The number of our CDBs increased by approximately 6.9 million, or 1,155%, from October 31, 2018 to October 31, 2019, primarily driven by the Acquisition of WageWorks.
HSAs are individually owned portable healthcare accounts. As HSA members transition between employers or health plans, they may no longer be enrolled in an HDHP that qualifies them to continue to make contributions to their HSA. If these HSA members deplete their custodial balance, we may consider the corresponding HSA no longer an Active HSA. We define an Active HSA as an HSA that (i) is associated with a Network Partner or a Client, in each case as of the end of the applicable period; or (ii) has held a custodial balance at any point during the previous twelve month period. Active HSAs increased 38% from 3.0 million as of October 31, 2018 to 4.1 million as of October 31, 2019.
HSA Assets
The following table sets forth our HSA Assets as of and for the periods indicated:
(in millions, except percentages)

October 31, 2019


October 31, 2018


% Change


January 31, 2019

HealthEquity HSA cash (custodial revenue) (1)

$
6,578


$
5,583


18
%

$
6,428

WageWorks HSA cash (custodial revenue) (2)
 
986




n/a



WageWorks HSA cash (no custodial revenue) (3)
 
381




n/a



Total HSA cash
 
7,945


5,583


42
%

6,428

HealthEquity HSA investments (custodial revenue) (1)

2,188


1,507


45
%

1,670

WageWorks HSA investments (no custodial revenue) (3)
 
326




n/a



Total HSA investments
 
2,514


1,507


67
%

1,670

Total HSA Assets

10,459


7,090


48
%

8,098

Average daily HealthEquity HSA cash - Year-to-date

6,435


5,503


17
%

5,586

Average daily HealthEquity HSA cash - Quarter-to-date

$
6,493


$
5,551


17
%

$
5,837

(1) HSA Assets administered by HealthEquity that generate custodial revenue
(2) HSA Assets administered by WageWorks that generate custodial revenue
(3) HSA Assets administered by WageWorks that do not currently generate custodial revenue

-28-


Our HSA Assets, which are our HSA members' assets for which we are the custodian or administrator, or for which we generate custodial revenue, consist of the following components: (i) cash deposits, which are deposits with our Depository Partners, (ii) custodial cash deposits invested in an annuity contract with our insurance company partner, and (iii) investments in mutual funds through our custodial investment fund partners. Measuring our HSA Assets is important because our custodial revenue is directly affected by average daily custodial balances for HSA Assets that are revenue generating.
Our Total HSA Assets increased by $3.4 billion, or 48%, from October 31, 2018 to October 31, 2019, primarily driven by the Acquisition of WageWorks and other HSA portfolio acquisitions, which added $1.7 billion in HSA Assets. The remaining $1.7 billion increase was due to additional HSA Assets from our existing HSA members and new HSA Assets from our new HSA members. Importantly, our HSA investment assets increased by $1.0 billion, or 67%, from October 31, 2018 to October 31, 2019, reflecting the Acquisition of WageWorks and our strategy to help our HSA members build wealth and invest for retirement.
Client-held funds
(in millions, except percentages)
 
October 31, 2019

 
October 31, 2018

 
% Change
 
January 31, 2019

Client-held funds (custodial revenue) (1)
 
$
670

 
$

 
n/a
 
$

Average daily Client-held funds - Year-to-date
 
$
268

 
$

 
n/a
 
$

Average daily Client-held funds - Quarter-to-date
 
$
500

 
$

 
n/a
 
$

(1) Client-held funds that generate custodial revenue
Our Client-held funds are interest earning deposits from which we generate custodial revenue. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of our other CDBs. These deposits are held with Depository Partners. The amount of our Client-held funds is important because our custodial revenue is affected by average daily Client-held fund balances.
Our total Client-held funds increased by $670.0 million from October 31, 2018 to October 31, 2019, primarily driven by the Acquisition of WageWorks.
Adjusted EBITDA
We define Adjusted EBITDA, which is a non-GAAP financial metric, as adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on marketable equity securities, and certain other non-operating items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses, and serves as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income (loss), the most comparable GAAP financial measure, to Adjusted EBITDA for each of the periods indicated:
 
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Net income (loss)
 
$
(21,334
)
 
$
15,686

 
$
39,854

 
$
60,780

Interest income
 
(2,046
)
 
(358
)
 
(5,273
)
 
(919
)
Interest expense
 
10,225

 
68

 
10,355

 
204

Income tax provision (benefit)
 
(9,918
)
 
1,745

 
3,908

 
(1,322
)
Depreciation and amortization
 
6,203

 
3,092

 
12,940

 
9,060

Amortization of acquired intangible assets
 
13,051

 
1,490

 
16,036

 
4,438

Stock-based compensation expense
 
8,222

 
5,734

 
21,840

 
15,461

Merger integration expenses (1)
 
17,675

 

 
20,459

 

Acquisition costs (2)
 
32,932

 
849

 
40,712

 
1,074

Gain on marketable equity securities
 
(285
)
 

 
(27,570
)
 

Other (3)
 
824

 
1,360

 
1,854

 
2,318

Adjusted EBITDA
 
$
55,549

 
$
29,666

 
$
135,115

 
$
91,094

(1)
Includes $1.2 million of stock-based compensation expense related to post-Acquisition merger integration activities.
(2)
Includes $13.7 million of stock-based compensation expense related to Acquisition-related cash and equity accelerations.
(3)
For the three months ended October 31, 2019 and 2018, Other consisted of other costs of $349 and $321, amortization of incremental costs to obtain a contract of $475 and $363, and loss on disposal of previously capitalized software development of $0 and $676, respectively. For the nine months ended October 31, 2019 and 2018, Other consisted of other costs of $479 and $597, amortization of

-29-


incremental costs to obtain a contract of $1,375 and $1,045, and loss on disposal of previously capitalized software development of $0 and $676, respectively.
The following table further sets forth our Adjusted EBITDA:

Three months ended October 31,
 


Nine months ended October 31,
 
 
 
(in thousands, except percentages)
2019

2018

$ Change

% Change

2019

2018

$ Change

% Change

Adjusted EBITDA
$
55,549

$
29,666

$
25,883

87
%
$
135,115

$
91,094

$
44,021

48
%
As a percentage of revenue
35
%
42
%
 
 
41
%
43
%
 
 
Our Adjusted EBITDA increased by $25.9 million, or 87%, from $29.7 million for the three months ended October 31, 2018 to $55.5 million for the three months ended October 31, 2019. The increase in Adjusted EBITDA was driven by the overall growth of our business, including a 123% increase in total revenue, primarily due to the inclusion of WageWorks' financial results following the Acquisition.
Our Adjusted EBITDA increased by $44.0 million, or 48%, from $91.1 million for the nine months ended October 31, 2018 to $135.1 million for the nine months ended October 31, 2019. The increase in Adjusted EBITDA was driven by the overall growth of our business, including a 56% increase in total revenue, primarily due to the inclusion of WageWorks' financial results following the Acquisition
Our use of Adjusted EBITDA has limitations as an analytical tool, and it should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
Key components of our results of operations
Acquisition of WageWorks
As the Acquisition closed on August 30, 2019, only two months of WageWorks' results of operations are included in our consolidated results of operations. Accordingly, the results of operations attributable to WageWorks may not be directly comparable to WageWorks' results of operations reported by WageWorks prior to the Acquisition.
Revenue
We generate revenue from three primary sources: service revenue, custodial revenue, and interchange revenue.
Service revenue.    We earn service revenue from the fees we charge our Network Partners, Clients and members for the administration services we provide in connection with the HSAs and other CDBs we offer. With respect to our Network Partners, our fees are generally based on a fixed tiered structure for the duration of our agreement with the relevant Network Partner and are paid to us on a monthly basis. We recognize revenue on a monthly basis as services are rendered to our Members and Clients.
Custodial revenue.    We earn custodial revenue, an increasing component of our overall revenue, primarily from our HSA Assets deposited with our Depository Partners and with our insurance company partner, Client-held funds deposited with our Depository Partners, and recordkeeping fees we earn in respect of mutual funds in which our members invest. We deposit the HSA custodial cash with our Depository Partners pursuant to contracts that (i) have terms up to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances deposited with the relevant Depository Partner, and (iii) have minimum and maximum required deposit balances. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. We earn custodial revenue on the HSA Assets and Client-held funds that is based on the interest rates offered to us by these Depository Partners. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA Assets in mutual funds through our custodial investment partner. We earn a recordkeeping fee, calculated as a percentage of custodial investments.
Interchange revenue.    We earn interchange revenue each time one of our Members uses one of our payment cards to make a qualified purchase. This revenue is collected each time a Member “swipes” our payment card to pay expenses. We recognize interchange revenue monthly based on reports received from third parties, namely, the card-issuing banks and card processors.
Cost of revenue
Cost of revenue includes costs related to servicing Member accounts, managing Client and Network Partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations (such as office rent, supplies, and other overhead expenses), new member and participant supplies, and other operating costs related to servicing our

-30-


members. Other components of cost of revenue include interest retained by members on custodial cash and interchange costs incurred in connection with processing card transactions for our members.
Service costs.    Service costs include the servicing costs described above. Additionally, for new accounts, we incur on-boarding costs associated with the new accounts, such as new member welcome kits, the cost associated with issuance of new payment cards and costs of marketing materials that we produce for our Network Partners.
Custodial costs.    Custodial costs are comprised of interest retained by our HSA members and fees we pay to banking consultants whom we use to help secure agreements with our Depository Partners. Interest retained by HSA members is calculated on a tiered basis. The interest rates retained by HSA members can change based on a formula or upon required notice.
Interchange costs.    Interchange costs are comprised of costs we incur in connection with processing payment transactions initiated by our members. Due to the substantiation requirement on FSA/HRA-linked payment card transactions, payment card costs are higher for FSA/HRA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the transaction.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including interest rates, the amount we charge our partners and members, how many services we deliver per account, and payment processing costs per account.
Operating expenses
Sales and marketing.    Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense allocations.
Technology and development.    Technology and development expenses include personnel and related expenses for software engineering, information technology, product development, and security. Technology and development expenses also include software engineering services, the costs of operating our on-demand technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
General and administrative.    General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, internal audit, compliance, and people departments. They also include depreciation, amortization, stock-based compensation and common expense allocations.
Amortization of acquired intangible assets.    Amortization of acquired intangible assets results primarily from intangible assets acquired in connection with business combinations. The assets include acquired customer relationships, acquired developed technology, and acquired trade names and trademarks, which we amortize over the assets' estimated useful lives, estimated to be 10-15 years, 2-5 years, and 3 years, respectively. We also acquired intangible HSA portfolios from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We evaluate our acquired intangible assets for impairment annually, or at a triggering event.
Merger integration.    Merger integration expenses include personnel and related expenses, including severance, professional fees, and technology-related expenses directly related to the integration activities to merge operations as a result of the Acquisition.
Interest expense
Interest expense consists of interest expense and amortization of financing costs associated with our Credit Agreement.
Other expense, net
Other expense, net, primarily consists of acquisition costs and non-income-based taxes, less interest income earned on corporate cash.
Income tax provision
We are subject to federal and state income taxes in the United States based on a calendar tax year which differs from our fiscal year-end for financial reporting purposes. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or

-31-


refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. As of October 31, 2019, we have recorded a net deferred tax liability. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Due to the positive evidence of current taxable income, reversing taxable temporary differences, and forecasted profitability, no valuation allowance was required as of October 31, 2019 for most of our deferred tax assets. However, we recorded a valuation allowance of $0.2 million as of October 31, 2019 and $0.1 million as of January 31, 2019. The increase in valuation allowance recorded is a result of state tax credits that are not expected to be utilized before they expire.
Comparison of the three and nine months ended October 31, 2019 and 2018
We incurred a net loss of $21.3 million during the three months ended October 31, 2019, compared to net income of $15.7 million during the three months ended October 31, 2018, and net income of $39.9 million for the nine months ended October 31, 2019, compared to net income of $60.8 million for the nine months ended October 31, 2018, due to the factors described below. The net loss during the three months ended October 31, 2019 includes $38.5 million, net of tax, of acquisition and merger integration expenses in connection with the Acquisition of WageWorks.
The following table sets forth our revenue for the periods indicated:


Three months ended October 31,
 




Nine months ended October 31,
 
 
 
 
 
(in thousands, except percentages)

2019

 
2018


$ Change


% Change

2019

 
2018

 
$ Change

 
% Change

Service revenue
 
$
87,620

 
$
25,041

 
$
62,579

 
250
%
$
140,710

 
$
74,797

 
$
65,913

 
88
%
Custodial revenue
 
46,972

 
31,564

 
15,408

 
49
%
132,538

 
90,713

 
41,825

 
46
%
Interchange revenue

22,526


13,890


8,636


62
%
57,545

 
45,956

 
11,589

 
25
%
Total revenue

$
157,118


$
70,495


$
86,623


123
%
$
330,793

 
$
211,466

 
$
119,327

 
56
%
Service revenue
The $62.6 million, or 250%, increase in service revenue from the three months ended October 31, 2018 to the three months ended October 31, 2019 was primarily due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $61.0 million of the increase. The remainder of the increase resulted from the increase in the number of HSAs, partially offset by lower service revenue per average HSA.
The $65.9 million, or 88%, increase in service revenue from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was primarily due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $61.0 million of the increase. The remainder of the increase resulted from an increase in the number of HSAs, partially offset by lower service revenue per average HSA.
The number of our HSAs increased by approximately 1.4 million, or 37%, from October 31, 2018 to October 31, 2019, primarily due to approximately 757,000 acquired HSAs. The remainder of the increase was due to HSA portfolio acquisitions and further penetration into existing Network Partners and the addition of new Network Partners.
Service revenue as a percentage of our total revenue increased primarily due to the inclusion of WageWorks' financial results, whose total revenue is comprised primarily of service revenue, following the Acquisition.
Custodial revenue
The $15.4 million, or 49%, increase in custodial revenue from the three months ended October 31, 2018 to the three months ended October 31, 2019 was primarily due to an increase in the yield on average HealthEquity HSA cash assets from 2.14% for the three months ended October 31, 2018 to 2.48% and an increase in average daily HealthEquity HSA cash assets of $0.9 billion, or 17%. The inclusion of WageWorks' financial results following the Acquisition contributed $3.7 million of custodial revenue during the period.
The $41.8 million, or 46%, increase in custodial revenue from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was primarily due to an increase in the yield on average HealthEquity HSA cash assets from 2.10% for the nine months ended October 31, 2018 to 2.52% and an increase in average daily HealthEquity HSA cash assets of $0.9 billion, or 17%. The inclusion of WageWorks' financial results following the Acquisition contributed $3.7 million of custodial revenue during the period.

-32-


Custodial revenue as a percentage of our total revenue decreased primarily due to the inclusion of WageWorks' financial results following the Acquisition, which has relatively little custodial revenue.
Interchange revenue
The $8.6 million, or 62%, increase in interchange revenue from the three months ended October 31, 2018 to the three months ended October 31, 2019 was primarily due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $7.4 million of the increase. The remainder of the increase resulted from an overall increase in the number of average HSAs, partially offset by lower card spend per average HSA.
The $11.6 million, or 25%, increase in interchange revenue from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was primarily due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $7.4 million of the increase. The remainder of the increase was as a result of an overall increase in the number of average HSAs, partially offset by lower card spend per average HSA.
Total revenue
Total revenue increased by $86.6 million, or 123%, and $119.3 million, or 56%, from the three and nine months ended October 31, 2018 to the three and nine months ended October 31, 2019, due to the impact of the WageWorks acquisition and related realized net synergies, which contributed $72.1 million.
Cost of revenue
The following table sets forth our cost of revenue for the periods indicated:
(in thousands, except percentages)

Three months ended October 31,
 




Nine months ended October 31,
 
 
 
 
 

2019

 
2018


$ Change


% Change

2019

 
2018

 
$ Change

 
% Change

Service costs

$
52,278


$
17,562


$
34,716


198
%
$
92,672

 
$
52,808

 
$
39,864

 
75
%
Custodial costs

4,384


3,551


833


23
%
12,716

 
10,492

 
2,224

 
21
%
Interchange costs

4,421


3,565


856


24
%
13,177

 
11,418

 
1,759

 
15
%
Total cost of revenue

$
61,083


$
24,678


$
36,405


148
%
$
118,565

 
$
74,718

 
$
43,847

 
59
%
Service costs
The $34.7 million, or 198%, increase in service costs from the three months ended October 31, 2018 to the three months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $32.0 million of the increase. The remainder of the increase resulted from the higher volume of accounts being serviced, including $1.6 million due to hiring additional personnel to implement and support our new Network Partners and HSAs, increases in stock-based compensation expense of $0.6 million, and increases in other expenses of $0.5 million.
The $39.9 million, or 75%, increase in service costs from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $32.0 million of the increase. The remainder of the increase resulted from the higher volume of accounts being serviced, including a $3.5 million increase due to the hiring of additional personnel to implement and support our new Network Partners and HSAs, increases in activation and processing costs of $1.6 million, increases in stock-based compensation expense of $1.3 million, and increases in other expenses of $1.5 million.
Custodial costs
The $0.8 million, or 23%, increase in custodial costs from the three months ended October 31, 2018 to the three months ended October 31, 2019 was due to an increase in average daily HealthEquity HSA cash assets, which increased from $5.6 billion for the three months ended October 31, 2018 to $6.5 billion for the three months ended October 31, 2019. Custodial interest costs on average HealthEquity HSA cash assets decreased slightly from 0.24% for the three months ended October 31, 2018 to 0.23% for the three months ended October 31, 2019.
The $2.2 million, or 21%, increase in custodial costs from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was due to an increase in average daily HealthEquity HSA cash assets, which increased from $5.5 billion for the nine months ended October 31, 2018 to $6.4 billion for the nine months ended October 31, 2019. Custodial interest costs on average HealthEquity HSA cash assets decreased slightly from 0.24% for the nine months ended October 31, 2018 to 0.23% for the nine months ended October 31, 2019.

-33-


Interchange costs
The $0.9 million, or 24%, and $1.8 million, or 15%, increase in interchange costs for the three and nine months ended October 31, 2018 compared to the three and nine months ended October 31, 2019 was due to an overall increase in average Total Accounts, partially offset by decreased card spend per average Total Accounts. In addition, the inclusion of WageWorks' results contributed $0.5 million to the increase.
Cost of revenue
As we continue to add Total Accounts, we expect that our cost of revenue will increase in dollar amount to support our Network Partners, Clients, and members. Cost of revenue will continue to be affected by a number of different factors, including our ability to scale our service delivery, Network Partner implementation and account management functions.
Operating expenses
The following table sets forth our operating expenses for the periods indicated:
(in thousands, except percentages)

Three months ended October 31,
 
 
 
 
 
Nine months ended October 31,
 
 
 
 
 

2019

 
2018

 
$ Change

 
% Change

2019

 
2018

 
$ Change

 
% Change

Sales and marketing

$
12,654


$
7,502


$
5,152


69
%
$
30,015

 
$
21,605

 
$
8,410

 
39
%
Technology and development

23,511


8,678


14,833


171
%
46,061

 
25,055

 
21,006

 
84
%
General and administrative

19,222


9,161


10,061


110
%
37,193

 
24,561

 
12,632

 
51
%
Amortization of acquired intangible assets

13,051


1,490


11,561


776
%
16,036

 
4,438

 
11,598

 
261
%
Merger integration
 
17,675

 

 
17,675

 
n/a

20,459

 

 
20,459

 
n/a

Total operating expenses

$
86,113


$
26,831


$
59,282


221
%
$
149,764

 
$
75,659

 
$
74,105

 
98
%
Sales and marketing
The $5.2 million, or 69%, increase in sales and marketing expense from the three months ended October 31, 2018 to the three months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $3.5 million of the increase. The remainder of the increase was as a result of increased staffing of $0.9 million, increases in other expenses of $0.5 million, and higher stock-based compensation expense of $0.3 million.
The $8.4 million, or 39%, increase in sales and marketing expense from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $3.5 million of the increase. The remainder of the increase was as a result of increased staffing of $3.2 million, higher stock-based compensation expense of $0.8 million, and increases in other expenses of $0.9 million.
Technology and development
The $14.8 million, or 171%, increase in technology and development expense from the three months ended October 31, 2018 to the three months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $10.5 million of the increase. The remainder of the increase was as a result of increased personnel-related expense of $2.3 million, increases in professional fees of $2.0 million, increased stock-based compensation expense of $0.8 million, increases in amortization and depreciation of $0.3 million, and other increases of $0.9 million, which were partially offset by increases in capitalized development of $2.0 million.
The $21.0 million, or 84%, increase in technology and development expense from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $10.5 million of the increase. The remainder of the increase was as a result of increased personnel-related expense of $6.3 million, increases in professional fees of $5.4 million, increases in stock-based compensation expense of $1.9 million, increases in amortization and depreciation of $0.8 million, and other increases of $1.7 million, which were partially offset by increases in capitalized development of $5.6 million.
General and administrative
The $10.1 million, or 110%, increase in general and administrative expense from the three months ended October 31, 2018 to the three months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $9.2 million of the increase. The remainder of the increase was as a result of increases in stock-based compensation expense of $0.8 million.

-34-


The $12.6 million, or 51%, increase in general and administrative expense from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was due to the inclusion of WageWorks' financial results following the Acquisition, which contributed $9.2 million of the increase. The remainder of the increase was as a result of increased personnel-related expense of $0.8 million, increases in stock-based compensation expense of $2.3 million, and increases in other expenses of $0.3 million.
Amortization of acquired intangible assets
The $11.6 million increase in amortization of acquired intangible assets for the three and nine months ended October 31, 2019 was a result of the acquired identified intangible assets due to the Acquisition of WageWorks.
Merger integration
The $17.7 million and $20.5 million in merger integration expense for the three and nine months ended October 31, 2019 was due to integration activities directly related to the Acquisition. We expect merger integration expenses to continue for the next 24 to 36 months following the closing of the Acquisition on August 30, 2019.
Interest expense
The increase in interest expense for the three and nine months ended October 31, 2019 was due to the $1.25 billion borrowed under the Term Loan Facility to finance the Acquisition.
Other expense, net
The change in other expense, net from the three months ended October 31, 2018 to the three months ended October 31, 2019 was primarily due to acquisition costs of $32.9 million, partially offset by interest income of $2.0 million and a gain of $0.3 million in connection with the cancellation of our equity investment in WageWorks.
The change in other expense, net from the nine months ended October 31, 2018 to the nine months ended October 31, 2019 was primarily due to acquisition costs of $40.7 million, partially offset by a gain of $27.6 million in connection with the cancellation of our equity investment in WageWorks, as well as interest income on corporate cash of $5.3 million, respectively.
Income tax provision (benefit)
Income tax benefit for the three months ended October 31, 2019 was $9.9 million and income tax provision for the nine months ended October 31, 2019 was $3.9 million as compared to an income tax provision of $1.7 million and an income tax benefit of $1.3 million for the three and nine months ended October 31, 2018, respectively. The decrease in the tax provision for the three months ended October 31, 2019 was $11.6 million compared to the three months ended October 31, 2018. The increase in the tax provision for the nine months ended October 31, 2019 compared to the nine months ended October 31, 2018 was $5.2 million. The change in the three and nine months ended October 31, 2019 and 2018 was primarily due to a gain in connection with our equity investment in WageWorks that will not be realized for income tax purposes offset by a decrease in excess tax benefits from stock-based compensation expense and certain costs incurred in connection with the Acquisition of WageWorks that are not deductible for income tax purposes.
Our effective income tax rate for the three and nine months ended October 31, 2019 was a benefit of 31.7% and an expense of 8.9%, compared to a provision of 10.0% and a benefit of 2.2% for the three and nine months ended October 31, 2018. The 21.7 percentage point change for the three months ended October 31, 2019 compared to the three months ended October 31, 2018 is primarily due to a gain in connection with our equity investment in WageWorks that will not be realized for income tax purposes offset by a decrease in excess tax benefits from stock-based compensation expense and certain costs incurred in connection with the Acquisition of WageWorks that are not deductible for income tax purposes. The 11.1 percentage point increase for the nine months ended October 31, 2019 compared to the nine months ended October 31, 2018 is primarily due to a decrease in excess tax benefits from stock-based compensation expense recognized in the provision for income taxes.
Seasonality
Seasonal concentration of our growth combined with our recurring revenue model create seasonal variation in our results of operations. A significant number of new and existing Network Partners bring us new HSAs and CDBs beginning in January of each year concurrent with the start of many employers’ benefit plan years. Before we realize any revenue from these new accounts, we incur costs related to implementing and supporting our new Network Partners and new accounts. These costs of services relate to activating accounts and hiring additional staff, including seasonal help to support our member support center. These expenses begin to ramp up during our third fiscal quarter with the majority of expenses incurred in our fourth fiscal quarter.

-35-


Liquidity and capital resources
Cash and cash equivalents overview
In connection with the closing of the Acquisition on August 30, 2019, we entered into a new credit facility with Wells Fargo Bank, N.A., which includes a $350.0 million revolving credit facility. As of October 31, 2019, our principal source of liquidity was our current cash and cash equivalents balances, collections from our service, custodial and interchange revenue activities, and availability under the revolving credit facility. We rely on cash provided by operating activities to meet our short-term liquidity requirements, which primarily relate to the payment of corporate payroll and other operating costs, and capital expenditures.
As of October 31, 2019 and January 31, 2019, cash and cash equivalents were $174.6 million and $361.5 million, respectively.
Capital resources
We have a “shelf” registration statement on Form S-3 on file with the SEC. This shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings. Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, including, but not limited to, working capital, sales and marketing activities, general and administrative matters and capital expenditures, and if opportunities arise, for the acquisition of, or investment in, assets, technologies, solutions or businesses that complement our business. Pending such uses, we may invest the net proceeds in interest-bearing securities. In addition, we may conduct concurrent or other financings at any time.
On July 12, 2019, the Company closed a follow-on public offering of 7,762,500 shares of common stock at a public offering price of $61.00 per share, less the underwriters' discount. The Company received net proceeds of approximately $458.5 million after deducting underwriting discounts and commissions of approximately $14.1 million and other offering expenses payable by the Company of approximately $0.9 million.
In connection with the closing of the Acquisition on August 30, 2019, the Company entered into a new $1.6 billion Credit Agreement, consisting of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion, the net proceeds of which were used by the Company to finance the Acquisition and related transactions, and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350.0 million, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments. For a description of the terms of the Credit Agreement, refer to Note 9—Indebtedness. We were in compliance with all covenants under the Credit Agreement as of October 31, 2019.
Use of cash
From February 1, 2019 to April 4, 2019, we acquired approximately 1.6 million shares of common stock of WageWorks for $53.8 million in open market purchases. On August 30, 2019, the Acquisition closed and we paid approximately $2.0 billion in cash to WageWorks stockholders, which was funded with net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.5 million, under the above term loan, and $816.9 million of cash on hand.
Capital expenditures for the nine months ended October 31, 2019 and 2018 were $22.4 million and $10.8 million, respectively. We expect our capital expenditures to increase for the remainder of the year ending January 31, 2020 as we continue to devote capital expenditures to improve the architecture and functionality of our technology platforms. Costs to improve the architecture of our technology platforms include computer hardware, personnel and related costs for software engineering and outsourced software engineering services. In addition, we plan to devote further resources to leasehold improvements and furniture and fixtures for our office space.
We believe our existing cash and cash equivalents will be sufficient to meet our operating and capital expenditure requirements for at least the next 12 months. To the extent these current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to raise additional funds through public or private equity or debt financing. In the event that additional financing is required, we may not be able to raise it on favorable terms, if at all.

-36-


The following table shows our cash flows from operating activities, investing activities and financing activities for the stated periods:


Nine months ended October 31,
 
(in thousands)

2019

 
2018

Net cash provided by operating activities

$
74,070


$
80,785

Net cash used in investing activities

(1,715,393
)

(12,588
)
Net cash provided by financing activities

1,454,405


21,338

Increase (decrease) in cash and cash equivalents

(186,918
)

89,535

Beginning cash and cash equivalents

361,475


199,472

Ending cash and cash equivalents

$
174,557


$
289,007

Cash flows provided by operating activities. Net cash provided by operating activities during the nine months ended October 31, 2019 resulted primarily from our net income of $39.9 million, adjusted for the exclusion of non-cash items totaling $34.6 million, which included a $27.6 million gain on marketable equity securities, $28.8 million of depreciation and amortization expense, $31.2 million of stock-based compensation expense, and other non-cash items totaling $2.2 million, as well as the effect of changes in working capital and other carrying balances that resulted in cash outflows of $0.4 million.
Net cash provided by operating activities during the nine months ended October 31, 2018 resulted primarily from our net income of $60.8 million, adjusted for the exclusion of non-cash items totaling $29.8 million, which included $13.5 million of depreciation and amortization expense, $15.5 million of stock-based compensation expense, and other non-cash items totaling $0.8 million, as well as the effect of changes in working capital and other carrying balances that resulted in cash outflows of $9.7 million.
Cash flows used in investing activities. Net cash used in investing activities for the nine months ended October 31, 2019 was primarily the result of the Acquisition of WageWorks for $1.63 billion, net of cash acquired, purchases of marketable equity securities of $53.8 million. We also continued development of our proprietary system and other software necessary to support our continued account growth. Purchases of software and capitalized software development costs for the nine months ended October 31, 2019 were $17.2 million, compared to purchases of software and capitalized software development costs of $7.4 million for the nine months ended October 31, 2018. Our purchases of property and equipment increased from $3.5 million for the nine months ended October 31, 2018 to $5.2 million for the nine months ended October 31, 2019, primarily as a result of increases in computer hardware. In addition, during the nine months ended October 31, 2019, purchases of intangible member assets resulted in cash outflows of $9.1 million, compared to $1.2 million for the nine months ended October 31, 2018.
Cash flows provided by financing activities. Cash flow provided by financing activities during the nine months ended October 31, 2019 resulted primarily from net borrowings of $1.22 billion, our follow-on offering where we received net proceeds of $458.9 million from the sale of 7,762,500 shares of our common stock, and the exercise of stock options of $7.3 million, compared to $21.3 million for the nine months ended October 31, 2018. These items were offset by $231.0 million of cash used to settle Client-held funds obligations.
Contractual obligations
The following table describes our contractual obligations for long-term debt obligations, future minimum lease payments, and other contractual payments as of October 31, 2019:
Fiscal year ending January 31, (in thousands)

Less than
1 year


1-3
years


3-5
years


More than
5 years


Total

Long-term debt obligations (1)
 
31,250

 
125,000

 
1,093,750

 

 
1,250,000

Interest on long-term debt obligations (2)
 
51,867

 
97,246

 
77,809

 

 
226,922

Operating lease obligations (3)
 
11,130

 
28,420

 
20,437

 
60,250

 
120,237

Other contractual obligations (4)
 
10,268

 
13,215

 
2,664

 
101

 
26,248

Total
 
$
104,515

 
$
263,881

 
$
1,194,660

 
$
60,351

 
$
1,623,407

(1) As of October 31, 2019, maximum total borrowings under the Revolving Credit Facility is $350.0 million with a base interest rate determined in accordance with the Credit Agreement terms (see Note 8—Indebtedness). The debt maturity date is August 31, 2024. As of October 31, 2019, our outstanding principal of $1.25 billion is presented net of debt issuance costs on our consolidated balance sheets. The debt issuance costs are not included in the table above.
(2) Estimated interest payments assume the interest rate applicable as of October 31, 2019 of 4.12% per annum on a $1.25 billion outstanding principal amount.

-37-


(3) We lease office space, data storage facilities, and other leases under non-cancelable operating leases expiring at various dates through 2030.
(4) Other contractual obligations consist of processing services agreements, telephony services, immaterial capital leases, and other contractual commitments.
Off-balance sheet arrangements
During the three months ended October 31, 2019 and 2018, other than outstanding letters of credit issued under our Revolving Credit Facility, we do not have any off-balance sheet arrangements. The majority of the standby letters of credit expire in one year. However, in the ordinary course of business, we will continue to renew or modify the terms of the letters of credit to support business requirements. The letters of credit are contingent liabilities, supported by our revolving credit facility, and are not reflected on our condensed consolidated balance sheets.
Critical accounting policies and significant management estimates
Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.
Our significant accounting policies are more fully described in Note 1 of the accompanying unaudited condensed consolidated financial statements and in Note 1 to our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended January 31, 2019. Other than the adoption of ASU 2016-02 and related subsequent amendments, Leases, updates to our Investment policies, and client held funds described in Note 1 of the accompanying unaudited condensed consolidated financial statements, there have been no significant or material changes in our critical accounting policies during the nine months ended October 31, 2019, as compared to those disclosed in “Management’s discussion and analysis of financial condition and results of operations – Critical accounting policies and significant management estimates” in our Annual Report on Form 10-K for the year ended January 31, 2019.
Recent accounting pronouncements
See Note 1. Summary of business and significant accounting policies within the interim financial statements included in this Form 10-Q for further discussion.
Item 3. Qualitative and quantitative disclosures about market risk
Market risk
Concentration of market risk. We derive a substantial portion of our revenue from providing services to tax-advantaged healthcare account holders. A significant downturn in this market or changes in state and/or federal laws impacting the preferential tax treatment of healthcare accounts such as HSAs could have a material adverse effect on our results of operations. During the three months ended October 31, 2019, no one customer accounted for greater than 10% of our total revenue. We monitor market and regulatory changes regularly and make adjustments to our business if necessary.
Inflation. Inflationary factors may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain current levels of expenses as a percentage of revenue if our revenue does not correspondingly increase with inflation.
Concentration of credit risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents. We maintain our cash and cash equivalents in bank and other depository accounts, which frequently may exceed federally insured limits. Our cash and cash equivalents as of October 31, 2019 were $174.6 million, of which $2.3 million was covered by federal depository insurance. We have not experienced any material losses in such accounts and believe we are not exposed to any significant credit risk with respect to our cash and cash equivalents. Our accounts receivable balance as of October 31, 2019 was $66.6 million. We have not experienced any significant write-offs to our accounts receivable and believe that we are not exposed to significant

-38-


credit risk with respect to our accounts receivable. We continue to monitor our credit risk and place our cash, cash equivalents, and marketable securities with reputable financial institutions.
Interest rate risk
HSA Assets and Client-held funds. As of October 31, 2019, we had HSA Assets of approximately $10.5 billion and Client-held funds of $670.0 million. We have entered into depository agreements with financial institutions for our HSA Assets and Client-held funds. The contracted interest rates were negotiated at the time the depository agreements were executed. A significant reduction in prevailing market interest rates may make it difficult for us to continue to place custodial deposits at the current contracted rates.
Cash and cash equivalents. We consider all highly liquid investments purchased with an original maturity of three months or less to be unrestricted cash equivalents. Our unrestricted cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market account that is unrestricted as to withdrawal or use. As of October 31, 2019, we had unrestricted cash and cash equivalents of $174.6 million. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our cash and cash equivalents as a result of changes in interest rates.
Credit agreement. At October 31, 2019, we had $1.25 billion outstanding under our Term Loan Facility and no amounts drawn under our Revolving Credit Facility.  Our overall interest rate sensitivity under these credit facilities is primarily influenced by any amounts borrowed and the prevailing interest rates on these instruments.  The interest rate on our Term Loan Credit Facility and Revolving Credit Facility is variable and was 4.12 percent at October 31, 2019.  Accordingly, we may incur additional expense if interest rates increase in future periods.  For example, a one percent increase in the interest rate on the amount outstanding under our credit facilities at October 31, 2019 would result in approximately $12.6 million of additional interest expense over the next 12 months. 
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of October 31, 2019, the end of the period covered by this Quarterly Report on Form 10-Q. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, and subject to the below exclusion, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. 
In accordance with interpretive guidance issued by SEC staff, companies are allowed to exclude acquired businesses from the assessment of internal control over financial reporting during the first year after completion of an acquisition and from the assessment of disclosure controls and procedures to the extent subsumed in such internal control over financial reporting. In accordance with this guidance, as the Company acquired WageWorks on August 30, 2019, management's evaluation and conclusion as to the effectiveness of the Company's disclosure controls and procedures as of October 31, 2019 excluded the portion of disclosure controls and procedures that are subsumed by internal control over financial reporting of WageWorks. WageWorks’ assets and revenues represented approximately 13%, excluding the effects of purchase accounting, and approximately 46% of the Company's consolidated total assets and consolidated total revenues, respectively, as of and for the fiscal quarter ended October 31, 2019.


-39-


Material Weaknesses in Internal Control over Financial Reporting related to the WageWorks Acquisition
The Company completed the Acquisition of WageWorks on August 30, 2019, and we are currently evaluating the impact of the Acquisition on our internal control over financial reporting.
WageWorks management had assessed the effectiveness of its internal control over financial reporting as of December 31, 2018. Based on the results of that evaluation, WageWorks management concluded that its internal control over financial reporting as of December 31, 2018 was not effective due to the existence of the material weaknesses in internal control over financial reporting described below.
Control Environment, Risk Assessment, Control Activities, Information and Communication and Monitoring
It was concluded that there was an inadequate open flow, transparency, communication and dissemination of relevant and pertinent information from former WageWorks senior management concerning a complex transaction with the federal government that contributed to an ineffective control environment driven by the tone at the top. WageWorks management’s failure to timely communicate all pertinent information resulted in an environment which led to errors in the financial statements.
Based on the assessment of control environment, it was noted that WageWorks did not maintain effective internal control over financial reporting related to the following areas: control environment, risk assessment, control activities information and communication and monitoring:
WageWorks did not have processes and controls to ensure there were adequate mechanisms and oversight to ensure accountability for the performance of internal control over financial reporting responsibilities and to ensure corrective actions were appropriately prioritized and implemented in a timely manner.
WageWorks did not effectively execute a strategy to attract, develop and retain a sufficient complement of qualified resources with an appropriate level of knowledge, experience, and training in certain areas important to financial reporting.
There was not an adequate assessment of changes in risks by management that could significantly impact internal control over financial reporting or an adequate determination and prioritization of how those risks should be managed.
WageWorks did not have adequate management oversight of accounting and financial reporting activities in implementing certain accounting practices to conform to its policies and GAAP.
WageWorks did not have adequate management oversight around completeness and accuracy of data material to financial reporting.
There was a lack of robust, established and documented accounting policies and insufficiently detailed procedures to put these policies into effective action.
Wageworks was not focused on a commitment to competency as it relates to creating priorities, allocating adequate resources and establishing cross functional procedures around managing complex contracts and non-routine transactions as well as managing change and attracting, developing and retaining qualified resources.
These deficiencies in WageWorks' internal control over financial reporting contributed to the following identified material weaknesses:
A.    Accounting Close and Financial Reporting
WageWorks had inadequate or ineffective senior accounting leadership and corresponding process level and monitoring controls in the area of accounting close and financial reporting specifically, but not exclusively, around the review of account reconciliations, account estimates and related cut-off, and monitoring of the accounting close cycle and some areas of related sub-processes such as equity. WageWorks also did not have effective business processes and controls to conduct an effective review of manual data feeds into journal entries for platforms which were not integrated with the main enterprise resource planning system.
WageWorks did not have robust, established and documented accounting policies that were implemented effectively, which led to adjustments in areas such as, but not exclusive to, impairment of internally developed software (IDS) and unclaimed liability. As a result of these adjustments, the accounts related to amortization of IDS, fixed assets, and operating expenses as they relate to interest and penalties were impacted.

-40-


WageWorks also did not have a robust process around managing change and corresponding assessment and implementation of accounting policies. Furthermore, it also resulted in the delayed assessment and design of controls for the timely implementation of controls around Accounting Standard 606 (ASC 606) for Revenue Recognition, which was effective January 2018. These gaps resulted in several adjustments in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
B.    Contract to Cash Process
WageWorks did not have effective controls around the contract-to-cash life cycle. The root cause of these gaps were due to inadequate or ineffective process level controls around billing set-up during customer implementation, managing change to existing customer billing terms and conditions, timely termination of customers, implementing complex and/or non-standard billing arrangements which require manual intervention or manual controls for billing to customers, processing timely adjustments, lack of robust, established and documented policies to assess collectability and reserve for revenue, bad debts and accounts receivable, and availability of customer contracts.
These gaps resulted in several adjustments in revenue, accounts receivable, and accounts receivable reserves in the WageWorks financial statement as of the fiscal year ended December 31, 2018.
C.    Risk Assessment and Management of Change
WageWorks did not maintain an effective risk assessment and monitoring process to manage the expansion of its business. Hence, there were inadequate and ineffective business and financial reporting control activities associated with change and growth in the business. Among other areas, the assessment of the control environment and the design of manual controls around financial system implementations was not performed adequately.
As a result, WageWorks did not properly estimate, reserve and record certain transactions that resulted in errors in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
D.    Review of New, Unusual or Significant Transactions and Contracts
WageWorks did not have adequate risk assessment controls to continuously formally assess the financial reporting risks associated with executing new, significant or unusual transactions, contracts or business initiatives. As a result, WageWorks did not adequately identify and analyze changes in the business and hence implement effective process level controls and monitoring controls that were responsive to these changes and aligned with financial reporting objectives. This failure to identify and analyze changes occurred in connection with the integration of acquisitions and the monitoring and recording of certain revenues associated with a complex government contract. As a result, WageWorks did not properly account for certain transactions including revenue and customer obligation accounts, which resulted in errors in the WageWorks financial statements as of the fiscal year ended December 31, 2018.
E.    Manual Reconciliations of High-Volume Standard Transactions
WageWorks did not have effective business processes and controls as well as resources with adequate training and support to conduct an effective review of manual reconciliations including the complex data feeds into the reconciliations of high-volume standard transactions. This resulted in several errors mainly to balance sheet classifications around accounts receivable, customer obligations and other related accounts as of December 31, 2018.
F.    Information Technology General Controls (ITGC)
WageWorks did not have effective controls related to information technology general controls (ITGCs) in the areas of logical access and change-management over certain information technology (IT) systems that supported its financial reporting processes. WageWorks’ business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted. WageWorks believed that these control deficiencies were a result of IT control processes having an inadequate risk-assessment process to identify and assess changes in business environment which would impact IT environments related to internal control over financial reporting. Hence, the control design, implementation, and documentation were not enhanced to adapt to the changing business environment. There was also insufficient training of IT personnel on how to design and implement ITGCs.
In addition to the material weaknesses noted above, WageWorks management identified several significant deficiencies and other deficiencies. These deficiencies relate to several areas that are partially rooted in the weaknesses in the internal control environment documented above.

-41-


These material weaknesses and other deficiencies could result in a misstatement of the aforementioned account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.
We are assessing plans to evaluate and remediate the material weaknesses outlined above.
Changes in Internal Control Over Financial Reporting
The Acquisition of WageWorks is considered a change in the Company's internal control over financial reporting. There were no other changes in the Company's internal control over financial reporting during the fiscal quarter ended October 31, 2019 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

-42-


Part II—Other Information
Item 1. Legal Proceedings
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Our wholly owned subsidiary, WageWorks, is party to certain pending material legal proceedings. However, as of October 31, 2019, we were not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations, cash flows or financial position. For a description of these legal proceedings, see Note 7—Commitments and contingencies of the Notes to condensed consolidated financial statements.
Item 1A. Risk factors
You should carefully consider the risks described below together with the other information set forth in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K, which could materially affect our business, financial condition and future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating results. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline.
Risks relating to the Acquisition and the integration of the WageWorks business into the Company
We may experience difficulties in integrating the operations of WageWorks into our business and in realizing the expected benefits of the Acquisition.
The success of the Acquisition depends in part on our ability to realize the anticipated business opportunities from combining the operations of WageWorks with our business in an efficient and effective manner. The integration process is an expensive multi-year process that could take longer and cost more than anticipated and result in the loss of Clients.
As part of the integration process, we plan to migrate certain Clients to different technology platforms, which could result in Client attrition if we are unable to meet Client expectations or if we are unable to meet the technical requirements of our Clients. Clients may also decide to not cooperate with the platform migration process, resulting in delays to and additional costs associated with this process or the loss of those Clients. The challenges associated with the platform migration process may result in Client dissatisfaction, potentially impairing our long-term relationship with our Clients. We may also face challenges in integrating the back-office systems and people associated with these technology platforms.
Another important aspect of the integration process is the integration of prior WageWorks acquisitions, as WageWorks historically allowed its acquired companies to continue functioning relatively independently, including through the use of independent technology platforms. For example, WageWorks was not able to completely integrate its acquisition of ADP’s Consumer Health Spending Account, COBRA, and direct bill businesses, resulting in the attrition of the clients associated with this business, which may continue to occur. Failure to successfully integrate these prior acquisitions as part of our overall integration process may adversely impact our ability to succeed as a combined company. 
The integration process has also resulted, and may continue to result in, the loss of team members, as some legacy HealthEquity team members and legacy WageWorks team members have decided to seek alternative employment, including members of the WageWorks finance team. In addition, our management team and other team members are spending significant amounts of time on integration efforts, which may distract our management team and other team members from their other responsibilities.
Integration could also disrupt each company's ongoing businesses, result in tax inefficiencies, or create inconsistencies in standards, controls, information technology systems, procedures and policies, any of which could adversely affect our ability to maintain relationships with third parties, or our ability to achieve the anticipated benefits of the Acquisition, and could harm our financial performance. In addition, it may be more difficult for us to accurately forecast our business and results of operations until we become more familiar with the WageWorks business.
If we are unable to successfully or timely integrate the operations of WageWorks with our business, we may incur unanticipated costs and be unable to realize the revenue growth, synergies and other anticipated benefits resulting

-43-


from the Acquisition, and our business, results of operations and financial condition could be materially and adversely affected.
The synergies attributable to the Acquisition may vary from expectations.
We may fail to realize our anticipated benefits and synergies expected from the Acquisition, which could adversely affect our business, financial condition and operating results. The success of the Acquisition will depend, in significant part, on our ability to successfully integrate the acquired business, grow the revenue of the combined company and realize the anticipated strategic benefits and synergies from the combination. We believe that the addition of WageWorks complements our strategy by giving us access to more of the fast-growing HSA market by expanding our direct distribution to employers and benefits advisors as a single source, premier provider of HSAs and complementary CDBs. However, achieving these goals requires growth of the revenue of the combined company, realization of target custodial and other revenue synergies and realization of the targeted cost synergies expected from the Acquisition. This growth and the anticipated benefits of the transaction may not be realized fully or at all, or may take longer or cost more to realize than expected. Actual operating, technological, strategic and revenue opportunities, if achieved at all, may be less significant than expected or may take longer or cost more to achieve than anticipated. If we are not able to achieve these objectives and realize the anticipated benefits and synergies expected from the Acquisition within the anticipated timing or at all, our business, financial condition and operating results may be adversely affected.
The restatement of WageWorks’ previously issued financial results resulted in securities class action and shareholder litigation, as well as government investigations that could result in enforcement actions, which could have a material adverse impact on us.
WageWorks and certain of its former directors and officers are subject to securities class action and shareholder litigation relating to its previous public disclosures. In addition, WageWorks and certain of its former directors and officers are subject to government investigations arising out of the misstatements in its previously issued financial statements. See Note 7—Commitments and contingencies of the Notes to condensed consolidated financial statements for a description of these legal proceedings and investigations. The legal proceedings may result in substantial liability and other adverse consequences. In addition, WageWorks could become subject to additional private litigation or investigations, or one or more government enforcement actions, arising out of alleged misstatements in its previously issued financial statements. Our management team has been and may continue to be required to devote significant time and attention to these matters, and these and any additional matters that arise could have a material adverse impact on our results of operations, financial condition, liquidity and cash flows. We may also incur significant additional expenses in connection with these proceedings and investigations in order to defend this litigation and to fulfill indemnification obligations to former officers and directors of WageWorks.
WageWorks previously identified material weaknesses in its internal control over financial reporting which could, if not remediated, adversely affect our ability to report our financial condition and results of operations in a timely and accurate manner.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. WageWorks determined previously that its internal control over financial reporting was not effective due to the existence of unremediated material weaknesses in its internal control over financial reporting. See Item 4 - Controls and Procedures for a description of WageWorks' material weaknesses in its internal control over financial reporting.
We are developing a remediation plan designed to address the material weaknesses, but our remediation efforts are ongoing. If our remedial measures are insufficient to address the material weaknesses, or if additional material weaknesses or significant deficiencies in our internal control are discovered or occur in the future, it may materially adversely affect our ability to report our financial condition and results of operations in a timely and accurate manner. If we are unable to report our results in a timely and accurate manner, we may not be able to comply with the applicable covenants in our Credit Agreement, and may be required to seek waivers or repay amounts under the Credit Agreement earlier than anticipated, which could adversely impact our liquidity and financial condition. Although we continually review and evaluate internal control systems to allow management to report on the sufficiency of our internal controls over financial reporting, we cannot assure you that we will not discover additional weaknesses in our internal control over financial reporting.



-44-


The complexity of the integration and transition associated with the Acquisition, together with the resulting increased scale and national presence, may affect our internal control over financial reporting and ability to effectively and timely report financial results.
The additional scale of the combined company's operations, together with the complexity of the integration effort, including the integration of, changes to or implementation of critical information technology systems, may adversely affect our ability to report financial results on a timely basis. In addition, we have to train new employees and third-party providers. The Acquisition requires significant modifications to our internal control systems, processes and information systems, both on a transition basis and over the longer-term as we fully integrate the combined company. Due to the complexity of the Acquisition, we cannot be certain that changes to our internal control over financial reporting will be effective for any period, or on an ongoing basis. If we are unable to accurately report our financial results in a timely manner or are unable to assert that our internal controls over financial reporting are effective, our business, financial condition and results of operations, and the market perception thereof, may be materially adversely affected.
WageWorks may have liabilities that are not known at this time.
As a result of the Acquisition, WageWorks became our subsidiary, subject to all of its liabilities, including the class action and derivative lawsuits and SEC investigation described above, as well as contractual indemnification obligations to its Clients arising from WageWorks' service delivery issues. There could be unasserted claims, assessments or contractual indemnification obligations that we failed or were unable to discover or identify in the course of performing due diligence investigations of WageWorks. Any such liabilities, individually or in the aggregate, could have a material adverse effect on our financial results. We may learn additional information about WageWorks that adversely affects us, such as unknown, unasserted or contingent liabilities and issues relating to compliance with applicable laws.
Risks relating to our business and industry
Our business is fundamentally dependent upon the availability and adoption of tax-advantaged health accounts and other CDBs by consumers and employers. Any diminution in, elimination of, or change in the availability of tax benefits or use of these accounts would materially adversely affect our results of operations, financial condition, business and prospects.
Substantially all of our revenue is earned from transactions involving tax-advantaged health accounts, such as HSAs, HRAs, FSAs, COBRA administration and other CDBs. Based on our experience with our customers, we believe that many consumers are not familiar with, or do not fully appreciate, the tax-advantaged benefits of HSAs and other similar tax-advantaged healthcare savings arrangements and CDBs. If employers reduce or cease to offer HSA, HRA, FSA or other CDB programs, the tax benefits for these accounts are reduced or eliminated, or the rate of adoption of these accounts decreases, our results of operations, financial condition, business and prospects would be materially and adversely affected.
Our industry is rapidly evolving and undergoing significant technological change. If we are not successful in adapting to the evolving environment and promoting and improving the benefits of our technology platforms, our growth may be limited, and our business may be adversely affected.
The market for our products and services is subject to rapid and significant change and competition. The market for technology-enabled services that empower healthcare consumers and consumers of other CDBs is characterized by rapid technological change, new product and service introductions, evolving industry standards, changing customer needs, existing competition and the entrance of non-traditional competitors. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of this market due in part to our rapidly evolving industry and the substantial resources available to our existing and potential competitors. It is uncertain whether our market will achieve and sustain high levels of demand and market adoption. In order to remain competitive, we are continually involved in a number of projects to develop new services or compete with these new market entrants. These projects carry risks, such as cost overruns, delays in delivery, performance problems and lack of acceptance by our customers.
Our success depends to a substantial extent on the willingness of consumers to increase their use of technology platforms to manage their saving and spending through HSAs and other CDBs, the ability of our platforms to increase consumer engagement, and our ability to demonstrate the value of our platforms to our existing customers and potential customers. If our existing customers do not recognize or acknowledge the benefits of our platforms or our platforms do not drive consumer engagement, then the market for our products and services might develop more slowly than we expect, which could adversely affect our operating results. In addition, we have limited insight into trends that might develop and affect our business. We might make errors in predicting and reacting to relevant

-45-


business, legal and regulatory trends, which could harm our business. If any of these events occur, it could materially adversely affect our business, financial condition or results of operations.
Finally, our competitors may have the ability to devote more financial and operational resources than we can to developing new technologies and services, including services that provide improved operating functionality, and adding features to their existing service offerings. If successful, their development efforts could render our services less desirable, resulting in the loss of our existing customers or a reduction in the fees we earn from our products and services.
We may be unable to compete effectively against our current and future competitors, which could have a material adverse effect on our results of operations, financial condition, business and prospects.
The market for our products and services is highly competitive, rapidly evolving and fragmented. We view our competition in terms of direct and indirect competitors. Our direct HSA competitors are HSA custodians that include state or federally chartered banks, such as Webster and Optum Bank, insurance companies, well-known retail investment companies, such as Fidelity Investments, and non-bank custodians approved by the U.S. Treasury as meeting certain ownership, capitalization, expertise and governance requirements. The HSA market is highly fragmented. We also have numerous indirect HSA competitors, including benefits administrators and health plans, that license technology platforms and partner with other HSA custodians to provide "white label" HSA offerings. Increased focus on HSA-favorable healthcare regulatory reforms may create renewed interest and investment by our competitors in their HSA offerings and lead to greater competition, which could make it harder for us to maintain our growth trajectory. Our competitors may also offer reduced fee or no-fee HSAs, which may permit them to increase market share in our market and lead to customer and Network Partner attrition, or cause us to reduce our fees; and this risk could be compounded if legal requirements or administrative rules are interpreted in a way that makes compliance more onerous for us than for our competitors. Our other CDB competitors include health insurance carriers, human resources consultants and outsourcers, payroll providers, national CDB specialists, regional third-party administrators and commercial banks. If one or more of our competitors were to merge or partner with another of our competitors, the change in the competitive landscape could materially adversely affect our ability to compete effectively. Our competitors may also establish or strengthen cooperative relationships with our current or future Network Partners or other strategic partners, thereby limiting our ability to promote our solution with these parties. Our Health Plan and Administrator Partners may also decide to offer HSAs or other CDBs directly, which would significantly reduce our channel partner opportunities.
Well-known retail mutual fund companies, such as Fidelity Investments, have entered the HSA business and Fidelity and other mutual fund companies may decide to expand their presence in the market. These investment companies have significant advantages over us in terms of brand name recognition, years of experience managing tax-advantaged retirement accounts (e.g., 401(k) and IRA), highly developed recordkeeping, trust functions, and fund advisory and customer relations management, among others. If we are unable to compete effectively with new competitors, our results of operations, financial condition, business and prospects could be materially adversely affected.
Many of our competitors, in particular banks, insurance companies, and other financial institutions, have longer operating histories and significantly greater financial, technical, marketing and other resources than we have. As a result, some of these competitors may be in a position to devote greater resources to the development, promotion, sale and support of their products and services and have offered, or may in the future offer, a wider range of products and services that are increasingly desired by potential customers, and they may also use advertising and marketing strategies that (including loss-leaders) achieve broader brand recognition or acceptance.
Developments in the rapidly changing healthcare industry could adversely affect our business.
Substantially all of our revenue is derived from healthcare-related saving and spending by consumers, which could be affected by changes affecting the broader healthcare industry, including decreased spending in the industry overall. General reductions in expenditures by healthcare industry participants could result from, among other things:
government regulation or private initiatives that affect the manner in which healthcare industry participants interact with consumers and the general public;
consolidation of healthcare industry participants;
reductions in governmental funding for healthcare; and
adverse changes in general business or economic conditions affecting healthcare industry participants.
Even if general expenditures by industry participants remain the same or increase, developments in the healthcare industry may result in reduced spending in some or all of the specific market segments that we serve now or in the

-46-


future. The healthcare industry has changed significantly in recent years, and we expect that significant changes will continue to occur. However, the timing and impact of developments in the healthcare industry are difficult to predict. We cannot assure you that the demand for our products and services will continue to exist at current levels or that we will have adequate technical, financial and marketing resources to react to changes in the healthcare industry.
If our members do not continue to utilize our payment cards, our results of operations, business and prospects would be materially adversely affected.
We derived 17% and 22% of our total revenue during nine months ended October 31, 2019 and October 31, 2018, respectively, from fees that are paid to us when our customers utilize our payment cards. These fees represent a percentage of the expenses transacted on each card. If our customers do not use these payment cards at the rate we expect, if they elect to withdraw funds using a non-revenue generating mechanism such as direct reimbursement, or if other alternatives to these payment cards develop, our results of operations, business and prospects would be materially adversely affected.
Data security, technological and intellectual property risks
As one of the largest providers of HSAs and other CDBs, we are frequently the target of cyber-attacks or other privacy or data security incidents. If our security measures are breached or unauthorized access to data is otherwise obtained, our technology platforms may be perceived as not being secure, our customers may reduce the use of, or stop using, our products and services, we may incur significant liabilities, our reputation may be harmed and we could lose sales and customers.
Our proprietary technology platforms enable the exchange of, and access to, sensitive information, and, as a result, we are frequently the target of cyber-attacks or other privacy or data security incidents. As a result of the Acquisition, we are one of the largest providers of HSAs and other CDBs and therefore an even more attractive target for cyber-attacks. The Acquisition has also added several new technology platforms that we must now secure and monitor.
Security breaches could result in the loss of this sensitive information, theft or loss of actual funds, litigation, indemnity obligations to our customers, fines and other liabilities, including under laws that protect the privacy of personal information, disrupt our operations and the services we provide to our members and Network Partners, damage our reputation and cause a loss of confidence in our products and services. While we have security measures in place, we have experienced data privacy incidents, including several incidents in 2018. As a result, or if our security measures are breached again or unauthorized access to data is otherwise obtained as a result of third-party action, employee error or otherwise, our reputation could be significantly damaged, our business may suffer and we could incur substantial liability which could result in loss of sales and customers.
In addition, we are continuing to evaluate the security measures associated with the technology platforms used by WageWorks, and we may find that current security measures for these platforms are not sufficient. The integration of the WageWorks technology platforms with our technology platforms may create further vulnerabilities in our systems. If third parties improperly obtain and use the personal information of our customers, we may be required to expend significant resources to resolve these problems.
A major breach of our network security and systems could have serious negative consequences for our businesses, including:
possible fines, penalties and damages;
reduced demand for our services;
an unwillingness of consumers and other data owners to provide us with their payment information;
an unwillingness of customers and other data owners to provide us with personal information; and
harm to our reputation and brand.
Because techniques used to obtain unauthorized access to or sabotage systems change frequently and generally are not identified until they are launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. Any or all of these issues could negatively impact our ability to attract new customers and increase engagement by existing customers, and/or subject us to third-party lawsuits, regulatory fines, contractual liability and/or other action or liability, thereby harming our operating results.




-47-


We have incurred, and expect to continue to incur, significant costs to protect against security breaches. We may incur significant additional costs in the future to address problems caused by our previous or any further security breaches. Cybersecurity breaches could compromise our data and the data of our customers and partners, which may expose us to liability and would likely cause our business and reputation to suffer.
Our ability to ensure the security of our technology platforms and thus sensitive customer and partner information is critical to our operations. We rely on standard Internet and other security systems to provide the security and authentication necessary to effect secure transmission of data. Despite our security measures, our information technology and infrastructure is vulnerable to cybersecurity threats, including attacks by hackers and other malfeasance. Such security breaches could compromise our networks and result in the information stored or transmitted there to be accessed, publicly disclosed, lost or stolen. Such access, disclosure or other loss of information could result in legal claims or proceedings leading to liability, including under laws that protect the privacy of personal information, disrupt our operations and the services we provide to our clients, damage our reputation and cause a loss of confidence in our products and services, which could adversely affect our business, operations and competitive position.
Fraudulent and other illegal activity involving our products and services, including our payment cards, could lead to financial and reputational damage to us and reduce the use and acceptance of our technology platforms.
Criminals are using increasingly sophisticated methods to capture personal information in order to engage in illegal activities such as counterfeiting and identity theft. We rely upon third parties for some transaction processing services, data feeds, and vendors, which subjects us to risks related to the vulnerabilities of those third parties. For example, we are exposed to risks relating to the theft of payment card numbers housed in a merchant's point of sale systems if our members use our payment cards at a merchant whose systems are compromised. We may make our customers whole for losses sustained when using our payment cards, even in instances where we are not directly responsible for the underlying cause of such loss. A single significant incident of fraud, or increases in the overall level of fraud, involving our payment cards, our custodial accounts or our reimbursement administration services, could result in financial and reputational damage to us, which could reduce the use and acceptance of our products and services, or cause our customers to cease doing business with us.
We rely on software licensed from third parties that may be difficult to replace or that could cause errors or failures of our technology platforms that could lead to lost customers or harm to our reputation.
We rely on certain cloud-based software licensed from third parties to run our business. This software may not continue to be available to us on commercially reasonable terms and any loss of the right to use any of this software could result in delays in the provisioning of our products and services until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated, which could harm our business. In addition, we have certain service level agreements with certain of our employer clients for which the availability of this software is critical. Any decrease in the availability of our service as a result of errors, defects, a disruption or failure of our licensed software may require us to provide significant fee credits or refunds to our customers. Our software licensed from third parties is also subject to change or upgrade, which may result in our incurring significant costs to implement such changes or upgrades.
Developing and implementing new and updated applications, features and services for our technology platforms may be more difficult than expected, may take longer and cost more than expected, or may result in the platforms not operating as expected, which may harm our operating results or may not result in sufficient increases in revenue to justify the costs.
Attracting and retaining new customers requires us to continue to improve the technology underlying our proprietary technology platforms and requires our technology to operate as expected. In addition, customers are increasingly seeking a bundled solution, encompassing a wide range of features. Accordingly, we must continue to develop new and updated applications, features and services, and maintain existing applications, features and services. If we are unable to do so on a timely basis or if we are unable to implement new applications, features and services that enhance our customers’ experience without disruption to our existing ones or if we encounter technical obstacles that result in the technology not operating properly, we may lose potential and existing customers. We rely on a combination of internal development, strategic relationships, licensing and acquisitions to develop our content offerings and HSA and CDB services. These efforts may:
cost more than expected;
take longer than originally expected;

-48-


require more testing than originally anticipated;
require significant cost to address or resolve technical defects or obstacles;
require additional advertising and marketing costs; and
require the acquisition of additional personnel and other resources.
The revenue opportunities earned from these efforts may fail to justify the amounts spent. In addition, material performance problems, defects or errors in our existing or new software may occur in the future, which may harm our operating results.
Our technology platforms are hosted by third-party data centers. Any disruption of service at our facilities or our third-party hosting providers could interrupt or delay our customers’ access to our products and services, which could harm our operating results.
The ability of our team members, members, Health Plan and Administrator Partners and Employer Partners to access our technology platforms is critical to our business. We cannot ensure that the measures we have taken will be effective to prevent or minimize interruptions to our operations. Our facilities and our third-party data centers are vulnerable to interruption or damage from a number of sources, many of which are beyond our control, including, without limitation:
extended power loss;
telecommunications failures from multiple telecommunications providers;
natural disaster or an act of terrorism;
software and hardware errors, or failures in our own systems or in other systems;
network environment disruptions such as computer viruses, hacking and similar problems in our own systems and in other systems;
theft and vandalism of equipment; and
actions or events caused by or related to third parties.
We attempt to mitigate these risks through various business continuity efforts, including redundant infrastructure, 24/7/365 system activity monitoring, backup and recovery procedures, use of a secure storage facility for backup media, separate test systems and change management and system security measures, but our precautions may not protect against all potential problems. Our data recovery centers are equipped with physical space, power, storage and networking infrastructure and Internet connectivity to support our technology platforms in the event of the interruption of services at our data centers. Even with these data recovery centers, our operations would be interrupted during the transition process should our primary data center experience a failure. Disruptions at our data centers could cause disruptions to our online platforms and data loss or corruption. We have experienced interruptions and delays in service and availability for data centers, and bandwidth and other technology issues in the past. Any future errors, failure, interruptions or delays experienced in connection with these third-party technologies could delay our customers’ access to our products, which would harm our business. This could damage our reputation, subject us to potential liability or costs related to defending against claims or cause our customers and strategic partners to cease doing business with us, any of which could negatively impact our revenue.
Interruption or failure of our information technology and communications systems could impair our ability to effectively deliver our products and services, which could cause us to lose customers and harm our operating results.
Our business depends on the continuing operation of our technology infrastructure and systems. Any damage to or failure of our systems could result in interruptions in our ability to deliver our products and services. Interruptions in our service could reduce our revenue and profits, and our reputation could be damaged if people believe our systems are unreliable. Our systems and operations are vulnerable to damage or interruption from earthquakes, terrorist attacks, floods, fires, power loss, break-ins, hardware or software failures, telecommunications failures, computer viruses or other attempts to harm our systems and similar events.
Any unscheduled interruption in our service could result in an immediate loss of revenue. Frequent or persistent system failures that result in the unavailability of our technology platforms or slower response times could reduce our customers’ ability to access our platforms, impair our delivery of our products and services and harm the perception of our platforms as reliable, trustworthy and consistent. Our insurance policies provide only limited coverage for service interruptions and may not adequately compensate us for any losses that may occur due to any failures or interruptions in our systems.
Some of our technology platforms may link to or utilize open source software, and any failure to comply with the terms of one or more of these open source licenses could negatively affect our business.

-49-


Some of our technology platforms may incorporate software covered by open source licenses. The terms of various open source licenses have not been interpreted by United States courts, and there is a risk that such licenses could be construed in a manner that imposes unfavorable conditions on us. For example, by the terms of certain open source licenses, we could be required to offer our technology platforms that incorporate the open source software for no cost, that we make publicly-available source code for modifications or derivative works that we created based upon, incorporating or using the open source software, and/or that we license such modifications or derivative works under the terms of the particular open source license.  If portions of our proprietary software are determined to be subject to an open source license, then the value of our technologies and services could be reduced. In addition to risks related to license requirements, usage of open source software may be riskier than use of third-party commercial software, as open source licensors generally do not provide warranties or controls on the origin of the software. Many of the risks associated with usage of open source software cannot be eliminated and could negatively affect our business.
We must adequately protect our brands and the intellectual property rights related to our products and services and avoid infringing on the proprietary rights of others.
We believe that the HealthEquity and WageWorks brands are critical to the success of our business, and we utilize trademark registration and other means to protect these brands. Our business would be harmed if we were unable to protect our brands against infringement and the value of our brands was to decrease as a result.
We rely on a combination of trademark and copyright laws, trade secret protection and confidentiality and license agreements to protect the intellectual property rights related to our products and services such as our applications and the content on our website. We also rely on intellectual property licensed from third parties. We may unknowingly violate the intellectual property or other proprietary rights of others and, thus, may be subject to claims by third parties. If so, we may be required to devote significant time and resources to defending against these claims or to protecting and enforcing our own rights. As a result of any such dispute, we may have to:
develop non-infringing technology;
pay damages;
enter into royalty or licensing agreements;
cease providing certain products or services; or
take other actions to resolve the claims.
Additionally, we have largely relied, and expect to continue to rely, on copyright, trade secret and trademark laws, as well as generally relying on confidentiality procedures and agreements with our team members, consultants, customers and vendors, to control access to, and distribution of, technology, software, documentation and other confidential information. Despite these precautions, it may be possible for a third party to copy or otherwise obtain, use or distribute our technology without authorization, particularly in foreign jurisdictions where some of our intellectual property rights may not be protected by intellectual property laws. If this were to occur, we could lose revenue as a result of competition from products infringing or misappropriating our technology and intellectual property and we may be required to initiate litigation to protect our proprietary rights and market position. U.S. copyright, trademark and trade secret laws offer us only limited protection and the laws of some foreign countries do not protect proprietary rights to the same extent. Accordingly, defense of our trademarks and proprietary technology may become an increasingly important issue as we continue to expand our operations.
Policing unauthorized use of our trademarks and technology is difficult and the steps we take may not prevent misappropriation of the trademarks or technology on which we rely. If competitors are able to use our trademarks or technology without recourse, our ability to compete would be harmed and our business would be materially and adversely affected. We may elect to initiate litigation in the future to enforce or protect our proprietary rights or to determine the validity and scope of the rights of others.
The loss of our intellectual property or the inability to secure or enforce our intellectual property rights or to defend successfully against an infringement action could harm our business, results of operations, financial condition and prospects.
If we fail to develop further brand awareness cost-effectively, our business may suffer.
We believe that developing and maintaining awareness of our brands in a cost-effective manner is critical to achieving widespread acceptance of our products and services and attracting new customers and strategic partners. Brand promotion activities may not generate customer awareness or increase revenue, and even if they do, any increase in revenue may not offset the expenses we incur in building our brands. If we fail to successfully promote and maintain our brands, or incur substantial expenses, we may fail to attract or retain a sufficient number

-50-


of customers and strategic partners necessary to realize a sufficient return on our brand-building efforts, or to achieve the widespread brand awareness that is critical for broad customer adoption of our products and services.
Confidentiality arrangements with team members and others may not adequately prevent disclosure of trade secrets and other proprietary information.
We have devoted substantial resources to the development of our technology, business operations and business plans. In order to protect our trade secrets and proprietary information, we rely in significant part on confidentiality arrangements with our team members, independent contractors, advisers and customers. These arrangements may not be effective to prevent disclosure of confidential information, including trade secrets, and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information, and in such cases we would not be able to assert trade secret rights against such parties. The loss of trade secret protection could make it easier for third parties to compete with our products and services by copying functionality. In addition, any changes in, or unexpected interpretations of, the trade secret and other intellectual property laws may compromise our ability to enforce our trade secret and intellectual property rights. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
If we cannot protect our domain name, our ability to successfully promote our brand will be impaired.
We currently own the web domain names www.healthequity.com and www.wageworks.com, which are critical to the operation of our business. The acquisition and maintenance of domain names, or Internet addresses, is generally regulated by governmental agencies and their designees. The regulation of domain names in the U.S. is subject to change. Governing bodies may establish additional top-level domains, appoint additional domain name registrars or modify the requirements for holding domain names. Furthermore, it is unclear whether laws protecting trademarks and similar proprietary rights will be extended to protect domain names. Therefore, we may be unable to prevent third parties from acquiring domain names that are similar to, infringe upon or otherwise decrease the value of our trademarks and other proprietary rights. We may not be able to successfully implement our business strategy of establishing strong branding if we cannot prevent others from using similar domain names or trademarks. This failure could impair our ability to increase our market share and revenue.
Legal and regulatory risks
The healthcare regulatory and political framework is uncertain and evolving, and we cannot predict the effect that further healthcare reform and other changes in government programs may have on our business, financial condition or results of operations.
Healthcare laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and results of operations. For example, the Affordable Care Act, which includes a variety of healthcare reform provisions and requirements that may become effective at varying times through 2022, substantially changes the way healthcare is financed by both governmental and private insurers and may significantly impact our industry. Further changes to the Affordable Care Act and related healthcare regulation remain under consideration. For example, it is unclear whether the “Cadillac Tax”, now delayed until 2022, will be modified so that employee contributions to FSAs and HSAs are excluded from the calculation or if the entire tax will be repealed. If employers are less incentivized to offer our products and services to employees because of the Cadillac Tax, the resulting increased regulatory burdens, costs or other impacts, could materially adversely affect our results of operations and financial condition, business and prospects.
In addition, current proposals to implement a single payer or "Medicare for all" system in the U.S., if adopted would likely have a material adverse effect on our business. The full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is unknown, and we are unable to predict what effect the Affordable Care Act or other healthcare reform measures that may be adopted in the future will have on our business.
Changes in applicable federal and state laws relating to the tax benefits available through tax-advantaged healthcare accounts such as HSAs and other healthcare-related CDBs would materially adversely affect our business.
The efforts of governmental and third-party payers to raise revenue or contain or reduce the costs of healthcare as well as legislative and regulatory proposals aimed at changing the U.S. healthcare system, which could include restructuring the tax benefits available through HSAs, HRAs, FSAs, and similar tax-advantaged healthcare accounts, may adversely affect our business, operating results, and financial condition. For example, the federal

-51-


government or states may seek to raise revenues by enacting tax laws that eliminate the tax deductions available to individuals who contribute to HSAs. Our business is substantially dependent on the tax benefits available through HSAs and other healthcare related CDBs. We cannot predict if any new healthcare reforms will ultimately become law, or if enacted, what their terms or the regulations promulgated pursuant to such reforms will be. If the laws or regulations are changed to limit or eliminate the tax benefits available through these accounts, such a change would have a material adverse effect on our business.
We are subject to privacy regulations, including regarding the access, use and disclosure of personally identifiable information.  If we or any of our third-party vendors experience a privacy breach, it could result in substantial financial and reputational harm, including possible criminal and civil penalties.
State and federal laws and regulations govern the collection, dissemination, access and use of personally identifiable information, including HIPAA and HITECH, which govern the treatment of protected health information, and the Gramm-Leach Bliley Act, which governs the treatment of nonpublic personal information. In the provision of services to our customers, we and our third-party vendors may collect, access, use, maintain and transmit personally identifiable information in ways that are subject to many of these laws and regulations. Although we have implemented measures to comply with these privacy laws, rules and regulations, we have experienced data privacy incidents. Any further unauthorized disclosure of personally identifiable information experienced by us or our third-party vendors could result in substantial financial and reputational harm, including possible criminal and civil penalties. In many cases, we are subject to HIPAA and other privacy regulations because we are a business associate providing services to covered entities; as a result, the covered entities direct HIPAA compliance matters in the event of a security breach, which complicates our ability to address harm caused by the breach. Additionally, as we have in connection with prior security incidents, we may be required to report breaches to partners, regulators, state attorney generals, and impacted individuals depending on the severity of the breach, our role, legal requirements and contractual obligations.
Privacy regulation has become a priority issue in many states, and as such the regulatory environment is continually changing. For example, the California Consumer Privacy Act ("CCPA") will come into effect on January 1, 2020. The CCPA requires companies, such as ours, that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, and allows consumers to opt out of certain data sharing with third parties and provides a new cause of action for data breaches. Other governmental authorities are also considering legislative and regulatory proposals concerning data protection. 
Continued compliance with current and potential new privacy laws, rules and regulations and meeting consumer expectations with respect to the control of personal data in a rapidly changing technology environment could result in higher compliance and technology costs for us, as well as costly penalties in the event we are deemed to no be in compliance with such laws, rules and regulations.
Changes in laws and regulations relating to interchange fees on payment card transactions would adversely affect our revenue and results of operations.
Existing laws and regulations limit the fees or interchange rates that can be charged on payment card transactions. For example, the Federal Reserve Board has the power to regulate payment card interchange fees and has issued a rule setting a cap on the interchange fee an issuer can receive from a single payment card transaction. Our HSA-linked payment cards are exempt from this rule (although we are subject to a general requirement of reasonable compensation for services rendered). To the extent that our payment cards lose their exempt status, the interchange rates applicable to transactions involving our payment cards could be impacted, which would decrease our revenue and profit and could have a material adverse effect on our financial condition and results of operations.
Changes in credit card association or other network rules or standards set by Visa or MasterCard, or changes in card association and debit network fees or products or interchange rates, could materially adversely affect our results of operations, business and financial position.
We, and the banks that issue our prepaid debit cards, are subject to Visa and MasterCard association rules that could subject us to a variety of fines or penalties that may be levied by the card associations or networks for acts or omissions by us or businesses that work with us, including card processors. The termination of the card association registrations held by us or any of the banks that issue our cards, or any changes in card association or other debit network rules or standards, including interpretation and implementation of existing rules, participants deciding to use PIN networks, standards or guidance that increase the cost of doing business or limit our ability to provide our products and services, or limit our ability to receive interchange fees, could have a material adverse effect on our results of operations, financial condition, business and prospects. In addition, from time-to-time, card associations increase the organization or processing fees that they charge, which could increase our operating expenses, reduce

-52-


our profit margin and materially adversely affect our results of operations, financial condition, business and prospects.
We are subject to complex regulation, and any compliance failures or regulatory action could adversely affect our business.
Our business, including many of the CDB plans we administer and our investment adviser and trust company subsidiaries, is subject to extensive, complex and frequently changing federal and state laws and regulations, including IRS, Health and Human Services (“HHS”), and Department of Labor (“DOL”) regulations; ERISA, HIPAA, HITECH and other privacy and data security regulations; the Advisors Act; state banking laws; and the Patient Protection and Affordable Care Act.
Our subsidiary HealthEquity Advisors, LLC is an SEC-registered investment adviser that provides automated web-only investment advisory services. As such, it must comply with the requirements of the Advisers Act and related SEC regulations and is subject to periodic inspections by the SEC staff. Such requirements relate to, among other things, fiduciary duties to clients, disclosure obligations, recordkeeping and reporting requirements, marketing restrictions, limitations on agency cross and principal transactions between the adviser and its clients, and general anti-fraud prohibitions. The SEC is authorized to institute proceedings and impose sanctions for violations of the Advisers Act, ranging from fines and censure to termination of an investment adviser’s registration. Investment advisers also are subject to certain state securities laws and regulations.
Our subsidiary HealthEquity Trust Company is a non-depository trust company and subject to regulation and supervision by the Wyoming Division of Banking.
Compliance with regulatory requirements may divert internal resources and take significant time and effort. Any claim of non-compliance, regardless of merit or ultimate outcome, could subject us to investigation by the HHS, the DOL, the SEC, the Wyoming Division of Banking or other regulatory authorities. This in turn could result in additional claims or class action litigation brought on behalf of our members or Network Partners, any of which could result in substantial cost to us and divert management’s attention and other resources away from our operations. Furthermore, investor perceptions of us may suffer, and this could cause a decline in the market price of our common stock. Our compliance processes may not be sufficient to prevent assertions that we failed to comply with any applicable law, rule or regulation. In addition, all of our business is subject, to varying degrees, to fiduciary and other service provider obligations under ERISA, the Internal Revenue Code, and underlying regulations. A failure to comply could subject us to disgorgement of profits, excise taxes, civil penalties, private lawsuits, and other costs, including reputational harm.
If we are unable to meet or exceed the net worth test required by the IRS, we could be unable to maintain our non-bank custodian status, which would have a material adverse impact on our ability to operate our business.
As a non-bank custodian, we are required to comply with Treasury Regulations Section 1.408-2(e), or the Treasury Regulations, including the net worth requirements set forth therein. If we should fail to comply with the Treasury Regulations’ non-bank custodian requirements, including the net worth requirements, such failure would materially and adversely affect our ability to maintain our current custodial accounts and grow by adding additional custodial accounts, and it could result in the institution of procedures for the revocation of our authorization to operate as a non-bank custodian.
Risks relating to our partners and service providers
Our distribution model relies on the cooperation of our Network Partners. If our Network Partners choose to partner with other providers of technology-enabled services that empower healthcare consumers, including HSA services, or otherwise reduce offering, or cease to offer, our products and services, our business could be materially and adversely affected.
Our business depends on our Network Partners’ willingness to partner with us to offer their customers and/or employees our products and services. In particular, certain of our Network Partners enjoy significant market share in various geographic regions. If these Network Partners choose to partner with our competitors, or otherwise reduce offering, or cease to offer, our products and services, our results of operations, business and prospects could be materially adversely affected.


-53-


We rely on a limited number of bank identification number sponsors for our payment cards, and a change in relationship with any of these sponsors or the failure by these sponsors to comply with certain banking regulations could materially and adversely affect our business.
We rely on a limited number of bank identification number, or BIN, sponsors in relation to the payment cards we issue. A BIN sponsor is a bank or credit union that provides the BIN that allows a prepaid card program to run on one of the major card brand networks (e.g., VISA, MasterCard, Discover or American Express). Our BIN sponsors enable us to link the payment cards that we offer our members to the VISA and Mastercard networks, thereby allowing our members to use our payment cards to pay for expenses with a “swipe” of the card. If any material adverse event were to affect our BIN sponsors, including a significant decline in the financial condition of any of our BIN sponsors, a decline in the quality of service provided by our BIN sponsors, the inability of our BIN sponsors to comply with applicable banking and financial service regulatory requirements, systems failure or the inability of our BIN sponsors to pay us fees, our business, financial condition and results of operations could be materially and adversely affected because we may be forced to reduce the availability of, or eliminate entirely, our payment card offering. In addition, we do not have long-term contracts with our BIN sponsors, and our BIN sponsors may increase the fees charged to us or terminate our relationship. If we were required to change BIN sponsors, we could not accurately predict the success of such change or that the terms of our agreement with a new BIN sponsor would be as favorable to us, especially in light of the recent increased regulatory scrutiny of the payment card industry, which has rendered the market for BIN sponsor services less competitive.
We rely on our federally insured custodial depository partners for certain custodial account services from which we earn fees. A business failure in any federally insured custodial depository partner would materially and adversely affect our business.
As a non-bank custodian, we rely on our federally insured custodial partners to hold our custodial cash assets. If any material adverse event were to affect one of our federally-insured custodial depository partners, including a significant decline in its financial condition, a decline in the quality of its service, loss of deposits, its inability to comply with applicable banking and financial services regulatory requirements, systems failure or its inability to pay us fees, our business, financial condition and results of operations could be materially and adversely affected. If we were required to change custodial depository partners, we could not accurately predict the success of such change or that the terms of our agreement with a new depository partner would be as favorable to us as our current agreements, especially in light of the consolidation in the banking industry, which has rendered the market for federally-insured retail banking services less competitive.
We receive important services from third-party vendors. Replacing them would be difficult and disruptive to our business.
We have entered into contracts with third-party vendors to provide critical services relating to our business, including the integration of the legacy WageWorks business into the legacy HealthEquity business, the redesign of our HSA technology platform, fraud management and other customer verification services, transaction processing and settlement, telephony services, and card production. In addition, WageWorks uses third-party vendors for its call centers and COBRA claims and transaction processing and also uses one of our competitors for other services. In the event that these service providers fail to maintain adequate levels of support, do not provide high quality service, increase the fees they charge us, discontinue their lines of business, terminate our contractual arrangements or cease or reduce operations, we may suffer additional costs and be required to pursue new third-party relationships, which could harm our reputation, materially disrupt our operations and our ability to provide our products and services, and could divert management’s time and resources. If we are unable to complete a transition to a new provider on a timely basis, or at all, we could be forced to temporarily or permanently discontinue certain services, which could disrupt services to our customers and adversely affect our business, financial condition and results of operations. We may also be unable to establish comparable new third-party relationships on as favorable terms or at all, which could materially and adversely affect our business, financial condition and results of operations.
Acquisition and growth-related risks
As part of our acquisition strategy, we seek to acquire or invest in other companies or technologies, which could divert management’s attention, fail to be consummated, or even if consummated, fail to meet our expectations, result in additional dilution to our stockholders, increase expenses, disrupt our operations and harm our operating results.
We have in the past acquired, and, as part of our strategy, seek to acquire or invest in, assets, businesses, products or technologies that we believe could complement or expand our products and services, enhance our technical

-54-


capabilities or otherwise offer growth opportunities. There is no assurance that we will be successful in consummating such acquisitions, or even if consummated, realize the anticipated benefits of these or any future acquisitions. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses related to identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated.
There are inherent risks in integrating and managing acquisitions. If we acquire additional businesses, we may not be able to assimilate or integrate the acquired personnel, operations and technologies successfully or effectively manage the combined business following the acquisition, and our management may be distracted from operating our business. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including, without limitation:
unanticipated costs or liabilities associated with the acquisition;
incurrence of acquisition-related costs, which would be recognized as a current period expense;
inability to earn sufficient revenue to offset acquisition or investment costs;
the inability to maintain relationships with customers and partners of the acquired business;
the difficulty of incorporating acquired technology and rights into our technology platforms and of maintaining quality and security standards consistent with our brand;
the need to integrate or implement additional controls, procedures and policies;
harm to our existing business relationships with customers and strategic partners as a result of the acquisition;
the diversion of management’s time and resources from our core business;
the potential loss of key team members;
use of resources that are needed in other parts of our business and diversion of management and employee resources;
our ability to coordinate organizations that are geographically diverse and that have different business cultures;
our inability to comply with the regulatory requirements applicable to the acquired business;
the inability to recognize acquired revenue in accordance with our revenue recognition policies; and
use of substantial portions of our available cash or the incurrence of debt to consummate the acquisition.
Acquisitions also increase the risk of unforeseen legal liability, including for potential violations of applicable law or industry rules and regulations, arising from prior or ongoing acts or omissions by the acquired businesses which are not discovered by due diligence during the acquisition process. Generally, if an acquisition fails to meet our expectations, our operating results, business and financial condition may suffer. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our business, results of operations or financial condition. Even if we are successful in completing and integrating an acquisition, the acquisition may not perform as we expect or enhance the value of our business as a whole.
We must be able to operate, integrate and scale our technology effectively to match our business growth.
Our ability to continue to provide our products and services to a growing number of customers, as well as to enhance our existing products and services, attract new customers and strategic partners, offer new products and services and integrate the legacy WageWorks business into our business, is dependent on our information technology systems. If we are unable to manage the technology associated with our business effectively, we could experience increased costs, reductions in system availability and customer loss. We are currently investing in a significant modernization of our proprietary technology platforms to ensure continued performance at scale, to reduce spending on maintenance activities and to enable us to execute technology innovation more quickly. If we are unsuccessful in implementing these upgrades to our platforms, we may be unable to adequately meet the needs of our customers and/or implement technology-based innovation in response to a rapidly changing market, which could harm our reputation and adversely impact our business, financial condition and results of operations.
Failure to manage future growth effectively could have a material adverse effect on our business, financial condition and results of operations.
The continued rapid expansion and development of our business, including as a result of the Acquisition, may place a significant strain upon our management and administrative, operational and financial infrastructure. As of October 31, 2019, we had approximately 5.0 million HSAs and $10.5 billion in HSA Assets representing growth of 37% and 48%, respectively, from October 31, 2018. For the nine months ended October 31, 2019, our total revenue and Adjusted EBITDA were approximately $330.8 million and $135.1 million, respectively, which represents year-over-year growth rates of approximately 56% and 48%, respectively. See “Key financial and operating metrics” for the definition of Adjusted EBITDA and a reconciliation of net income, the most comparable GAAP measure, to

-55-


Adjusted EBITDA. Our growth strategy contemplates further increasing the number of our HSAs and our HSA Assets at relatively higher growth rates than industry averages. However, the rate at which we have been able to add new HSAs in the past may not be indicative of the rate at which we will be able to add additional HSAs in the future.
Our success depends in part upon the ability of our executive officers to manage growth effectively. Our ability to grow also depends upon our ability to successfully hire, train, supervise, and manage new team members, obtain financing for our capital needs, expand our systems effectively, control increasing costs, allocate our human resources optimally, maintain clear lines of communication between our operational functions and our finance and accounting functions, and manage the pressures on our management and administrative, operational and financial infrastructure. There can be no assurance that we will be able to accurately anticipate and respond to the changing demands we will face as we continue to expand our operations or that we will be able to manage growth effectively or to achieve further growth at all. If our business does not continue to grow or if we fail to effectively manage any future growth, our business, financial condition and results of operations could be materially and adversely affected.
We plan to extend and expand our products and services and introduce new products and services, and we may not accurately estimate the impact of developing, introducing and updating these products and services on our business.
We intend to continue to invest in technology and development to create new and enhanced products and services to offer our customers and to enhance the capabilities of our platforms. We may not be able to anticipate or manage new risks and obligations or legal, compliance or other requirements that may arise in these areas. The anticipated benefits of such new and improved products and services may not outweigh the costs and resources associated with their development. Some new services may be received negatively by our existing and/or potential customers and strategic partners and have to be put on hold or canceled entirely.
Our ability to attract and retain new customer revenue from existing customers will depend in large part on our ability to enhance and improve our existing products and services and to introduce new products and services. The success of any enhancement or new product or service depends on several factors, including the timely completion, introduction and market acceptance of the enhancement or new product or service. Any new product or service we develop or acquire may not be introduced in a timely or cost-effective manner and may not achieve the broad market acceptance necessary to earn significant revenue. If we are unable to successfully develop or acquire new products or services or enhance our existing products or services to meet member or network partner requirements, our results of operations, financial condition, business or prospects may be materially adversely affected.
We have recorded a significant amount of intangible assets, which increased substantially as a result of the Acquisition. We may need to record write-downs from future impairments of identified intangible assets and goodwill, which could adversely affect our costs and business operations.
Our consolidated balance sheet includes significant intangible assets, including approximately $1.3 billion in goodwill and $796.2 million in intangible assets, together representing approximately 83% of our total assets as of October 31, 2019. The determination of related estimated useful lives and whether these assets are impaired involves significant judgments. We test our goodwill for impairment each fiscal year, but we also test goodwill and other intangible assets for impairment at any time when there is a change in circumstances that indicates that the carrying value of these assets may be impaired. Any future determination that these assets are carried at greater than their fair value could result in substantial non-cash impairment charges, which could significantly impact our reported operating results.
Risks relating to our service and culture
Any failure to offer high-quality customer support services could adversely affect our relationships with our customers and strategic partners and our operating results.
Our customers depend on our support and customer education organizations to educate them about, and resolve technical issues relating to, our products and services. We may be unable to respond quickly enough to accommodate short-term increases in customer demand for education and support services. Increased customer demand for these services, without a corresponding increase in revenue, could increase costs and adversely affect our operating results. In addition, our sales process is highly dependent on the reputation of our products, services and business and on positive recommendations from our existing customers. Further, WageWorks uses third-party vendors for its call centers and COBRA claims and transaction processing, including certain offshore vendors, which vendors may not provide the same quality of support services for our Clients and members. Any failure to maintain high-quality education and technical support, or a market perception that we do not maintain high-quality education support, could adversely affect our reputation, our ability to sell our products and services to existing and

-56-


prospective customers and our business and operating results. We promote 24/7/365 education and support along with our proprietary technology platforms. Interruptions or delays that inhibit our ability to meet that standard may hurt our reputation or ability to attract and retain customers.
We rely on our management team and key team members and our business could be harmed if we are unable to retain qualified personnel.
Our success depends, in part, on the skills, working relationships and continued services of our founder and senior management team and other key personnel. While we have entered into offer letters or employment agreements with certain of our executive officers, all of our team members are “at-will” employees, and their employment can be terminated by us or them at any time, for any reason and without notice, subject, in certain cases, to severance payment rights. In order to retain valuable team members, in addition to salary and cash incentives, we provide stock options and other equity-based awards that vest over time or based on performance. The value to team members of these awards will be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract offers from other organizations. The departure of key personnel could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. Volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart.
Our success also depends on our ability to attract, retain, and motivate additional skilled management personnel. For example, competition for qualified personnel in our field and geographic market is intense due to the limited number of individuals who possess the skills and experience required by our industry, particularly in the technology-related fields. In addition, we have experienced employee turnover as a result of the Acquisition and expect to continue to experience employee turnover in the future. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New team members may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. If our retention efforts are not successful or our employee turnover rate increases in the future, our business will be harmed.
If we cannot maintain our corporate culture as we grow, we could lose the innovation, teamwork, passion and focus on execution that we believe contribute to our success, and our business may be harmed.
We believe that a critical component to our success has been our corporate culture. We have invested substantial time and resources in building our team. As we continue to grow, including through the integration of WageWorks team members, we may find it difficult to maintain these important aspects of our corporate culture. Any failure to preserve our culture could negatively affect our future success, including our ability to retain and recruit personnel and to effectively focus on and pursue our corporate objectives.
Financing, tax and related risks
We may require significant capital to fund our business, and our inability to generate and obtain such capital could harm our business, operating results, financial condition, and prospects.
To fund our expanding business, we must have sufficient working capital to continue to make significant investments in our service offerings, advertising, technology, and other activities. As a result, in addition to the revenue we earn from our business, we may need additional equity or debt financing to provide the funds required for these endeavors. If such financing is not available on satisfactory terms or at all, we may be unable to operate or expand our business in the manner and at the rate desired. The debt we incurred in connection with the Acquisition of WageWorks may make it more challenging to incur additional debt, as the associated Credit Agreement includes prohibitions against incurring additional debt without approval from our existing lenders, and other lenders may not be willing to take on the risk of adding to our existing leverage, In addition, debt financing increases expenses, may contain covenants that restrict the operation of our business and must be repaid regardless of operating results. Equity financing, or debt financing that is convertible into equity, could result in additional dilution to our existing stockholders, and any new securities we issue could have rights, preferences and privileges superior to those associated with our common stock. Furthermore, the current economic environment may make it difficult for us to raise additional capital or obtain additional credit, when needed, on acceptable terms or at all.
Our inability to generate or obtain the financial resources needed to fund our business and growth strategies may require us to delay, scale back or eliminate some or all of our operations or the expansion of our business, which may have a material adverse effect on our business, operating results, financial condition and prospects.

-57-


The terms of our credit facility require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility.
On August 30, 2019, we entered into a new $1.6 billion Credit Agreement, which consists of (i) a five-year senior secured term loan A facility in the aggregate principal amount of $1.25 billion and (ii) a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350 million. The Credit Agreement is secured by a lien covering substantially all of our assets. The Credit Agreement contains customary affirmative and negative covenants, including covenants related to the following subjects: mergers, and sales of assets; limitations on the incurrence of certain liens; limitations on certain indebtedness; limitations on the ability to pay dividends; certain affiliate transactions; and financial performance covenants. If we default under the Credit Agreement, the lenders will be able to declare all obligations immediately due and payable and take control of our pledged assets, potentially requiring us to renegotiate the Credit Agreement on terms less favorable to us or to immediately cease operations. The lenders' rights to repayment would be senior to the rights of the holders of our common stock to receive any proceeds.
We may be adversely affected by interest rate changes due to the floating interest rate under our Credit Agreement.
Borrowings under the Credit Agreement bear interest at an annual rate equal to, at the option of the Company, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As such, our financial position may be adversely affected by fluctuations in interest rates.
A decline in interest rate levels, including an environment of negative interest rates, or lower asset values due to market conditions or other factors may reduce our ability to earn income on our HSA Assets and client-held funds and to attract HSA contributions, which would adversely affect our profitability.
As a non-bank custodian, we partner with our Depository Partners to hold our HSA Assets and other client-held funds. We earn a significant portion of our consolidated revenue from fees we earn from our Depository Partners, approximately 40% in the nine months ended October 31, 2019. A decline in prevailing interest rates or a negative interest rate environment may negatively affect our business by reducing the yield we realize on our HSA Assets and other client-held funds. In addition, if we do not offer competitive interest rates, our members may choose another HSA custodian. Similarly, if the value of the invested funds we hold declines, whether due to market conditions or other factors, our fees, which are based on a percentage of the asset values, would be adversely affected. Any such scenario could materially and adversely affect our business and results of operations.
Our ability to secure insurance may not be sufficient to cover potential liabilities.
We maintain various forms of liability insurance coverage, including coverage for errors and omissions, fiduciary, cybersecurity, employment practices, directors and officers insurance. It is possible, however, that claims could exceed the amount of our applicable insurance coverage, if any, or that this coverage may not continue to be available on acceptable terms or in sufficient amounts. Even if these claims do not result in liability to us, investigating and defending against them could be expensive and time-consuming and could divert management’s attention away from our operations. In addition, negative publicity caused by these events may affect the current market acceptance of our products and services, any of which could materially adversely affect our reputation and our business. Finally, our post-Acquisition liability insurance may not be sufficient to provide the combined company with all of the types of coverage mentioned above.
We are subject to taxes in numerous jurisdictions. Legislative, regulatory and legal developments involving income taxes could adversely affect our results of operations and cash flows.
We are subject to U.S. federal, U.S. state income, payroll, property, sales and use, and other types of taxes in numerous jurisdictions. Significant judgment is required in determining our provisions for income taxes. Changes in tax rates, enactments of new tax laws, revisions of tax regulations, and claims or litigation with taxing authorities could result in substantially higher taxes.
If one or more jurisdictions successfully assert that we should have collected or in the future should collect additional sales and use taxes on our fees, we could be subject to additional liability with respect to past or future sales and the results of our operations could be adversely affected.
We do not collect sales and use taxes in all jurisdictions in which our customers are located, based on our belief that such taxes are not applicable. Sales and use tax laws and rates vary by jurisdiction and such laws are subject to interpretation. In those jurisdictions and in those cases where we do believe sales taxes are applicable, we

-58-


collect and file timely sales tax returns. Currently, such taxes are minimal. Jurisdictions in which we do not collect sales and use taxes may assert that such taxes are applicable, which could result in the assessment of such taxes, interest and penalties, and we could be required to collect such taxes in the future. This additional sales and use tax liability could adversely affect the results of our operations.
Acts of terrorism, acts of war and other unforeseen events may cause damage or disruption to us or our customers, which could materially and adversely affect our business, financial condition and operating results.
Natural disasters, acts of war, terrorist attacks and the escalation of military activity in response to such attacks or otherwise may have negative and significant effects, such as imposition of increased security measures, changes in applicable laws, market disruptions and job losses. Such events may have an adverse effect on the economy in general. Moreover, the potential for future terrorist attacks and the national and international responses to such threats could affect the business in ways that cannot be predicted. The effect of any of these events or threats could have a material adverse effect on our business, financial condition and results of operations.
Risks relating to owning our common stock
If we are unable to maintain effective internal controls over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.
As a public company, we are required to maintain internal controls over financial reporting and to report any material weaknesses in such internal controls. A material weakness is a deficiency, or a combination of deficiencies, in financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. Section 404 of the Sarbanes-Oxley Act, or Sarbanes-Oxley, requires that we evaluate and determine the effectiveness of our internal controls over financial reporting and provide a management report on internal controls over financial reporting. Sarbanes-Oxley also requires that our management report on internal controls over financial reporting be attested to by our independent registered public accounting firm. As described above, these risks are magnified as we integrate Wageworks into our internal controls and seek to rectify WageWorks' various material weaknesses.
If we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. If we identify material weaknesses in our internal controls over financial reporting, if we are unable to comply with the requirements of Section 404 of Sarbanes-Oxley in a timely manner, if we are unable to assert that our internal controls over financial reporting are effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected. In addition, we could become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources.
Our quarterly operating results may fluctuate significantly from period to period, which could adversely impact the value of our common stock.
Our quarterly operating results, including our revenue, gross profit, net income and cash flows, may vary significantly in the future, which could cause our stock price to decline rapidly, may lead analysts to change their long-term models for valuing our common stock, could cause short-term liquidity issues, may impact our ability to retain or attract key personnel or cause other unanticipated issues. In addition, our operating results will be impacted by the Acquisition of WageWorks and may impact our ability to achieve the expectations of research analysts and investors. If our quarterly operating results or guidance fall below the expectations of research analysts or investors, the price of our common stock could decline substantially. Our quarterly operating expenses and operating results may vary significantly in the future and period-to-period comparisons of our operating results may not be meaningful. You should not rely on the results of one quarter as an indication of future performance.
The market price of our common stock has been, and may continue to be, volatile.
The stock market in general has been highly and increasingly volatile. The market price and trading volume for our common stock has been, and may continue to be, highly volatile, and investors in our common stock may experience a decrease in the value of their shares, including decreases unrelated to our operating performance or prospects. Factors that could cause the market price of our common stock to fluctuate significantly include:
our operating and financial performance and prospects and the performance of other similar companies;
our quarterly or annual earnings or those of other companies in our industry;

-59-


conditions that impact demand for our products and services;
the public’s reaction to our press releases, financial guidance and other public announcements, and filings with the SEC;
changes in earnings estimates or recommendations by securities or research analysts who track our common stock;
market and industry perception of our success, or lack thereof, in pursuing our growth strategy;
our ability to integrate the operations of WageWorks and to realize the expected synergies and other benefits of the Acquisition;
changes in short-term interest rates or expectations of what short-term interest rates will be;
strategic actions by us or our competitors, such as acquisitions or restructurings;
any data breaches or interruptions in our services;
changes in government and other regulations, particularly those relating to the benefits of HSAs and other CDBs;
changes in accounting standards, policies, guidance, interpretations or principles;
arrival and departure of key personnel;
sales of common stock by us, our investors or members of our Board and management team; and
changes in general market, economic and political conditions in the U.S. and global economies or financial markets, including those resulting from natural disasters, telecommunications failure, cyber-attack, civil unrest in various parts of the world, acts of war, terrorist attacks or other catastrophic events.
Any of these factors may result in large and sudden changes in the trading volume and market price of our common stock and may prevent you from being able to sell your shares at or above the price you paid for your shares of our common stock. Following periods of volatility in the market price of a company’s securities, stockholders often file securities class-action lawsuits against such company. Our involvement in a class-action lawsuit could divert our senior management’s attention and, if adversely determined, could have a material and adverse effect on our business, financial condition and results of operations.
We do not intend to pay regular cash dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
We have no current plans to declare and pay any cash dividends for the foreseeable future. We currently intend to retain all our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future and the success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.
Future offerings of debt or equity securities, which may rank senior to our common stock, may adversely affect the market price of our common stock.
If we decide to issue debt securities in the future, which would rank senior to shares of our common stock, it is likely that they will be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Additionally, any equity securities or convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of our common stock and may result in dilution to owners of our common stock. We and, indirectly, our stockholders will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, holders of our common stock will bear the risk of our future offerings reducing the market price of our common stock and diluting the value of their shareholdings in us.
Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable.
Certain provisions in our governing documents could make a merger, tender offer or proxy contest involving us difficult; even if such events would be beneficial to the interests of our stockholders. These provisions include the inability of our stockholders to act by written consent and certain advance notice procedures with respect to stockholder proposals and nominations for candidates for the election of directors. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law which, subject to certain exceptions, prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Accordingly, our board of directors could rely upon these or other provisions in our governing documents and Delaware law to prevent or delay a transaction involving a change in control of our company, even if doing so would benefit our stockholders.

-60-




Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or team members.
Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim for breach of a fiduciary duty owed by any of our directors and officers to us or our stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other team members, which may discourage such lawsuits against us and our directors, officers and other team members. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.
Item 6. Exhibits
 
 
 
Incorporate by reference
Exhibit
no.
 
Description
Form
File No.
Exhibit
Filing Date
10.1
 

S-1
333-173709
10.1
July 19, 2011
10.2
 


8-K
001-36568
10.2
August 30, 2019
10.3
 
S-1
333-173709
10.3
July 19, 2011
10.4
 
S-1
333-173709
10.11
April 25, 2011
10.5
 
S-1
333-173709
10.12
April 25, 2011
10.6
 
S-1
333-173709
10.25
June 8, 2011
10.7
 
S-1
333-173709
10.13
April 25, 2011
10.8
 
S-1
333-173709
10.14
April 25, 2011
10.9
 
S-1
333-173709
10.15
April 25, 2011
10.10
 
S-1
333-173709
10.16
April 25, 2011
10.11
 
S-1
333-173709
10.17
April 25, 2011

-61-


 
 
 
Incorporate by reference
Exhibit
no.
 
Description
Form
File No.
Exhibit
Filing Date
10.12
 
S-1
333-173709
10.18
April 25, 2011
10.13
 
10-K
001-35232
10.26
February 26, 2015
10.14
 
10-K
001-35232
10.27
February 26, 2015
10.15
 
10-K
001-35232
10.27A
February 26, 2015
10.16
 
10-K
001-35232
10.27B
February 26, 2015
10.17
 
10-K
001-35232
10.27C
February 26, 2015
10.18
 
10-K
001-35232
10.27D
February 26, 2015
10.19
 
10-Q
001-35232
10.1
May 5, 2015
10.20
 
10-Q
001-35232
10.2
May 5, 2015
10.21
 
10-Q
001-35232
10.3
May 5, 2015
10.22
 
10-Q
001-35232
10.36
August 8, 2019
31.1+
 
 
 
 
 
31.2+
 
 
 
 
 
32.1*#
 
 
 
 
 
32.2*#
 
 
 
 
 

-62-


 
 
 
Incorporate by reference
Exhibit
no.
 
Description
Form
File No.
Exhibit
Filing Date
101.INS
 
XBRL Instance document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
 
101.SCH
 
Inline XBRL Taxonomy schema linkbase document
 
 
 
 
101.CAL
 
Inline XBRL Taxonomy calculation linkbase document
 
 
 
 
101.DEF
 
Inline XBRL Taxonomy definition linkbase document
 
 
 
 
101.LAB
 
Inline XBRL Taxonomy labels linkbase document
 
 
 
 
101.PRE
 
Inline XBRL Taxonomy presentation linkbase document
 
 
 
 
104
 
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended October 31, 2019, formatted in Inline XBRL.

 
 
 
 
+
 
Filed herewith.
*
 
Furnished herewith.
#
 
These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference in any filing the registrant makes under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.

-63-


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
HEALTHEQUITY, INC.
Date: December 5, 2019
By:
 
/s/ Darcy Mott

 
Name:
 
Darcy Mott
 
Title:
 
Executive Vice President and Chief Financial Officer

-64-
EX-31.1 2 exhibit311-ceo302x2019.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Jon Kessler, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: December 5, 2019
 
 
 
 
By:
 
/s/ Jon Kessler

Name:
 
Jon Kessler
Title:
 
Chief Executive Officer
 (Principal Executive Officer)



EX-31.2 3 exhibit312-cfo302x2019.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
Certification of Principal Financial Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Darcy Mott, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: December 5, 2019
 
 
 
By:
 
/s/ Darcy Mott

Name:
 
Darcy Mott
Title:
 
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)



EX-32.1 4 exhibit321-ceo906x2019.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jon Kessler, the Chief Executive Officer (Principal Executive Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.
Our Quarterly Report on Form 10-Q for the quarter ended October 31, 2019 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: December 5, 2019
 
 
 
 
By:
 
/s/ Jon Kessler

Name:
 
Jon Kessler
Title:
 
Chief Executive Officer
(Principal Executive Officer)



EX-32.2 5 exhibit322-cfo906x2019.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Darcy Mott, Executive Vice President and Chief Financial Officer (Principal Financial Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.
Our Quarterly Report on Form 10-Q for the quarter ended October 31, 2019 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: December 5, 2019
 
 
 
 
By:
 
/s/ Darcy Mott

Name:
 
Darcy Mott
Title:
 
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 



EX-101.SCH 6 hqy-20191031.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2107100 - Disclosure - Business combination link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Business combination (Acquired Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Business combination (Consideration Transferred) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Business combination (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - Business combination (Pro Forma Results) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Business combination (Tables) link:presentationLink link:calculationLink link:definitionLink 2134100 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2434403 - Disclosure - Commitments and contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2434402 - Disclosure - Commitments and contingencies Operating Lease Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2334301 - Disclosure - Commitments and contingencies Operating Lease Maturity (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed consolidated balance sheets link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Condensed consolidated balance sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed consolidated statements of cash flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink 2136100 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2436401 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2135100 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 2435403 - Disclosure - Indebtedness (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2435402 - Disclosure - Indebtedness Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2435404 - Disclosure - Indebtedness Schedule of Maturities of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2335301 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Intangible assets and goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2428403 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Leases (Lease Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2422404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Leases (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2422405 - Disclosure - Leases (Supplemental Cash Flow Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Net income (loss) per share link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Net income (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2139100 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 2439405 - Disclosure - Stock-based compensation (Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2439404 - Disclosure - Stock-based compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2439407 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2439403 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details) link:presentationLink link:calculationLink link:definitionLink 2439406 - Disclosure - Stock-based compensation (Stock option activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2439402 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 2339301 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of business and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Summary of business and significant accounting policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of business and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Supplemental financial statement information link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Supplemental financial statement information (Other expense, net) (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Supplemental financial statement information (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hqy-20191031_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hqy-20191031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hqy-20191031_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold improvements Leasehold Improvements [Member] Furniture and fixtures Furniture and Fixtures [Member] Computer equipment Computer Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Depreciation expense Depreciation Interest income Investment Income, Nonoperating Gain on marketable equity securities Equity Securities, FV-NI, Gain (Loss) Acquisition costs Business Combination, Acquisition Related Costs Other expense Other Nonoperating Expense Total other expense, net Other Nonoperating Income (Expense) Business Combinations [Abstract] Total Consideration Paid Schedule of Business Acquisitions, by Acquisition [Table Text Block] Preliminary Allocation of Consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Preliminary Allocation of Consideration Paid to Acquired Identified Intangible Assets Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Earnings Per Share [Abstract] Net income (loss) per share Earnings Per Share [Text Block] Commitments and Contingencies Disclosure [Abstract] Operating lease liability maturity schedule Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Principles of consolidation Consolidation, Policy [Policy Text Block] Basis of presentation Basis of Accounting, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Investments in equity securities Investment, Policy [Policy Text Block] Client-held funds Client Held Funds [Policy Text Block] Client Held Funds [Policy Text Block] Recent adopted and issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Business combination Business Combination Disclosure [Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] WageWorks, Inc WageWorks Inc. [Member] WageWorks Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Operating lease right-of-use assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Goodwill Goodwill Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Client-held funds obligation Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Total consideration paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Property and equipment Property, Plant and Equipment [Table Text Block] Other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Statement of Financial Position [Abstract] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, issued (in shares) Preferred Stock, Shares Issued Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common Stock, Shares, Issued Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Goodwill and Intangible Assets Disclosure [Abstract] Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair value Fair Value Disclosures [Text Block] Leases [Abstract] Leases Lessee, Operating Leases [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Software and software development costs Software and Software Development Costs [Member] Acquired HSA portfolios Acquired HSA Intangible Assets [Member] Acquired HSA Intangible Assets [Member] Acquired customer relationships Customer Relationships [Member] Acquired developed technology Developed Technology Rights [Member] Acquired trade names Trade Names [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Amortizable intangible assets, gross Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Total amortizable intangible assets, net Finite-Lived Intangible Assets, Net Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-process software development costs In Process Research and Development [Member] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Acquired in-process software development costs Indefinite-lived Intangible Assets (Excluding Goodwill) Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Lease cost Lease, Cost [Table Text Block] Operating lease liability maturity schedule Lessee, Operating Lease, Liability, Maturity [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Limited partnership Limited Partnership For Early Stage Companies In Healthcare Industry [Member] Limited Partnership For Early Stage Companies In Healthcare Industry [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Limited partnership Technology Based Financial Healthcare Products Limited Partnership [Member] Technology Based Financial Healthcare Products Limited Partnership [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Merger related costs, price per share Business Acquisition, Share Price Aggregate fair value of WageWorks stock acquired Business Combination, Consideration Transferred Investment ownership percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Equity method investment ownership percentage Equity Method Investment, Ownership Percentage Equity method investments Equity Method Investments Non-marketable equity securities Equity Securities without Readily Determinable Fair Value, Amount Remaining operating lease terms Lessee, Operating Lease, Remaining Lease Term Lessee, Operating Lease, Remaining Lease Term Lease renewal terms extension Lessee, Operating Lease, Renewal Term Client-held funds, total Client Held Funds, Total Client Held Funds, Total Client held funds, included in corporate cash Client Held Funds, Included In Corporate Cash Client Held Funds, Included In Corporate Cash Client-held funds, non-assets Client Held Funds, Off-Balance Sheet Client Held Funds, Off-Balance Sheet Segregated client-held funds Payments To Settle Client Held Funds Payments To Settle Client Held Funds Operating lease liabilities Operating Lease, Liability Operating lease right of use asset Operating Lease, Right-of-Use Asset Income Statement [Abstract] Statement [Table] Statement [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Service revenue Service [Member] Custodial revenue Financial Service, Other [Member] Interchange revenue Credit and Debit Card [Member] Statement [Line Items] Statement [Line Items] Revenue: Revenues [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Cost of revenue: Cost of Revenue [Abstract] Total cost of revenue Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Sales and marketing Selling and Marketing Expense Technology and development Research and Development Expense General and administrative General and Administrative Expense Amortization of acquired intangible assets Amortization Of Acquired Intangible Amortization of Acquired Intangible Merger integration Business Combination, Integration Related Costs Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Interest expense Interest Expense Other expense, net Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax provision (benefit) Income Tax Expense (Benefit) Net income (loss) Net Income (Loss) Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net income (loss) per share: Earnings Per Share, Basic and Diluted [Abstract] Basic (in usd per share) Earnings Per Share, Basic Diluted (in usd per share) Earnings Per Share, Diluted Weighted-average number of shares used in computing net income (loss) per share: Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Intangible assets Finite-lived Intangible and Indefinite-lived Intangible Assets Acquired Finite-lived Intangible and Indefinite-lived Intangible Assets Acquired Fair value Finite-lived Intangible Assets Acquired Useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Capitalized software development costs Capitalized Computer Software, Additions Software development costs incurred and expensed Research and Development Expense, Software (Excluding Acquired in Process Cost) Amortization expense Amortization of Intangible Assets Goodwill Goodwill, Acquired During Period Change in goodwill Goodwill, Period Increase (Decrease) Schedule of earnings (loss) per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Line of Credit [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Cash paid Payments to Acquire Businesses, Gross Borrowing pursuant to term loan facility Business Combination, Consideration Transferred, Liabilities Incurred Lender fees Debt Issuance Costs, Gross Acquisition costs Contribution of revenue Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Operating expenses Business Combination, Pro Forma Information, Operating Expenses Since Acquisition Date, Actual Business Combination, Pro Forma Information, Operating Expenses Since Acquisition Date, Actual Debt Disclosure [Abstract] Term loan facility Long-term Debt, Gross Unamortized loan issuance costs Debt Issuance Costs, Net Total Long-term Debt Revenue Business Acquisition, Pro Forma Revenue Net income (loss) Business Acquisition, Pro Forma Net Income (Loss) Equity Interest Type [Axis] Equity Interest Type [Axis] Equity Interest Issued or Issuable, Type [Domain] Equity Interest Issued or Issuable, Type [Domain] WageWorks stock acquired Common Stock [Member] Equity awards exchanged for cash attributable to pre-Acquisition service Equity Awards Exchanged For Cash Attributable To Pre-Acquisition Service [Member] Equity Awards Exchanged For Cash Attributable To Pre-Acquisition Service [Member] Equity awards replaced attributable to pre-Acquisition service Equity Awards Assumed Attributable To Pre-Acquisition Service [Member] Equity Awards Assumed Attributable To Pre-Acquisition Service [Member] Aggregate fair value of WageWorks stock acquired Business Combination, Consideration Transferred, Payments To Acquire And Liabilities Incurred Business Combination, Consideration Transferred, Payments To Acquire And Liabilities Incurred Fair value of equity awards Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair value of previously owned investment in WageWorks stock Business Combination, Consideration Transferred, Equity Interests Previously Owned Business Combination, Consideration Transferred, Equity Interests Previously Owned Total consideration paid Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Remaining 2020 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2021 Long-term Debt, Maturities, Repayments of Principal in Year Two 2022 Long-term Debt, Maturities, Repayments of Principal in Year Three 2023 Long-term Debt, Maturities, Repayments of Principal in Year Four 2024 Long-term Debt, Maturities, Repayments of Principal in Year Five Thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five Total Assets Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net of allowance for doubtful accounts as of October 31, 2019 and January 31, 2019 of $1,021 and $125, respectively Accounts Receivable, after Allowance for Credit Loss, Current Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Operating lease right-of-use assets Intangible assets, net Deferred tax asset Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued liabilities Accrued Liabilities, Current Current portion of long-term debt Long-term Debt, Current Maturities Operating lease liabilities Operating Lease, Liability, Current Total current liabilities Liabilities, Current Long-term debt, net of issuance costs Long-term Debt, Excluding Current Maturities Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Deferred tax liability Deferred Income Tax Liabilities, Net Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (see note 7) Commitments and Contingencies Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively Preferred Stock, Value, Issued Common stock, $0.0001 par value, 900,000 shares authorized, 70,832 and 62,446 shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated earnings Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Share-based Payment Arrangement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected stock price volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected life of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Prior To Acquisition Prior Credit Agreement [Member] Prior Credit Agreement [Member] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Secured Debt Secured Debt [Member] Secured Revolving Credit Facility Revolving Credit Facility [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Customary Base Rate Base Rate [Member] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Debt covenant, beginning August 30, 2019 Debt Covenant Period One [Member] Debt Covenant Period One Debt covenant, beginning July 31, 2020 Debt Covenant Period Two [Member] Debt Covenant Period Two Debt covenant, beginning July 31, 2021 Debt Covenant Period Three [Member] Debt Covenant Period Three Debt covenant, acquisition holiday provision Debt Covenant Period Four [Member] Debt Covenant Period Four Debt Instrument [Line Items] Debt Instrument [Line Items] Credit facility, amount Line of Credit Facility, Maximum Borrowing Capacity Facility term Debt Instrument, Term Long-term line of credit Long-term Line of Credit Variable rate borrowing spread Debt Instrument, Basis Spread on Variable Rate Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Maximum leverage ratio Debt Instrument, Covenant Description, Leverage Ratio Debt Instrument, Covenant Description, Leverage Ratio Acquisition threshold for maximum total net leverage ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Minimum interest coverage ratio Debt Instrument, Covenant Description, Interest Coverage Ratio Debt Instrument, Covenant Description, Interest Coverage Ratio Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Incentive Plan Incentive Plan [Member] Incentive Plan [Member] Restricted stock units Restricted Stock Units (RSUs) [Member] Pre-acquisition restricted stock units Pre-Acquisition Restricted Stock Units (RSUs) [Member] Pre-Acquisition Restricted Stock Units (RSUs) [Member] Post-acquisition restricted stock units Post-Acquisition Restricted Stock Units (RSUs) [Member] Post-Acquisition Restricted Stock Units (RSUs) [Member] Equity awards Equity Awards [Member] Equity Awards [Member] Pre-acquisition equity awards Post-acquisition equity awards Post-Acquisition Equity Awards [Member] Post-Acquisition Equity Awards [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Stock options Share-based Payment Arrangement, Option [Member] Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Performance restricted stock awards Performance Restricted Stock Awards [Member] Performance Restricted Stock Awards [Member] Restricted stock awards Restricted Stock [Member] Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of common stock issuable (in shares) Common Stock, Capital Shares Reserved for Future Issuance Percentage of capital stock Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Forfeiture period Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period Weighted-average vesting period of non-vested awards expected to vest Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized stock compensation expense to be recognized in future Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Number of service-based common stock (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Aggregate fair value of WageWorks stock acquired Share-based compensation expense Share-based Payment Arrangement, Expense Performance units awards (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Award vesting rights percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating lease not yet commenced undiscounted amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Operating lease not yet commenced term of contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Operating lease cost Operating Lease, Expense Sublease income Sublease Income Net operating lease cost Lease, Cost Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] RSUs and PRSUs RSAs and PRSAs Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Released (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, ending balance (in shares) Weighted-average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, beginning balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Released (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, ending balance (usd per share) Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Acquisition awards exchanged for cash Equity Awards Exchanged For Cash In Business Combination [Member] Equity Awards Exchanged For Cash In Business Combination [Member] Performance stock options Performance Shares [Member] Restricted stock units Total non-cash stock-based compensation expense Total Noncash Share-Based Payment Arrangement Expense [Member] Total Noncash Share-Based Payment Arrangement Expense [Member] Total stock-based compensation expense Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Operating cash flows from operating leases Operating Lease, Payments ROU assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Remaining 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease liabilities Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Opening balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Ending balance (shares) Vested and expected to vest as of year end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Exercisable as of year end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Range of exercise prices (usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Beginning balance, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Beginning balance, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Granted, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted Granted, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted Exercised, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Exercised, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Forfeited, minimum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited Forfeited, maximum (usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited Ending balance, minimum (usd per share) Ending balance, maximum (usd per share) Weighted- average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Opening balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Ending balance (usd per share) Vested and expected to vest as of year end, weighted average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Exercisable as of year end, weighted-average exercise price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted- average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest as of year end, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Exercisable as of year end, weighted-average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested and expected to vest as of year end, aggregate intrinsic value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercisable as of year end, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Supplemental financial statement information Additional Financial Information Disclosure [Text Block] Income Tax Disclosure [Abstract] Income taxes Income Tax Disclosure [Text Block] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Customer relationships Trade names & trademarks Trademarks and Trade Names [Member] Identified intangible assets subject to amortization Identified Intangible Assets Subject To Amortization [Member] Identified Intangible Assets Subject To Amortization [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Weighted-average remaining amortization period (years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life In-process software development costs Indefinite-lived Intangible Assets Acquired Total acquired intangible assets Sublease income Operating Leases, Rent Expense, Sublease Rentals Rent expense Sublease income Number of derivative lawsuits Loss Contingency Number Of Lawsuits Loss Contingency Number Of Lawsuits Numerator (basic and diluted): Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Net income (loss) Denominator (basic): Weighted Average Number of Shares Outstanding, Basic [Abstract] Weighted-average common shares outstanding (in shares) Denominator (diluted): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average common shares outstanding (in shares) Weighted-average dilutive effect of stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted-average common shares outstanding (in shares) Net income (loss) per share: Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization (Gains) losses on marketable equity securities and other Equity And Other Securities, FV-NI, Gain (Loss) Equity And Other Securities, FV-NI, Gain (Loss) Deferred taxes Deferred Income Tax Expense (Benefit) Stock-based compensation Share-based Payment Arrangement, Noncash Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Other assets Increase (Decrease) in Prepaid Expense Operating lease right-of-use assets Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Employee Related Liabilities Accrued liabilities and other current liabilities Increase (Decrease) in Accrued Liabilities Operating lease liabilities, non-current Increase (Decrease) In Operating Lease Liability, Noncurrent Increase (Decrease) In Operating Lease Liability, Noncurrent Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Purchases of intangible member assets Payments to Acquire Intangible Assets Purchases of marketable equity securities and other Payments to Acquire Investments Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of software and capitalized software development costs Payments for Software Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from long-term debt Proceeds from Issuance of Long-term Debt Payment of debt issuance costs Payments of Debt Issuance Costs Settlement of client-held funds obligation Proceeds from follow-on equity offering, net of payment for offering costs Proceeds from Issuance of Common Stock Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Beginning cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Ending cash and cash equivalents Computer software intangible asset Computer Software, Intangible Asset [Member] Supplemental cash flow data: Supplemental Cash Flow Information [Abstract] Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Income taxes paid in cash, net of refunds received Income Taxes Paid, Net Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Equity-based acquisition consideration Other Significant Noncash Transaction, Value of Consideration Given Purchases of property and equipment included in accounts payable or accrued liabilities at period end Capital Expenditures Incurred but Not yet Paid Purchases of intangible assets Noncash or Part Noncash Acquisition, Intangible Assets Acquired Exercise of common stock options receivable Exercise of Stock Options Receivable Exercise of Stock Options Receivable Summary of share based compensation recognized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of stock-based compensation expense by award type Share-based Payment Arrangement, Cost by Plan [Table Text Block] Summary of assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of stock option activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of restricted stock unit activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenue Cost of Sales [Member] Sales and marketing Sales and Marketing [Member] Sales and Marketing [Member] Technology and development Technology and Development [Member] Technology and Development [Member] General and administrative General and Administrative Expense [Member] Merger integration Merger Integration [Member] Merger Integration [Member] Other expense, net Other Nonoperating Income (Expense) [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent Gross unrecognized tax benefits Unrecognized Tax Benefits Unrecognized tax benefit Unrecognized Tax Benefit, Net Unrecognized Tax Benefit, Net Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Office Lease Office Lease [Member] Office Lease [Member] Other Agreements Other Agreements [Member] Other Agreements [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] 2020 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2021 Operating Leases, Future Minimum Payments, Due in Two Years 2022 Operating Leases, Future Minimum Payments, Due in Three Years 2023 Operating Leases, Future Minimum Payments, Due in Four Years 2024 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Indebtedness Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Cumulative effect from adoption of ASU 2016-01 Accounting Standards Update 2016-01 [Member] Cumulative effect from adoption of ASC 606 Accounting Standards Update 2014-09 [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common stock Additional paid-in capital Additional Paid-in Capital [Member] Accumulated comprehensive loss AOCI Attributable to Parent [Member] Accumulated earnings Retained Earnings [Member] Beginning balance Issuance of common stock upon exercise of stock options, and for restricted stock Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Issuance of common stock Stock Issued During Period, Value, New Issues Other issuance of common stock Stock Issued During Period, Value, Other Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Cumulative effect from adoption of accounting standard updates Cumulative Effect of New Accounting Principle in Period of Adoption Ending balance Stock-based compensation Share-based Payment Arrangement [Text Block] Summary of business and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] EX-101.PRE 10 hqy-20191031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Intangible assets and goodwill (Narrative) (Details) - USD ($)
3 Months Ended 9 Months Ended
Aug. 30, 2019
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Finite-Lived Intangible Assets [Line Items]          
Capitalized software development costs   $ 7,000,000.0 $ 2,200,000 $ 14,700,000 $ 6,400,000
Software development costs incurred and expensed   6,200,000 3,400,000 13,800,000 10,000,000.0
Amortization expense   15,700,000 3,700,000 23,600,000 10,900,000
Change in goodwill     $ 0   $ 0
Acquired HSA portfolios          
Finite-Lived Intangible Assets [Line Items]          
Fair value       $ 7,700,000  
Useful life of intangible assets       15 years  
WageWorks, Inc          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets $ 711,500,000 711,500,000      
Fair value $ 707,700,000        
Goodwill   $ 1,300,000,000      
XML 12 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Indebtedness Schedule of Long-term Debt (Details)
$ in Millions
Oct. 31, 2019
USD ($)
Debt Disclosure [Abstract]  
Term loan facility $ 1,250
Unamortized loan issuance costs (23)
Total $ 1,227
XML 13 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation (Summary of share based compensation recognized) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 23,156 $ 5,734 $ 36,774 $ 15,461
Cost of revenue        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,415 788 3,285 2,008
Sales and marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,304 990 3,469 2,586
Technology and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 2,171 1,386 5,600 3,677
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 3,332 2,570 9,486 7,190
Merger integration        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,220 0 1,220 0
Other expense, net        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 13,714 $ 0 $ 13,714 $ 0
XML 14 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of business and significant accounting policies
9 Months Ended
Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of business and significant accounting policies Summary of business and significant accounting policies
Business
HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. HealthEquity, Inc. is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Acquisition of WageWorks, Inc.
On August 30, 2019, HealthEquity, Inc. closed the acquisition of WageWorks, Inc. (“WageWorks”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), for $51.35 per share in cash, or approximately $2.0 billion to WageWorks stockholders (the “Acquisition”). 
As a result of the Acquisition, HealthEquity, Inc. gained access to more of the HSA market by expanding its direct distribution to employers and benefits advisors as a single source provider of HSAs and other CDBs, including flexible spending accounts, health reimbursement arrangements, COBRA administration, commuter and other benefits.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, HealthEquity Retirement Services, LLC, and, after the closing of the Acquisition on August 30, 2019, WageWorks, Inc. and its subsidiaries MyFlexMobile, Inc., WageWorks India, Inc. and WageWorks Services, LLP (collectively referred to as the "Company").
Prior to the closing of the Acquisition, the Company held a 4% ownership interest in WageWorks. The Company measured the investment at fair value, and all gains on the investment were recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). In connection with the closing of the Acquisition on August 30, 2019, the Company's investment in WageWorks was canceled, and WageWorks became a wholly owned subsidiary of the Company.
The Company has a 22% ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately $0.2 million as of October 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 1% ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at $0.5 million as of October 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
Acquisitions of businesses, including the Acquisition of WageWorks, are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.
Basis of presentation
The accompanying condensed consolidated financial statements as of October 31, 2019 and for the three and nine months ended October 31, 2019 and 2018 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended January 31, 2019. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies, other than the additions of the policies described below for leases, investments in equity securities, and client-held funds, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended January 31, 2019.
Leases. The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
The Company has entered into various operating leases consisting of office space, data storage facilities, and other leases with remaining lease terms of approximately less than 1 year to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.
Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019.
Investments in equity securities. Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and were classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). As a result of the Acquisition on August 30, 2019, the Company's marketable equity security investment in WageWorks was canceled.
Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as other assets on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).
Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in other assets on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).
The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding
charge through other expense, net in the condensed consolidated statements of operations and comprehensive income (loss).
Client-held funds. Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”, respectively) and commuter accounts. These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's condensed consolidated balance sheets.
Prior to the closing of the Acquisition, Wageworks included all Client-held funds with its corporate cash assets on its balance sheet, with an offsetting Client-held funds obligation. As of the closing of the Acquisition on August 30, 2019, WageWorks held approximately $682 million of Client-held funds, of which $238 million was combined with its corporate cash within WageWorks' corporate bank accounts; therefore, the Company determined that this $238 million of Client-held funds were assets of the Company, while the approximately $444 million of remaining Client-held funds were not assets of the Company. Prior to October 31, 2019, the Company segregated $231 million of Client-held funds from its corporate bank accounts. Accordingly, as of October 31, 2019, $7 million of Client-held funds remained combined within the Company's corporate bank accounts and therefore remained on the Company's condensed consolidated balance sheets in cash and cash equivalents, with an offsetting liability included in accrued liabilities.
Recent adopted accounting pronouncements
In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (codified as "ASC 842"), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.
The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of $40.6 million and ROU assets of $38.0 million, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and nine-month period ended October 31, 2019.
In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This ASU permits the capitalization of implementation costs incurred in a software hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. The Company elected to early adopt the new standard as of October 31, 2019 using the prospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
Recent issued accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.
In August 2018, FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed consolidated balance sheets (Parenthetical) - USD ($)
$ in Thousands
Oct. 31, 2019
Jan. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 1,021 $ 125
Preferred stock, par value (usd per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 100,000,000 100,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (usd per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 900,000,000 900,000,000
Common stock, issued (in shares) 70,832,000 62,446,000
Common stock, outstanding (in shares) 70,832,000 62,446,000
ZIP 16 0001428336-19-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-19-000026-xbrl.zip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end XML 18 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Business combination (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Aug. 30, 2019
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Jan. 31, 2019
Business Acquisition [Line Items]            
Goodwill   $ 1,335,187   $ 1,335,187   $ 4,651
Acquisition costs   32,932 $ 849 40,712 $ 1,074  
WageWorks, Inc            
Business Acquisition [Line Items]            
Merger related costs, price per share $ 51.35          
Aggregate fair value of WageWorks stock acquired $ 2,122,100          
Cash paid 816,900          
Borrowing pursuant to term loan facility 1,220,000          
Goodwill   1,330,500   1,330,500    
Acquisition costs   32,900   $ 40,700    
Contribution of revenue   72,100        
Operating expenses   $ 39,900        
Line of Credit | Term Loan Facility | WageWorks, Inc            
Business Acquisition [Line Items]            
Lender fees $ 30,500          

XML 19 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Indebtedness (Tables)
9 Months Ended
Oct. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
As of October 31, 2019, long-term debt consisted of the following:
(in millions)
 
October 31, 2019

Term loan facility
 
$
1,250

Less: unamortized loan issuance costs
 
(23
)
Long-term debt, net of issuance costs
 
$
1,227


Schedule of Maturities of Long-term Debt
The loans made under the Term Loan Facility are required to be repaid as described in the following table:
Fiscal year ending January 31, (in millions)
 
Principal payments

Remaining 2020
 
$
8

2021
 
39

2022
 
63

2023
 
70

2024
 
101

Thereafter
 
969

Total principal payments
 
$
1,250


XML 20 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental financial statement information (Tables)
9 Months Ended
Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Property and equipment
Property and equipment consisted of the following as of October 31, 2019 and January 31, 2019:
(in thousands)
 
October 31, 2019

 
January 31, 2019

Leasehold improvements
 
$
19,404

 
$
3,583

Furniture and fixtures
 
6,889

 
4,476

Computer equipment
 
22,890

 
9,242

Property and equipment, gross
 
49,183

 
17,301

Accumulated depreciation
 
(13,984
)
 
(9,078
)
Property and equipment, net
 
$
35,199

 
$
8,223


Other income (expense), net
Other expense, net, consisted of the following:
 
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Interest income
 
$
2,046

 
$
358

 
$
5,273

 
$
919

Gain on marketable equity securities
 
285

 

 
27,570

 

Acquisition costs
 
(32,932
)
 
(849
)
 
(40,712
)
 
(1,074
)
Other expense
 
(348
)
 
(996
)
 
(478
)
 
(1,272
)
Total other expense, net
 
$
(30,949
)
 
$
(1,487
)
 
$
(8,347
)
 
$
(1,427
)

XML 21 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Fair value
9 Months Ended
Oct. 31, 2019
Fair Value Disclosures [Abstract]  
Fair value Fair value
Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of October 31, 2019 due to the short-term nature of these instruments.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and contingencies
9 Months Ended
Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Commitments
In addition to the indebtedness described in Note 8 below, the Company’s principal commitments consist of operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments.
Future minimum lease payments under non-cancelable operating leases, excluding the contractual sublease income of $6.0 million, which is expected to be received through February 2023, and other agreements, are as follows:
Year ending January 31, (in thousands)
 
Operating leases

 
Other agreements

 
Total

2020
 
$
375

 
$
2,524

 
$
2,899

2021
 
14,340

 
10,325

 
24,665

2022
 
15,692

 
7,182

 
22,874

2023
 
12,191

 
4,602

 
16,793

2024
 
9,922

 
1,212

 
11,134

Thereafter
 
67,717

 
403

 
68,120

Total
 
$
120,237

 
$
26,248

 
$
146,485


Rent expense was $3.4 million and $5.5 million for the three and nine months ended October 31, 2019, respectively. Sublease income was $0.2 million for the three months ended October 31, 2019.
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
WageWorks is pursuing affirmative claims against the Office of Personnel Management ("OPM") to obtain payment for services provided by WageWorks between March 1, 2016 and August 31, 2016 pursuant to its contract with OPM. In connection with WageWorks' claims against OPM, OPM has also claimed that an erroneous statement in a certificate signed by a former executive officer constituted a violation of the False Claims Act and moved to dismiss part of WageWorks' claim against OPM as a result. As with all legal proceedings, no assurance can be provided as to the outcome of these matters or if WageWorks or OPM will be successful.
On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks, its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleges claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering.
On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages and fees and costs.
Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint.
WageWorks voluntarily contacted the San Francisco office of the SEC Division of Enforcement regarding the restatement of WageWorks' financial statements and related independent investigation. WageWorks is providing information and documents to the SEC and continues to cooperate with the SEC’s investigation into these matters.
The U.S. Attorney’s Office for the Northern District of California also opened an investigation. WageWorks has provided documents and information to the U.S. Attorney’s Office and continues to cooperate with any inquiries by the U.S. Attorney’s Office regarding the matter.
Beginning on July 30, 2019, putative class action suits were filed in the U.S. District Court Courts for the Southern District of New York, the District of Delaware, and the Northern District of California asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks and the former members of its board of directors. The complaints generally allege disclosure violations in the proxy statement issued by WageWorks in connection with the stockholder vote on the proposed merger with the Company. After WageWorks issued certain supplemental disclosures, these actions were voluntarily dismissed, but WageWorks may still be required to pay attorneys fees to the plaintiffs' lawyers.
WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense of its former directors and officers in the legal proceedings described above.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. While it is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, the Company believes, based on current knowledge, that such litigation, proceedings and claims will not have a material impact on the Company’s financial position, results of operations and cash flows for the period.
The Company maintains liability insurance coverage that is intended to cover the legal matters described above; however, it is possible that claims may be denied by our insurance carriers or could exceed the amount of our applicable insurance coverage, we may be required by our insurance carriers to contribute to the payment of claims, and our insurance coverage may not continue to be available to us on acceptable terms or in sufficient amounts.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
XML 23 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Business combination (Consideration Transferred) (Details) - WageWorks, Inc
$ in Millions
Aug. 30, 2019
USD ($)
Business Acquisition [Line Items]  
Fair value of previously owned investment in WageWorks stock $ 81.4
Total consideration paid 2,122.1
WageWorks stock acquired  
Business Acquisition [Line Items]  
Aggregate fair value of WageWorks stock acquired 2,018.8
Equity awards exchanged for cash attributable to pre-Acquisition service  
Business Acquisition [Line Items]  
Fair value of equity awards 18.1
Equity awards replaced attributable to pre-Acquisition service  
Business Acquisition [Line Items]  
Fair value of equity awards $ 3.8
XML 24 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental financial statement information (Property and equipment) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Jan. 31, 2019
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 49,183   $ 49,183   $ 17,301
Accumulated depreciation (13,984)   (13,984)   (9,078)
Property and equipment, net 35,199   35,199   8,223
Depreciation expense 3,600 $ 900 5,400 $ 2,600  
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 19,404   19,404   3,583
Furniture and fixtures          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross 6,889   6,889   4,476
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment, gross $ 22,890   $ 22,890   $ 9,242
XML 26 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Maturities of Operating Lease Liabilities) (Details)
$ in Thousands
Oct. 31, 2019
USD ($)
Leases [Abstract]  
Remaining 2020 $ 375
2021 14,340
2022 14,135
2023 10,595
2024 8,287
Thereafter 55,389
Total lease payments 103,121
Less imputed interest (19,289)
Total lease liabilities 83,832
Operating lease liabilities 10,780
Operating lease liabilities, non-current $ 73,052
XML 27 R51.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation (Assumptions) (Details) - shares
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected dividend yield   0.00% 0.00% 0.00%
Expected stock price volatility   37.09%    
Expected stock price volatility, minimum     35.98% 37.09%
Expected stock price volatility, maximum     36.53% 37.84%
Risk-free interest rate   2.79%    
Risk-free interest rate, minimum     2.21% 2.52%
Risk-free interest rate, maximum     2.43% 2.79%
Expected life of options   6 years 3 months    
Granted (shares) 0   108,000  
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected life of options     4 years 11 months 12 days 5 years 2 months 1 day
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected life of options     5 years 1 month 2 days 6 years 3 months
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation
9 Months Ended
Oct. 31, 2019
Share-based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:


Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Cost of revenue

$
1,415

 
$
788

 
$
3,285

 
$
2,008

Sales and marketing

1,304

 
990

 
3,469

 
2,586

Technology and development

2,171

 
1,386

 
5,600

 
3,677

General and administrative

3,332

 
2,570

 
9,486

 
7,190

Merger integration
 
1,220

 

 
1,220

 

Other expense, net
 
13,714

 

 
13,714

 

Total stock-based compensation expense

$
23,156

 
$
5,734

 
$
36,774

 
$
15,461


The following table shows stock-based compensation by award type:


Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Stock options

$
1,631

 
$
1,917

 
$
5,140

 
$
5,664

Performance stock options


 
178

 

 
503

Restricted stock units

14,099

 
1,956

 
20,718

 
5,543

Performance restricted stock units

1,422

 
793

 
3,467

 
1,843

Restricted stock awards

164

 
172

 
491

 
399

Performance restricted stock awards

260

 
718

 
1,378

 
1,509

Total non-cash stock-based compensation expense
 
17,576

 
5,734

 
31,194

 
15,461

Acquisition awards exchanged for cash
 
5,580

 

 
5,580

 

Total stock-based compensation expense

$
23,156

 
$
5,734

 
$
36,774

 
$
15,461


Stock award plans
Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock. As described below, in connection with the Acquisition, the shares of common stock available for issuance under the Incentive Plan were increased by 5.3 million shares.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors.
WageWorks Incentive Plan. At the closing of the Acquisition, and in accordance with the Merger Agreement, certain RSUs with respect to WageWorks common stock, granted under WageWorks, Inc. 2010 Equity Incentive Plan (the "WageWorks Incentive Plan"), were replaced by the Company and converted into RSUs with respect to 523,318 shares of common stock of the Company.
In connection with the Acquisition, an additional 5,255,027 shares of the Company, representing the remaining number of shares of common stock of WageWorks that were available for issuance under the WageWorks Incentive Plan immediately prior to the Acquisition, became available for issuance under the Incentive Plan. The additional shares may be utilized for equity-based awards to be granted under the Incentive Plan, provided that (i) the period during which such shares are available under the Incentive Plan may not be extended beyond the period during which they would have been available under the WageWorks Incentive Plan, absent the Acquisition, and (ii) such equity-based awards may not be granted to individuals who were employees, directors or consultants of HealthEquity or its affiliates at the time the Acquisition was consummated.
Stock options
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.
Valuation assumptions. The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.
Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.
The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:
  

Three months ended October 31,
 
 
Nine months ended October 31,
 
  

2019
 
2018

 
2019

 
2018

Expected dividend yield

*

%
 
%
 
%
Expected stock price volatility

*

37.09
%
 
35.98% - 36.53%

 
37.09% - 37.84%

Risk-free interest rate

*

2.79
%
 
2.21% - 2.43%

 
2.52% - 2.79%

Expected life of options

*

6.25 years

 
4.95 - 5.09 years

 
5.17 - 6.25 years


* No stock options were granted during the three months ended October 31, 2019.
The Company historically used the "simplified" method to estimate the expected life of an option as determined under Staff Accounting Bulletin No. 110 due to limited option exercise history as a public company. Commencing February 1, 2019, the Company began estimating the expected life of an option using its own historical option exercise and termination data. Expected volatility is determined using weighted average volatility of the Company's
historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations.
A summary of stock option activity is as follows:
  

Outstanding stock options
 
(in thousands, except for exercise prices and term)

Number of
options


Range of
exercise
prices

Weighted-
average
exercise
price


Weighted-
average
contractual
term
(in years)

Aggregate
intrinsic
value

Outstanding as of January 31, 2019

2,444


$0.10 - 82.39

$
27.37


6.74

$
85,971

Granted

108


$63.64 - 73.61

$
73.27





Exercised

(314
)

$0.10 - 44.53

$
23.42





Forfeited

(36
)

$24.36 - 44.53

$
30.15





Outstanding as of October 31, 2019

2,202


$0.10 - 82.39

$
30.14


6.13

$
61,562

Vested and expected to vest as of October 31, 2019

2,202




$
30.14


6.13

$
61,562

Exercisable as of October 31, 2019

1,501




$
22.91


5.50

$
51,131


The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.
As of October 31, 2019, the weighted-average vesting period of non-vested awards expected to vest is approximately 1.5 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately $8.8 million.
Restricted stock units and restricted stock awards
The Company grants RSUs and RSAs to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate.
Acquisition of WageWorks. As described above, at the closing of the Acquisition, and in accordance with the Merger Agreement, 523,318 service-based RSUs with respect to WageWorks common stock were replaced by the Company and converted into RSUs with respect to common stock of the Company. These replaced awards are included in the granted amounts in the summary of RSU and RSA activity below.
The awards replaced by the Company in the Acquisition were measured at the Acquisition date based on the estimated fair value of $29.7 million. A portion of that fair value, $3.8 million, which represented the pre-Acquisition service provided by team members to WageWorks, was included in the total consideration paid as part of the Acquisition. As of the closing of the Acquisition, the remaining portion of the fair value of those awards was $25.9 million, representing post-Acquisition share-based compensation expense, $8.1 million of which was recognized during the three months ended October 31, 2019 as acquisition-related costs, and the remainder of which will be recognized in the ordinary course as these team members provide service over the remaining vesting periods.
Additionally, at the closing of the Acquisition, and in accordance with the Merger Agreement, the Company exchanged for cash certain WageWorks equity awards measured at the Acquisition date based on the estimated fair value of $23.6 million. A portion of that fair value, $18.1 million, which represented the pre-Acquisition service provided by team members to WageWorks, was included in the total consideration paid as part of the Acquisition. As of the closing of the Acquisition, the remaining portion of the fair value of the awards exchanged for cash
was $5.6 million, representing post-Acquisition share-based compensation expense that was recognized during the three months ended October 31, 2019.
Performance restricted stock units and awards. In March 2017, the Company awarded 146,964 performance-based RSUs ("PRSUs"). Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2020. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 150% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.
In March 2018, the Company awarded 227,760 performance-based RSAs ("PRSAs"). Vesting of the PRSAs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2021. The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred at the grant date. The Company believes it is probable that the PRSAs will vest at least in part. The vesting of the PRSAs will ultimately range from 0% to 200% based on the level of achievement of the performance goals. The PRSAs were issued at the 200% level of achievement. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.
In March 2019, the Company awarded 129,963 PRSUs. Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2022. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from 0% to 200% of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.
A summary of the RSU and RSA activity is as follows:


RSUs and PRSUs
 

RSAs and PRSAs
 
(in thousands, except weighted-average grant date fair value)

Shares


Weighted-average grant date fair value


Shares


Weighted-average grant date fair value

Outstanding as of January 31, 2019

647


$
55.18


256


$
61.93

Granted

1,124


64.61





Released

(320
)

58.01


(11
)

62.75

Forfeited

(83
)

56.02


(10
)

61.72

Outstanding as of October 31, 2019

1,368


$
62.22


235


$
61.91


For the nine months ended October 31, 2019, the aggregate intrinsic value of RSUs and RSAs released was $19.9 million and $0.8 million, respectively. For the nine months ended October 31, 2018, the aggregate intrinsic value of RSUs released was $5.5 million.
Total unrecorded stock-based compensation expense as of October 31, 2019 associated with RSUs and PRSUs was $67.1 million, which is expected to be recognized over a weighted-average period of 2.6 years. Total unrecorded stock-based compensation expense as of October 31, 2019 associated with RSAs and PRSAs was $4.3 million, which is expected to be recognized over a weighted-average period of 1.6 years.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Intangible assets and goodwill
9 Months Ended
Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill Intangible assets and goodwill
Intangible assets
During the three months ended October 31, 2019, the Company recorded $711.5 million of acquired identified intangible assets as a result of the Acquisition of WageWorks. For further information about these acquired identified intangible assets, see Note 3—Business Combination.
During the nine months ended October 31, 2019, the Company acquired the rights to act as a custodian of HSA portfolios for $7.7 million. The Company has determined the acquired intangible HSA assets to have a useful life of 15 years. The assets are being amortized using the straight-line amortization method, which has been determined to be appropriate to reflect the pattern over which the economic benefits of existing assets are realized.
During the three months ended October 31, 2019 and 2018, the Company capitalized software development costs of $7.0 million and $2.2 million, respectively, and $14.7 million and $6.4 million, respectively, for the nine months ended October 31, 2019 and 2018, related to significant enhancements and upgrades to its technology-enabled services platforms.
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2019 and January 31, 2019:
(in thousands)
 
October 31, 2019

 
January 31, 2019

Amortizable intangible assets:
 
 
 
 
Software and software development costs
 
$
66,633

 
$
44,835

Acquired HSA portfolios
 
92,770

 
85,110

Acquired customer relationships
 
601,382

 
2,882

Acquired developed technology
 
96,924

 

Acquired trade names
 
12,300

 

Amortizable intangible assets, gross
 
870,009

 
132,827

Accumulated amortization
 
(77,017
)
 
(53,161
)
Total amortizable intangible assets, net
 
792,992

 
79,666

Acquired in-process software development costs
 
3,236

 

Total intangible assets, net
 
$
796,228

 
$
79,666


During the three months ended October 31, 2019 and 2018, the Company expensed a total of $6.2 million and $3.4 million, respectively, and $13.8 million and $10.0 million for the nine months ended October 31, 2019 and 2018, respectively, in software development costs primarily related to the post-implementation and operation stages of its technology platforms.
Amortization expense for the three months ended October 31, 2019 and 2018 was $15.7 million and $3.7 million, respectively, and $23.6 million and $10.9 million, respectively, for the nine months ended October 31, 2019 and 2018.
Goodwill
During the three months ended October 31, 2019, the Company recorded $1.3 billion of goodwill from the Acquisition of WageWorks. For further information about the resulting goodwill, see Note 3—Business Combination.
There were no other changes to the goodwill carrying value during the three and nine months ended October 31, 2019 and 2018.
JSON 30 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-2019x10x3110q.htm": { "axisCustom": 1, "axisStandard": 20, "contextCount": 211, "dts": { "calculationLink": { "local": [ "hqy-20191031_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20191031_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "hqy-2019x10x3110q.htm" ] }, "labelLink": { "local": [ "hqy-20191031_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hqy-20191031_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hqy-20191031.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 490, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 39, "http://healthequity.com/20191031": 11, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 55 }, "keyCustom": 33, "keyStandard": 356, "memberCustom": 28, "memberStandard": 34, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20191031", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Supplemental financial statement information", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformation", "shortName": "Supplemental financial statement information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - Leases", "role": "http://healthequity.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - Intangible assets and goodwill", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwill", "shortName": "Intangible assets and goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134100 - Disclosure - Commitments and contingencies", "role": "http://healthequity.com/role/CommitmentsAndContingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135100 - Disclosure - Indebtedness", "role": "http://healthequity.com/role/Indebtedness", "shortName": "Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136100 - Disclosure - Income taxes", "role": "http://healthequity.com/role/IncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139100 - Disclosure - Stock-based compensation", "role": "http://healthequity.com/role/StockBasedCompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140100 - Disclosure - Fair value", "role": "http://healthequity.com/role/FairValue", "shortName": "Fair value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of business and significant accounting policies (Policies)", "role": "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies", "shortName": "Summary of business and significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Net income (loss) per share (Tables)", "role": "http://healthequity.com/role/NetIncomeLossPerShareTables", "shortName": "Net income (loss) per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed consolidated balance sheets", "role": "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed consolidated balance sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Business combination (Tables)", "role": "http://healthequity.com/role/BusinessCombinationTables", "shortName": "Business combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Supplemental financial statement information (Tables)", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformationTables", "shortName": "Supplemental financial statement information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322301 - Disclosure - Leases (Tables)", "role": "http://healthequity.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328301 - Disclosure - Intangible assets and goodwill (Tables)", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwillTables", "shortName": "Intangible assets and goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334301 - Disclosure - Commitments and contingencies Operating Lease Maturity (Tables)", "role": "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityTables", "shortName": "Commitments and contingencies Operating Lease Maturity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335301 - Disclosure - Indebtedness (Tables)", "role": "http://healthequity.com/role/IndebtednessTables", "shortName": "Indebtedness (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339301 - Disclosure - Stock-based compensation (Tables)", "role": "http://healthequity.com/role/StockBasedCompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Summary of business and significant accounting policies (Narrative) (Details)", "role": "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of business and significant accounting policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ConsolidationPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Net income (loss) per share (Details)", "role": "http://healthequity.com/role/NetIncomeLossPerShareDetails", "shortName": "Net income (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Business combination (Narrative) (Details)", "role": "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "shortName": "Business combination (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "D2020Q3Aug30_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001001 - Statement - Condensed consolidated balance sheets (Parenthetical)", "role": "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed consolidated balance sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "D2020Q3Aug30_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "hqy:BusinessCombinationConsiderationTransferredEquityInterestsPreviouslyOwned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Business combination (Consideration Transferred) (Details)", "role": "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "shortName": "Business combination (Consideration Transferred) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "D2020Q3Aug30_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "hqy:BusinessCombinationConsiderationTransferredEquityInterestsPreviouslyOwned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details)", "role": "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails", "shortName": "Business combination (Preliminary Allocation of Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "D2020Q3Aug30_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Business combination (Acquired Intangible Assets) (Details)", "role": "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "shortName": "Business combination (Acquired Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "D2020Q3Aug30_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:IndefinitelivedIntangibleAssetsAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407406 - Disclosure - Business combination (Pro Forma Results) (Details)", "role": "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails", "shortName": "Business combination (Pro Forma Results) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD_us-gaap_BusinessAcquisitionAxis_hqy_WageWorksInc.Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Supplemental financial statement information (Property and equipment) (Details)", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails", "shortName": "Supplemental financial statement information (Property and equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Supplemental financial statement information (Other expense, net) (Details)", "role": "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails", "shortName": "Supplemental financial statement information (Other expense, net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-5", "first": true, "lang": null, "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422402 - Disclosure - Leases (Narrative) (Details)", "role": "http://healthequity.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-5", "first": true, "lang": null, "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422403 - Disclosure - Leases (Lease Cost) (Details)", "role": "http://healthequity.com/role/LeasesLeaseCostDetails", "shortName": "Leases (Lease Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details)", "role": "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Leases (Maturities of Operating Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422405 - Disclosure - Leases (Supplemental Cash Flow Information) (Details)", "role": "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases (Supplemental Cash Flow Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "role": "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "shortName": "Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareAdditions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428402 - Disclosure - Intangible assets and goodwill (Narrative) (Details)", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "shortName": "Intangible assets and goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareAdditions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428403 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details)", "role": "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails", "shortName": "Intangible assets and goodwill (Schedule of intangible assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434402 - Disclosure - Commitments and contingencies Operating Lease Maturity (Details)", "role": "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails", "shortName": "Commitments and contingencies Operating Lease Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseSubleaseRentals1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434403 - Disclosure - Commitments and contingencies (Details)", "role": "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseSubleaseRentals1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435402 - Disclosure - Indebtedness Schedule of Long-term Debt (Details)", "role": "http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails", "shortName": "Indebtedness Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-6", "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "I2016Q3Sep30_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_hqy_PriorCreditAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435403 - Disclosure - Indebtedness (Narrative) (Details)", "role": "http://healthequity.com/role/IndebtednessNarrativeDetails", "shortName": "Indebtedness (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "I2016Q3Sep30_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_DebtInstrumentAxis_hqy_PriorCreditAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435404 - Disclosure - Indebtedness Schedule of Maturities of Long-term Debt (Details)", "role": "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails", "shortName": "Indebtedness Schedule of Maturities of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436401 - Disclosure - Income taxes (Details)", "role": "http://healthequity.com/role/IncomeTaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439402 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails", "shortName": "Stock-based compensation (Summary of share based compensation recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439403 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "shortName": "Stock-based compensation (Stock-based compensation expense by award type) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed consolidated statements of stockholders' equity (unaudited)", "role": "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed consolidated statements of stockholders' equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2020Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439404 - Disclosure - Stock-based compensation (Narrative) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-based compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2019Q3QTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439405 - Disclosure - Stock-based compensation (Assumptions) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "shortName": "Stock-based compensation (Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2019Q3QTD", "decimals": "4", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439406 - Disclosure - Stock-based compensation (Stock option activity) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-based compensation (Stock option activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439407 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details)", "role": "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "shortName": "Stock-based compensation (Restricted stock unity activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Condensed consolidated statements of cash flows (unaudited)", "role": "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed consolidated statements of cash flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of business and significant accounting policies", "role": "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPolicies", "shortName": "Summary of business and significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Net income (loss) per share", "role": "http://healthequity.com/role/NetIncomeLossPerShare", "shortName": "Net income (loss) per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Business combination", "role": "http://healthequity.com/role/BusinessCombination", "shortName": "Business combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "FD2020Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hqy-2019x10x3110q.htm", "contextRef": "I2019Q1Feb01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - hqy-2019x10x3110q.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - hqy-2019x10x3110q.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 67, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hqy_AcquiredHSAIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired HSA Intangible Assets [Member]", "label": "Acquired HSA Intangible Assets [Member]", "terseLabel": "Acquired HSA portfolios" } } }, "localname": "AcquiredHSAIntangibleAssetsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "hqy_AmortizationOfAcquiredIntangible": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Acquired Intangible", "label": "Amortization Of Acquired Intangible", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangible", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationConsiderationTransferredEquityInterestsPreviouslyOwned": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Previously Owned", "label": "Business Combination, Consideration Transferred, Equity Interests Previously Owned", "terseLabel": "Fair value of previously owned investment in WageWorks stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsPreviouslyOwned", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationConsiderationTransferredPaymentsToAcquireAndLiabilitiesIncurred": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Payments To Acquire And Liabilities Incurred", "label": "Business Combination, Consideration Transferred, Payments To Acquire And Liabilities Incurred", "terseLabel": "Aggregate fair value of WageWorks stock acquired" } } }, "localname": "BusinessCombinationConsiderationTransferredPaymentsToAcquireAndLiabilitiesIncurred", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationProFormaInformationOperatingExpensesSinceAcquisitionDateActual": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Pro Forma Information, Operating Expenses Since Acquisition Date, Actual", "label": "Business Combination, Pro Forma Information, Operating Expenses Since Acquisition Date, Actual", "terseLabel": "Operating expenses" } } }, "localname": "BusinessCombinationProFormaInformationOperatingExpensesSinceAcquisitionDateActual", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedClientHeldFundsObligation": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Client Held Funds Obligation", "negatedTerseLabel": "Client-held funds obligation" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedClientHeldFundsObligation", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseRightofuseAssets": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseRightofuseAssets", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ClientHeldFundsIncludedInCorporateCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Client Held Funds, Included In Corporate Cash", "label": "Client Held Funds, Included In Corporate Cash", "terseLabel": "Client held funds, included in corporate cash" } } }, "localname": "ClientHeldFundsIncludedInCorporateCash", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ClientHeldFundsOffBalanceSheet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Client Held Funds, Off-Balance Sheet", "label": "Client Held Funds, Off-Balance Sheet", "terseLabel": "Client-held funds, non-assets" } } }, "localname": "ClientHeldFundsOffBalanceSheet", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ClientHeldFundsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Client Held Funds [Policy Text Block]", "label": "Client Held Funds [Policy Text Block]", "terseLabel": "Client-held funds" } } }, "localname": "ClientHeldFundsPolicyTextBlock", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hqy_ClientHeldFundsTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Client Held Funds, Total", "label": "Client Held Funds, Total", "terseLabel": "Client-held funds, total" } } }, "localname": "ClientHeldFundsTotal", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Four", "label": "Debt Covenant Period Four [Member]", "terseLabel": "Debt covenant, acquisition holiday provision" } } }, "localname": "DebtCovenantPeriodFourMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period One", "label": "Debt Covenant Period One [Member]", "terseLabel": "Debt covenant, beginning August 30, 2019" } } }, "localname": "DebtCovenantPeriodOneMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Three", "label": "Debt Covenant Period Three [Member]", "terseLabel": "Debt covenant, beginning July 31, 2021" } } }, "localname": "DebtCovenantPeriodThreeMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant Period Two", "label": "Debt Covenant Period Two [Member]", "terseLabel": "Debt covenant, beginning July 31, 2020" } } }, "localname": "DebtCovenantPeriodTwoMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "label": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "terseLabel": "Acquisition threshold for maximum total net leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_DebtInstrumentCovenantDescriptionInterestCoverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "label": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "terseLabel": "Minimum interest coverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionInterestCoverageRatio", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCovenantDescriptionLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Description, Leverage Ratio", "label": "Debt Instrument, Covenant Description, Leverage Ratio", "terseLabel": "Maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionLeverageRatio", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_EquityAndOtherSecuritiesFVNIGainLoss": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity And Other Securities, FV-NI, Gain (Loss)", "label": "Equity And Other Securities, FV-NI, Gain (Loss)", "negatedTerseLabel": "(Gains) losses on marketable equity securities and other" } } }, "localname": "EquityAndOtherSecuritiesFVNIGainLoss", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_EquityAwardsAssumedAttributableToPreAcquisitionServiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Awards Assumed Attributable To Pre-Acquisition Service [Member]", "label": "Equity Awards Assumed Attributable To Pre-Acquisition Service [Member]", "terseLabel": "Equity awards replaced attributable to pre-Acquisition service" } } }, "localname": "EquityAwardsAssumedAttributableToPreAcquisitionServiceMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails" ], "xbrltype": "domainItemType" }, "hqy_EquityAwardsExchangedForCashAttributableToPreAcquisitionServiceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Awards Exchanged For Cash Attributable To Pre-Acquisition Service [Member]", "label": "Equity Awards Exchanged For Cash Attributable To Pre-Acquisition Service [Member]", "terseLabel": "Equity awards exchanged for cash attributable to pre-Acquisition service", "verboseLabel": "Pre-acquisition equity awards" } } }, "localname": "EquityAwardsExchangedForCashAttributableToPreAcquisitionServiceMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_EquityAwardsExchangedForCashInBusinessCombinationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Awards Exchanged For Cash In Business Combination [Member]", "label": "Equity Awards Exchanged For Cash In Business Combination [Member]", "terseLabel": "Acquisition awards exchanged for cash" } } }, "localname": "EquityAwardsExchangedForCashInBusinessCombinationMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "hqy_EquityAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Awards [Member]", "label": "Equity Awards [Member]", "terseLabel": "Equity awards" } } }, "localname": "EquityAwardsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_ExerciseofStockOptionsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exercise of Stock Options Receivable", "label": "Exercise of Stock Options Receivable", "terseLabel": "Exercise of common stock options receivable" } } }, "localname": "ExerciseofStockOptionsReceivable", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_FinitelivedIntangibleandIndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finite-lived Intangible and Indefinite-lived Intangible Assets Acquired", "label": "Finite-lived Intangible and Indefinite-lived Intangible Assets Acquired", "terseLabel": "Intangible assets", "totalLabel": "Total acquired intangible assets" } } }, "localname": "FinitelivedIntangibleandIndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_IdentifiedIntangibleAssetsSubjectToAmortizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified Intangible Assets Subject To Amortization [Member]", "label": "Identified Intangible Assets Subject To Amortization [Member]", "terseLabel": "Identified intangible assets subject to amortization" } } }, "localname": "IdentifiedIntangibleAssetsSubjectToAmortizationMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "hqy_IncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Plan [Member]", "label": "Incentive Plan [Member]", "terseLabel": "Incentive Plan" } } }, "localname": "IncentivePlanMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "label": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "terseLabel": "Operating lease not yet commenced undiscounted amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Remaining Lease Term", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining operating lease terms" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_LimitedPartnershipForEarlyStageCompaniesInHealthcareIndustryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Limited Partnership For Early Stage Companies In Healthcare Industry [Member]", "label": "Limited Partnership For Early Stage Companies In Healthcare Industry [Member]", "terseLabel": "Limited partnership" } } }, "localname": "LimitedPartnershipForEarlyStageCompaniesInHealthcareIndustryMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_LossContingencyNumberOfLawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency Number Of Lawsuits", "label": "Loss Contingency Number Of Lawsuits", "terseLabel": "Number of derivative lawsuits" } } }, "localname": "LossContingencyNumberOfLawsuits", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "hqy_MergerIntegrationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Merger Integration [Member]", "label": "Merger Integration [Member]", "terseLabel": "Merger integration" } } }, "localname": "MergerIntegrationMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_OfficeLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Office Lease [Member]", "label": "Office Lease [Member]", "terseLabel": "Office Lease" } } }, "localname": "OfficeLeaseMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "domainItemType" }, "hqy_OtherAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Agreements [Member]", "label": "Other Agreements [Member]", "terseLabel": "Other Agreements" } } }, "localname": "OtherAgreementsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "domainItemType" }, "hqy_PaymentsToSettleClientHeldFunds": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments To Settle Client Held Funds", "label": "Payments To Settle Client Held Funds", "negatedTerseLabel": "Settlement of client-held funds obligation", "terseLabel": "Segregated client-held funds" } } }, "localname": "PaymentsToSettleClientHeldFunds", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_PerformanceRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Awards [Member]", "label": "Performance Restricted Stock Awards [Member]", "terseLabel": "Performance restricted stock awards" } } }, "localname": "PerformanceRestrictedStockAwardsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "hqy_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Restricted Stock Units [Member]", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance restricted stock units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "hqy_PostAcquisitionEquityAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Post-Acquisition Equity Awards [Member]", "label": "Post-Acquisition Equity Awards [Member]", "terseLabel": "Post-acquisition equity awards" } } }, "localname": "PostAcquisitionEquityAwardsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_PostAcquisitionRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Post-Acquisition Restricted Stock Units (RSUs) [Member]", "label": "Post-Acquisition Restricted Stock Units (RSUs) [Member]", "terseLabel": "Post-acquisition restricted stock units" } } }, "localname": "PostAcquisitionRestrictedStockUnitsRSUsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_PreAcquisitionRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre-Acquisition Restricted Stock Units (RSUs) [Member]", "label": "Pre-Acquisition Restricted Stock Units (RSUs) [Member]", "terseLabel": "Pre-acquisition restricted stock units" } } }, "localname": "PreAcquisitionRestrictedStockUnitsRSUsMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_PriorCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prior Credit Agreement [Member]", "label": "Prior Credit Agreement [Member]", "terseLabel": "Credit Agreement Prior To Acquisition" } } }, "localname": "PriorCreditAgreementMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_SalesandMarketingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales and Marketing [Member]", "label": "Sales and Marketing [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SalesandMarketingMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeiturePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Forfeiture Period", "terseLabel": "Forfeiture period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeiturePeriod", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "terseLabel": "Exercised, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Forfeited", "terseLabel": "Forfeited, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitForfeited", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Granted", "terseLabel": "Granted, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitGranted", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "periodEndLabel": "Ending balance, minimum (usd per share)", "periodStartLabel": "Beginning balance, minimum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "terseLabel": "Exercised, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Forfeited", "terseLabel": "Forfeited, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitForfeited", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitGranted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Granted", "terseLabel": "Granted, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitGranted", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "periodEndLabel": "Ending balance, maximum (usd per share)", "periodStartLabel": "Beginning balance, maximum (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "terseLabel": "Percentage of capital stock" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_TechnologyBasedFinancialHealthcareProductsLimitedPartnershipMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Technology Based Financial Healthcare Products Limited Partnership [Member]", "label": "Technology Based Financial Healthcare Products Limited Partnership [Member]", "terseLabel": "Limited partnership" } } }, "localname": "TechnologyBasedFinancialHealthcareProductsLimitedPartnershipMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_TechnologyandDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Technology and Development [Member]", "label": "Technology and Development [Member]", "terseLabel": "Technology and development" } } }, "localname": "TechnologyandDevelopmentMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Facility [Member]", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_TotalNoncashShareBasedPaymentArrangementExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Noncash Share-Based Payment Arrangement Expense [Member]", "label": "Total Noncash Share-Based Payment Arrangement Expense [Member]", "terseLabel": "Total non-cash stock-based compensation expense" } } }, "localname": "TotalNoncashShareBasedPaymentArrangementExpenseMember", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "hqy_UnrecognizedTaxBenefitNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefit, Net", "label": "Unrecognized Tax Benefit, Net", "terseLabel": "Unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefitNet", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "hqy_WageWorksInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "WageWorks Inc. [Member]", "label": "WageWorks Inc. [Member]", "terseLabel": "WageWorks, Inc" } } }, "localname": "WageWorksInc.Member", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails", "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "label": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://healthequity.com/20191031", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r101", "r151", "r153", "r287", "r288" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Cumulative effect from adoption of ASC 606" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]", "terseLabel": "Cumulative effect from adoption of ASU 2016-01" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r13", "r102", "r103", "r152" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts as of October 31, 2019 and January 31, 2019 of $1,021 and $125, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r23", "r133" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r38", "r39", "r40", "r232" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted-average remaining amortization period (years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental financial statement information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r155", "r157", "r193", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r157", "r187", "r192" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r19", "r104", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r67", "r117", "r126" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r91" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r99", "r267", "r278" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r37" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r159", "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Customary Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails", "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails", "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Number of service-based common stock (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails", "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r212", "r213" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "verboseLabel": "Merger related costs, price per share" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r212", "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net income (loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r212", "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r210" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition costs", "terseLabel": "Acquisition costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r224", "r225", "r226" ], "calculation": { "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Aggregate fair value of WageWorks stock acquired", "totalLabel": "Total consideration paid" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r224", "r225" ], "calculation": { "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Aggregate fair value of WageWorks stock acquired", "verboseLabel": "Fair value of equity awards" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r223", "r224", "r225", "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Borrowing pursuant to term loan facility" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Merger integration" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r211" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Contribution of revenue" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedTerseLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r199", "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r216", "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total consideration paid" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedTerseLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r216", "r217" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r71", "r72", "r73" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable or accrued liabilities at period end" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "auth_ref": [ "r118" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additions made to capitalized computer software costs during the period.", "label": "Capitalized Computer Software, Additions", "terseLabel": "Capitalized software development costs" } } }, "localname": "CapitalizedComputerSoftwareAdditions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r20", "r69" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r63", "r69", "r74" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending cash and cash equivalents", "periodStartLabel": "Beginning cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r63", "r238" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r137", "r271", "r283" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r136", "r138" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of common stock issuable (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock", "verboseLabel": "WageWorks stock acquired" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r144" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 900,000 shares authorized, 70,832 and 62,446 shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r42", "r44", "r45" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r118", "r124", "r221" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer software intangible asset" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r75", "r231", "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r52" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Total cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditAndDebitCardMember": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Card issued to user to facilitate payment for purchase of product and service paid directly to merchant by issuer, or from user's checking account.", "label": "Credit and Debit Card [Member]", "terseLabel": "Interchange revenue" } } }, "localname": "CreditAndDebitCardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect from adoption of accounting standard updates" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships", "verboseLabel": "Acquired customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Indebtedness" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Indebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r8", "r9", "r10", "r268", "r269", "r277" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate borrowing spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r10", "r141", "r269", "r277" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Term loan facility", "totalLabel": "Total" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails", "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r31", "r77", "r145", "r146", "r147", "r148", "r240", "r241", "r243", "r276" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Facility term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Lender fees" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r24", "r242" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized loan issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r205" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r67", "r76", "r206", "r207" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r200", "r205" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r67", "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r67", "r97" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r222" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r49", "r82", "r86", "r88", "r89", "r90", "r93", "r274", "r285" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income (loss) per share:", "verboseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r49", "r82", "r86", "r88", "r89", "r90", "r93", "r274", "r285" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r78", "r201", "r202" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r195", "r201" ], "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "negatedTerseLabel": "Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average vesting period of non-vested awards expected to vest" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock compensation expense to be recognized in future" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of equity interests that are issued or issuable in a business combination.", "label": "Equity Interest Type [Axis]", "terseLabel": "Equity Interest Type [Axis]" } } }, "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.", "label": "Equity Interest Issued or Issuable, Type [Domain]", "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]" } } }, "localname": "EquityInterestIssuedOrIssuableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r21", "r100", "r108" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r107" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "Gain on marketable equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Non-marketable equity securities" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialServiceOtherMember": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.", "label": "Financial Service, Other [Member]", "terseLabel": "Custodial revenue" } } }, "localname": "FinancialServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Preliminary Allocation of Consideration Paid to Acquired Identified Intangible Assets" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r125" ], "calculation": { "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r118", "r122", "r125", "r128", "r265" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r125", "r265" ], "calculation": { "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Amortizable intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r118", "r124" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r125" ], "calculation": { "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total amortizable intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r119" ], "calculation": { "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails": { "order": 1.0, "parentTag": "hqy_FinitelivedIntangibleandIndefinitelivedIntangibleAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Fair value" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r112", "r113" ], "calculation": { "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails", "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Change in goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r51" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-process software development costs" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r47", "r82", "r266", "r272", "r286" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r98", "r208" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid in cash, net of refunds received" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r66" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r66" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r66" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r66" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r66" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r87", "r92" ], "calculation": { "http://healthequity.com/role/NetIncomeLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted-average dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r121", "r127" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r127" ], "calculation": { "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "verboseLabel": "Acquired in-process software development costs" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r121", "r127" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails": { "order": 2.0, "parentTag": "hqy_FinitelivedIntangibleandIndefinitelivedIntangibleAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-lived Intangible Assets Acquired", "terseLabel": "In-process software development costs" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r116", "r123" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r46", "r96", "r239", "r242", "r275" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r62", "r64", "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r54" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments in equity securities" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r261", "r263" ], "calculation": { "http://healthequity.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net operating lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease not yet commenced term of contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating lease liability maturity schedule" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remaining 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r262" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal terms extension" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesNarrativeDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r270", "r281" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r10", "r269", "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r10", "r142", "r269", "r279" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r79", "r139" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r79", "r139" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r79", "r139" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r79", "r139" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r79", "r139" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r79" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year", "terseLabel": "Remaining 2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of issuance costs" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r31", "r140" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Investment ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r63", "r65", "r68" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r41", "r43", "r48", "r68", "r92", "r273", "r284" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator (basic and diluted):" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r81", "r83" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent adopted and issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r71", "r72", "r73" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Purchases of intangible assets" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r250" ], "calculation": { "http://healthequity.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease cost", "verboseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r249" ], "calculation": { "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r249" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r249" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r251", "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r248" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r260", "r263" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r259", "r263" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r244", "r245" ], "calculation": { "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r244", "r245" ], "calculation": { "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r244", "r245" ], "calculation": { "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r244", "r245" ], "calculation": { "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r244", "r245" ], "calculation": { "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r244", "r245" ], "calculation": { "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r244", "r245" ], "calculation": { "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.", "label": "Operating Leases, Rent Expense, Sublease Rentals", "terseLabel": "Sublease income" } } }, "localname": "OperatingLeasesRentExpenseSubleaseRentals1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r80", "r95", "r235" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of business and significant accounting policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r55" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "totalLabel": "Total other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": { "auth_ref": [ "r71", "r72", "r73" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Value of Consideration Given", "terseLabel": "Equity-based acquisition consideration" } } }, "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r57" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Purchases of software and capitalized software development costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r61" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r56", "r227" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r56" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r57" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of intangible member assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r58" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of marketable equity securities and other" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r159", "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r59" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from follow-on equity offering, net of payment for offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r60" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r59", "r190" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r23", "r134" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r22", "r132" ], "calculation": { "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r7", "r134", "r282" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r6", "r134" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r6", "r132" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r197", "r290" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Technology and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "Software development costs incurred and expensed" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r91" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock awards", "verboseLabel": "RSAs and PRSAs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "netLabel": "Restricted stock units", "terseLabel": "Restricted stock units", "verboseLabel": "RSUs and PRSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r149", "r280" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r150", "r151" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Secured Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r258", "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails", "http://healthequity.com/role/BusinessCombinationNarrativeDetails", "http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails", "http://healthequity.com/role/BusinessCombinationProFormaResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Total Consideration Paid" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense by award type" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r31", "r77", "r145", "r146", "r147", "r148", "r240", "r241", "r243", "r276" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings (loss) per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r157", "r186", "r192" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of share based compensation recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r118", "r124" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r118", "r124" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Operating lease liability maturity schedule" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r127", "r129" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r127", "r129" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of indefinite-lived intangible assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r23", "r134" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Preliminary Allocation of Consideration" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r159", "r189" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of restricted stock unit activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r164", "r175", "r177" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r66" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Performance units awards (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, ending balance (in shares)", "periodStartLabel": "Unvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r171" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, ending balance (usd per share)", "periodStartLabel": "Unvested, beginning balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails", "http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable as of year end, weighted-average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails", "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r166", "r189" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Opening balance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (usd per share)", "periodStartLabel": "Opening balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest as of year end, aggregate intrinsic value (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable as of year end (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r177" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest as of year end (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest as of year end, weighted average exercise price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r156", "r163" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails", "http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails", "http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]", "terseLabel": "Range of exercise prices (usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r181", "r191" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable as of year end, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable as of year end, weighted-average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest as of year end, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r35", "r144" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r12", "r144", "r149", "r168" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r144", "r149" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Other issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r11", "r12", "r149", "r158", "r176" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock upon exercise of stock options, and for restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r16", "r17", "r105" ], "calculation": { "http://healthequity.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets", "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r256", "r263" ], "calculation": { "http://healthequity.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income", "terseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsAndContingenciesDetails", "http://healthequity.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow data:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Acquired trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade names & trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r198", "r203" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Gross unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r204" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r85", "r90" ], "calculation": { "http://healthequity.com/role/NetIncomeLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator (diluted):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r84", "r90" ], "calculation": { "http://healthequity.com/role/NetIncomeLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Weighted-average common shares outstanding (in shares)", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator (basic):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthequity.com/role/NetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r291": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r292": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r293": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r294": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r295": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r296": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" } }, "version": "2.1" } XML 31 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Supplemental Cash Flow Information) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 2,746 $ 4,575
ROU assets obtained in exchange for new operating lease obligations $ 34,196 $ 34,394
XML 32 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Business combination (Preliminary Allocation of Consideration) (Details) - USD ($)
$ in Thousands
Oct. 31, 2019
Jan. 31, 2019
Business Acquisition [Line Items]    
Goodwill $ 1,335,187 $ 4,651
WageWorks, Inc    
Business Acquisition [Line Items]    
Cash and cash equivalents 406,800  
Other current assets 56,500  
Property, plant, and equipment 26,600  
Operating lease right-of-use assets 42,500  
Intangible assets 715,300  
Goodwill 1,330,500  
Other assets 5,900  
Client-held funds obligation (237,500)  
Other current liabilities (69,100)  
Other long-term liabilities (26,700)  
Deferred tax liability (128,700)  
Total consideration paid $ 2,122,100  
XML 33 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental financial statement information (Other expense, net) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Interest income $ 2,046 $ 358 $ 5,273 $ 919
Gain on marketable equity securities 285 0 27,570 0
Acquisition costs (32,932) (849) (40,712) (1,074)
Other expense (348) (996) (478) (1,272)
Total other expense, net $ (30,949) $ (1,487) $ (8,347) $ (1,427)
XML 34 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation (Narrative) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 30, 2019
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2017
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of shares authorized (in shares)         2,600,000   2,600,000  
Percentage of capital stock         3.00%   3.00%  
Expected dividend yield           0.00% 0.00% 0.00%
Unrecognized stock compensation expense to be recognized in future         $ 8,800   $ 8,800  
Share-based compensation expense         23,156 $ 5,734 $ 36,774 $ 15,461
Restricted stock units                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Weighted-average vesting period of non-vested awards expected to vest             2 years 7 months 6 days  
Award vesting period             4 years  
Share-based compensation expense         14,099 1,956 $ 20,718 5,543
Performance units awards (in shares)             1,124,000  
Aggregate intrinsic value         19,900 5,500 $ 19,900 5,500
Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future         67,100   $ 67,100  
Stock options                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Expiration period             10 years  
Forfeiture period             90 days  
Weighted-average vesting period of non-vested awards expected to vest             1 year 6 months  
Share-based compensation expense         1,631 1,917 $ 5,140 5,664
Performance restricted stock units                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Share-based compensation expense         1,422 793 3,467 1,843
Performance units awards (in shares)   129,963   146,964        
Performance restricted stock units | Minimum                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Award vesting rights percentage   0.00%   0.00%        
Performance restricted stock units | Maximum                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Award vesting rights percentage   200.00%   150.00%        
Performance restricted stock awards                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Share-based compensation expense         260 718 $ 1,378 1,509
Performance units awards (in shares)     227,760          
Performance restricted stock awards | Minimum                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Award vesting rights percentage     0.00%          
Performance restricted stock awards | Maximum                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Award vesting rights percentage     200.00%          
Restricted stock awards                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Weighted-average vesting period of non-vested awards expected to vest             1 year 7 months 6 days  
Award vesting period             4 years  
Share-based compensation expense         164 $ 172 $ 491 $ 399
Performance units awards (in shares)             0  
Aggregate intrinsic value         800   $ 800  
Unrecognized stock-based compensation expense related to restricted stock units to be recognized in future         4,300   $ 4,300  
WageWorks, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Share-based compensation expense         $ 8,100      
Restricted stock units | WageWorks, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of service-based common stock (in shares) 523,318              
Aggregate fair value of WageWorks stock acquired $ 29,700              
Pre-acquisition restricted stock units | WageWorks, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Aggregate fair value of WageWorks stock acquired 3,800              
Post-acquisition restricted stock units | WageWorks, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Aggregate fair value of WageWorks stock acquired 25,900              
Equity awards | WageWorks, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Aggregate fair value of WageWorks stock acquired 23,600              
Pre-acquisition equity awards | WageWorks, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Aggregate fair value of WageWorks stock acquired 18,100              
Post-acquisition equity awards | WageWorks, Inc                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Aggregate fair value of WageWorks stock acquired $ 5,600              
Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of common stock issuable (in shares) 5,255,027              
XML 35 hqy-2019x10x3110q_htm.xml IDEA: XBRL DOCUMENT 0001428336 2019-02-01 2019-10-31 0001428336 2019-12-02 0001428336 2019-01-31 0001428336 2019-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-02-01 2019-10-31 0001428336 2018-02-01 2018-10-31 0001428336 2018-08-01 2018-10-31 0001428336 2019-08-01 2019-10-31 0001428336 us-gaap:ServiceMember 2019-02-01 2019-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-02-01 2018-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-02-01 2019-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2018-08-01 2018-10-31 0001428336 us-gaap:CreditAndDebitCardMember 2019-08-01 2019-10-31 0001428336 us-gaap:ServiceMember 2019-08-01 2019-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-02-01 2018-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2019-08-01 2019-10-31 0001428336 us-gaap:ServiceMember 2018-02-01 2018-10-31 0001428336 us-gaap:FinancialServiceOtherMember 2018-08-01 2018-10-31 0001428336 us-gaap:ServiceMember 2018-08-01 2018-10-31 0001428336 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2019-07-31 0001428336 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-02-01 2018-10-31 0001428336 us-gaap:CommonStockMember 2018-02-01 2018-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-08-01 2019-10-31 0001428336 us-gaap:CommonStockMember 2018-01-31 0001428336 us-gaap:RetainedEarningsMember 2018-07-31 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:RetainedEarningsMember 2018-02-01 0001428336 us-gaap:RetainedEarningsMember 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0001428336 us-gaap:CommonStockMember 2018-07-31 0001428336 us-gaap:CommonStockMember 2019-08-01 2019-10-31 0001428336 us-gaap:RetainedEarningsMember 2018-02-01 2018-10-31 0001428336 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-31 0001428336 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-08-01 2018-10-31 0001428336 us-gaap:RetainedEarningsMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001428336 us-gaap:CommonStockMember 2018-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2019-10-31 0001428336 us-gaap:CommonStockMember 2019-10-31 0001428336 us-gaap:CommonStockMember 2019-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0001428336 us-gaap:CommonStockMember 2018-08-01 2018-10-31 0001428336 us-gaap:CommonStockMember 2019-02-01 2019-10-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001428336 us-gaap:RetainedEarningsMember 2018-08-01 2018-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0001428336 2018-07-31 0001428336 us-gaap:CommonStockMember 2019-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-07-31 0001428336 us-gaap:RetainedEarningsMember 2018-01-31 0001428336 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001428336 us-gaap:RetainedEarningsMember 2019-08-01 2019-10-31 0001428336 us-gaap:RetainedEarningsMember 2019-02-01 2019-10-31 0001428336 us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-02-01 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-02-01 2018-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2018-02-01 2018-10-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-02-01 2019-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-02-01 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-30 0001428336 hqy:WageWorksInc.Member 2019-08-29 0001428336 srt:MinimumMember 2019-02-01 2019-10-31 0001428336 hqy:LimitedPartnershipForEarlyStageCompaniesInHealthcareIndustryMember 2019-10-31 0001428336 srt:MinimumMember 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-30 0001428336 hqy:TechnologyBasedFinancialHealthcareProductsLimitedPartnershipMember 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-30 2019-08-30 0001428336 us-gaap:AccountingStandardsUpdate201602Member 2019-02-01 0001428336 srt:MaximumMember 2019-02-01 2019-10-31 0001428336 srt:MaximumMember 2019-10-31 0001428336 hqy:WageWorksInc.Member hqy:EquityAwardsAssumedAttributableToPreAcquisitionServiceMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:EquityAwardsExchangedForCashAttributableToPreAcquisitionServiceMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:CommonStockMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member 2019-10-31 0001428336 hqy:WageWorksInc.Member 2019-08-01 2019-10-31 0001428336 hqy:WageWorksInc.Member 2018-02-01 2018-10-31 0001428336 hqy:WageWorksInc.Member 2018-08-01 2018-10-31 0001428336 hqy:WageWorksInc.Member 2019-02-01 2019-10-31 0001428336 hqy:WageWorksInc.Member hqy:TermLoanFacilityMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:CustomerRelationshipsMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:DevelopedTechnologyRightsMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:IdentifiedIntangibleAssetsSubjectToAmortizationMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:TrademarksAndTradeNamesMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2019-08-30 2019-08-30 0001428336 us-gaap:LeaseholdImprovementsMember 2019-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-01-31 0001428336 us-gaap:ComputerEquipmentMember 2019-10-31 0001428336 us-gaap:LeaseholdImprovementsMember 2019-10-31 0001428336 us-gaap:FurnitureAndFixturesMember 2019-10-31 0001428336 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-31 0001428336 us-gaap:TradeNamesMember 2019-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-10-31 0001428336 us-gaap:TradeNamesMember 2019-10-31 0001428336 us-gaap:CustomerRelationshipsMember 2019-01-31 0001428336 us-gaap:InProcessResearchAndDevelopmentMember 2019-10-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2019-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-10-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2019-10-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2019-01-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-10-31 0001428336 2018-02-01 2019-01-31 0001428336 2018-06-22 2018-06-22 0001428336 hqy:OfficeLeaseMember 2019-01-31 0001428336 hqy:OtherAgreementsMember 2019-01-31 0001428336 2018-09-06 2018-09-06 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtCovenantPeriodFourMember 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtCovenantPeriodOneMember 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtCovenantPeriodFourMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtCovenantPeriodTwoMember 2019-08-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember hqy:DebtCovenantPeriodThreeMember 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-08-30 2019-08-30 0001428336 srt:MinimumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:PriorCreditAgreementMember us-gaap:LineOfCreditMember 2015-09-30 2015-09-30 0001428336 srt:MaximumMember us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2019-08-30 2019-08-30 0001428336 us-gaap:LineOfCreditMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2019-08-30 2019-08-30 0001428336 us-gaap:PerformanceSharesMember 2018-08-01 2018-10-31 0001428336 us-gaap:RestrictedStockMember 2018-08-01 2018-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-02-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-02-01 2019-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-08-01 2018-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2018-02-01 2018-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-02-01 2019-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2019-08-01 2019-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-08-01 2019-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2019-08-01 2019-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-02-01 2019-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-08-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-08-01 2019-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2019-08-01 2019-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2018-02-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2019-02-01 2019-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-02-01 2018-10-31 0001428336 us-gaap:RestrictedStockMember 2019-02-01 2019-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2018-08-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-02-01 2018-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2018-08-01 2018-10-31 0001428336 hqy:TotalNoncashShareBasedPaymentArrangementExpenseMember 2019-02-01 2019-10-31 0001428336 us-gaap:RestrictedStockMember 2018-02-01 2018-10-31 0001428336 us-gaap:PerformanceSharesMember 2019-08-01 2019-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-02-01 2018-10-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2018-08-01 2018-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-08-01 2019-10-31 0001428336 hqy:EquityAwardsExchangedForCashInBusinessCombinationMember 2019-02-01 2019-10-31 0001428336 us-gaap:EmployeeStockOptionMember 2018-08-01 2018-10-31 0001428336 us-gaap:RestrictedStockMember 2019-08-01 2019-10-31 0001428336 us-gaap:PerformanceSharesMember 2019-02-01 2019-10-31 0001428336 us-gaap:PerformanceSharesMember 2018-02-01 2018-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-01-31 0001428336 us-gaap:RestrictedStockMember 2019-10-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2019-10-31 0001428336 hqy:WageWorksInc.Member hqy:PreAcquisitionRestrictedStockUnitsRSUsMember 2019-08-30 2019-08-30 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 hqy:IncentivePlanMember 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:PostAcquisitionEquityAwardsMember 2019-08-30 2019-08-30 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2017-03-01 2017-03-31 0001428336 hqy:WageWorksInc.Member us-gaap:RestrictedStockUnitsRSUMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:EquityAwardsMember 2019-08-30 2019-08-30 0001428336 hqy:WageWorksInc.Member hqy:PostAcquisitionRestrictedStockUnitsRSUsMember 2019-08-30 2019-08-30 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2018-10-31 0001428336 hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2019-03-01 2019-03-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockAwardsMember 2018-03-01 2018-03-31 0001428336 hqy:MergerIntegrationMember 2019-08-01 2019-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-08-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-08-01 2019-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2018-02-01 2018-10-31 0001428336 hqy:SalesandMarketingMember 2018-02-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-02-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-08-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-02-01 2018-10-31 0001428336 hqy:SalesandMarketingMember 2019-08-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2018-08-01 2018-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-08-01 2019-10-31 0001428336 us-gaap:CostOfSalesMember 2018-08-01 2018-10-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2019-02-01 2019-10-31 0001428336 us-gaap:CostOfSalesMember 2019-02-01 2019-10-31 0001428336 hqy:MergerIntegrationMember 2018-02-01 2018-10-31 0001428336 hqy:MergerIntegrationMember 2018-08-01 2018-10-31 0001428336 hqy:SalesandMarketingMember 2018-08-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-08-01 2018-10-31 0001428336 us-gaap:CostOfSalesMember 2019-08-01 2019-10-31 0001428336 hqy:TechnologyandDevelopmentMember 2019-02-01 2019-10-31 0001428336 hqy:SalesandMarketingMember 2019-02-01 2019-10-31 0001428336 us-gaap:CostOfSalesMember 2018-02-01 2018-10-31 0001428336 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-02-01 2018-10-31 0001428336 hqy:MergerIntegrationMember 2019-02-01 2019-10-31 0001428336 srt:MinimumMember 2018-02-01 2018-10-31 0001428336 srt:MaximumMember 2018-02-01 2018-10-31 hqy:lawsuit shares iso4217:USD iso4217:USD shares pure false --01-31 Q3 2020 0001428336 2 0.10 24.36 63.64 0.10 0.10 44.53 44.53 73.61 82.39 82.39 125000 1021000 0.0001 0.0001 900000000 900000000 62446000 70832000 62446000 70832000 15686000 60780000 -21334000 39854000 P5Y P5Y 0 0.0001 0.0001 100000000 100000000 0 0 0 0 P4Y P4Y 0.3784 0.3653 0.3709 0.3598 0.0279 0.0243 0.0252 0.0221 P6Y3M P5Y2M1D P5Y1M2D P4Y11M12D 10-Q true 2019-10-31 false 001-36568 HEALTHEQUITY, INC. DE 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper, UT 84020 801 727-1000 Common stock, par value $0.0001 per share HQY NASDAQ Yes Yes Large Accelerated Filer false false false 70879268 174557000 361475000 66647000 25668000 29119000 7534000 270323000 394677000 35199000 8223000 88515000 796228000 79666000 1335187000 4651000 0 1677000 34469000 21122000 2559921000 510016000 7966000 3520000 37559000 16981000 54305000 8552000 31250000 0 10780000 141860000 29053000 1196016000 0 73052000 128642000 916000 2590000 2968000 1542160000 32937000 0 0 7000 6000 806050000 305223000 211704000 171850000 1017761000 477079000 2559921000 510016000 87620000 25041000 140710000 74797000 46972000 31564000 132538000 90713000 22526000 13890000 57545000 45956000 157118000 70495000 330793000 211466000 52278000 17562000 92672000 52808000 4384000 3551000 12716000 10492000 4421000 3565000 13177000 11418000 61083000 24678000 118565000 74718000 96035000 45817000 212228000 136748000 12654000 7502000 30015000 21605000 23511000 8678000 46061000 25055000 19222000 9161000 37193000 24561000 13051000 1490000 16036000 4438000 17675000 0 20459000 0 86113000 26831000 149764000 75659000 9922000 18986000 62464000 61089000 10225000 68000 10355000 204000 -30949000 -1487000 -8347000 -1427000 -31252000 17431000 43762000 59458000 -9918000 1745000 3908000 -1322000 -21334000 15686000 39854000 60780000 -0.30 0.25 0.61 0.98 -0.30 0.25 0.59 0.96 70524000 62088000 65727000 61718000 70524000 63923000 67150000 63628000 1017031000 432619000 477079000 346274000 7000 6000 6000 6000 0 0 0 0 0 0 1000 0 7000 6000 7000 6000 783986000 289568000 305223000 261237000 712000 2762000 7363000 21366000 3776000 0 462270000 0 17576000 5734000 31194000 15461000 806050000 298064000 806050000 298064000 0 0 0 -269000 269000 0 0 0 0 233038000 143045000 171850000 85300000 -21334000 15686000 39854000 60780000 13007000 -356000 211704000 158731000 211704000 158731000 1017761000 456801000 1017761000 456801000 39854000 60780000 28791000 13498000 25303000 -895000 690000 394000 31194000 15461000 2817000 2863000 4937000 4568000 -3340000 524000 -1087000 -8012000 -2617000 13655000 451000 -2859000 -50000 441000 74070000 80785000 1630066000 0 9070000 1195000 53845000 574000 5180000 3467000 17232000 7352000 -1715393000 -12588000 1250000000 0 30504000 0 230928000 0 458495000 0 7342000 21338000 1454405000 21338000 -186918000 89535000 361475000 199472000 174557000 289007000 249000 162000 9127000 628000 3776000 0 168000 6000 316000 156000 -151000 0 21000 28000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Summary of business and significant accounting policies</span><span style="font-family:Arial;font-size:12pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Business</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002. HealthEquity, Inc. is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Acquisition of WageWorks, Inc.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On August 30, 2019, HealthEquity, Inc. closed the acquisition of WageWorks, Inc. (“WageWorks”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), for </span><span style="font-family:Arial;font-size:10pt;"><span>$51.35</span></span><span style="font-family:Arial;font-size:10pt;"> per share in cash, or approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:10pt;"> to WageWorks stockholders (the “Acquisition”). </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As a result of the Acquisition, HealthEquity, Inc. gained access to more of the HSA market by expanding its direct distribution to employers and benefits advisors as a single source provider of HSAs and other CDBs, including flexible spending accounts, health reimbursement arrangements, COBRA administration, commuter and other benefits.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Principles of consolidation</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, HealthEquity Retirement Services, LLC, and, after the closing of the Acquisition on August 30, 2019, WageWorks, Inc. and its subsidiaries MyFlexMobile, Inc., WageWorks India, Inc. and WageWorks Services, LLP (collectively referred to as the "Company").</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior to the closing of the Acquisition, the Company held a </span><span style="font-family:Arial;font-size:10pt;"><span>4%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in WageWorks. The Company measured the investment at fair value, and all gains on the investment were recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). In connection with the closing of the Acquisition on August 30, 2019, the Company's investment in WageWorks was canceled, and WageWorks became a wholly owned subsidiary of the Company. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>22%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at </span><span style="font-family:Arial;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisitions of businesses, including the Acquisition of WageWorks, are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Basis of presentation </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The accompanying condensed consolidated financial statements as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and for the </span><span style="font-family:Arial;font-size:10pt;">three and nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Significant accounting policies </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">There have been no material changes in the Company’s significant accounting policies, other than the additions of the policies described below for leases, investments in equity securities, and client-held funds, as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases. </span><span style="font-family:Arial;font-size:10pt;">The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has entered into various operating leases consisting of office space, data storage facilities, and other leases with remaining lease terms of approximately less than </span><span style="font-family:Arial;font-size:10pt;"><span>1</span></span><span style="font-family:Arial;font-size:10pt;"> year to </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> years, often with one or more Company options to renew. These renewal terms can extend the lease term from </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Investments in equity securities. </span><span style="font-family:Arial;font-size:10pt;">Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and were classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). As a result of the Acquisition on August 30, 2019, the Company's marketable equity security investment in WageWorks was canceled.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as other assets on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss). </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in other assets on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">charge through other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Client-held funds. </span><span style="font-family:Arial;font-size:10pt;">Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”, respectively) and commuter accounts. These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's condensed consolidated balance sheets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior to the closing of the Acquisition, Wageworks included all Client-held funds with its corporate cash assets on its balance sheet, with an offsetting Client-held funds obligation. As of the closing of the Acquisition on August 30, 2019, WageWorks held approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$682 million</span></span><span style="font-family:Arial;font-size:10pt;"> of Client-held funds, of which </span><span style="font-family:Arial;font-size:10pt;"><span>$238 million</span></span><span style="font-family:Arial;font-size:10pt;"> was combined with its corporate cash within WageWorks' corporate bank accounts; therefore, the Company determined that this </span><span style="font-family:Arial;font-size:10pt;"><span>$238 million</span></span><span style="font-family:Arial;font-size:10pt;"> of Client-held funds were assets of the Company, while the approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$444 million</span></span><span style="font-family:Arial;font-size:10pt;"> of remaining Client-held funds were not assets of the Company. Prior to October 31, 2019, the Company segregated </span><span style="font-family:Arial;font-size:10pt;"><span>$231 million</span></span><span style="font-family:Arial;font-size:10pt;"> of Client-held funds from its corporate bank accounts. Accordingly, as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>$7 million</span></span><span style="font-family:Arial;font-size:10pt;"> of Client-held funds remained combined within the Company's corporate bank accounts and therefore remained on the Company's condensed consolidated balance sheets in cash and cash equivalents, with an offsetting liability included in accrued liabilities.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent adopted accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">(codified as "ASC 842"), </span><span style="font-family:Arial;font-size:10pt;">which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of </span><span style="font-family:Arial;font-size:10pt;"><span>$40.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and ROU assets of </span><span style="font-family:Arial;font-size:10pt;"><span>$38.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;">-month period ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Arial;font-size:10pt;">. This ASU permits the capitalization of implementation costs incurred in a software hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. The Company elected to early adopt the new standard as of October 31, 2019 using the prospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent issued accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments,</span><span style="font-family:Arial;font-size:10pt;"> which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Simplifying the Test for Goodwill Impairment,</span><span style="font-family:Arial;font-size:10pt;"> which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, FASB issued ASU 2018-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Arial;font-size:10pt;"> (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div> 51.35 2000000000.0 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Principles of consolidation</span><span style="font-family:Arial;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, HealthEquity Retirement Services, LLC, and, after the closing of the Acquisition on August 30, 2019, WageWorks, Inc. and its subsidiaries MyFlexMobile, Inc., WageWorks India, Inc. and WageWorks Services, LLP (collectively referred to as the "Company").</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Prior to the closing of the Acquisition, the Company held a </span><span style="font-family:Arial;font-size:10pt;"><span>4%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in WageWorks. The Company measured the investment at fair value, and all gains on the investment were recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). In connection with the closing of the Acquisition on August 30, 2019, the Company's investment in WageWorks was canceled, and WageWorks became a wholly owned subsidiary of the Company. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>22%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has a </span><span style="font-family:Arial;font-size:10pt;"><span>1%</span></span><span style="font-family:Arial;font-size:10pt;"> ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at </span><span style="font-family:Arial;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and is included in investments on the accompanying condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisitions of businesses, including the Acquisition of WageWorks, are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.</span></div> 0.04 0.22 200000 0.01 500000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Basis of presentation </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The accompanying condensed consolidated financial statements as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and for the </span><span style="font-family:Arial;font-size:10pt;">three and nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div> Certain reclassifications have been made to prior year amounts to conform to the current year presentation. <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Leases. </span><span style="font-family:Arial;font-size:10pt;">The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has entered into various operating leases consisting of office space, data storage facilities, and other leases with remaining lease terms of approximately less than </span><span style="font-family:Arial;font-size:10pt;"><span>1</span></span><span style="font-family:Arial;font-size:10pt;"> year to </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> years, often with one or more Company options to renew. These renewal terms can extend the lease term from </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019. </span></div> P1Y P11Y P3Y P10Y <div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Investments in equity securities. </span><span style="font-family:Arial;font-size:10pt;">Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and were classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). As a result of the Acquisition on August 30, 2019, the Company's marketable equity security investment in WageWorks was canceled.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as other assets on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss). </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in other assets on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">charge through other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). </span></div> <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Client-held funds. </span><span style="font-family:Arial;font-size:10pt;">Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”, respectively) and commuter accounts. These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's condensed consolidated balance sheets.</span></div> 682000000 238000000 238000000 444000000 231000000 7000000 <div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent adopted accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">(codified as "ASC 842"), </span><span style="font-family:Arial;font-size:10pt;">which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of </span><span style="font-family:Arial;font-size:10pt;"><span>$40.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and ROU assets of </span><span style="font-family:Arial;font-size:10pt;"><span>$38.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;">-month period ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Arial;font-size:10pt;">. This ASU permits the capitalization of implementation costs incurred in a software hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. The Company elected to early adopt the new standard as of October 31, 2019 using the prospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Recent issued accounting pronouncements</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments,</span><span style="font-family:Arial;font-size:10pt;"> which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04,</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> Simplifying the Test for Goodwill Impairment,</span><span style="font-family:Arial;font-size:10pt;"> which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In August 2018, FASB issued ASU 2018-13, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Arial;font-size:10pt;"> (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.</span></div> 40600000 38000000.0 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Net income (loss) per share</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator (basic and diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(21,334</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,854</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (basic):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,718</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,718</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average dilutive effect of stock options and restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,910</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,923</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss) per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>3.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>36,000</span></span><span style="font-family:Arial;font-size:10pt;"> shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, approximately </span><span style="font-family:Arial;font-size:10pt;"><span>0.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except per share data)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator (basic and diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(21,334</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,854</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>60,780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (basic):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,718</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator (diluted):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,718</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average dilutive effect of stock options and restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,910</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted weighted-average common shares outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>70,524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,923</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss) per share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Basic </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> -21334000 15686000 39854000 60780000 70524000 62088000 65727000 61718000 70524000 62088000 65727000 61718000 0 1835000 1423000 1910000 70524000 63923000 67150000 63628000 -0.30 0.25 0.61 0.98 -0.30 0.25 0.59 0.96 3200000 36000 300000 100000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Business combination</span><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Acquisition of WageWorks</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Overview and total consideration paid</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On August 30, 2019, the Company closed the Acquisition of WageWorks for </span><span style="font-family:Arial;font-size:10pt;"><span>$51.35</span></span><span style="font-family:Arial;font-size:10pt;"> per share in cash, or approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:10pt;"> to WageWorks stockholders. The Company financed the transaction through a combination of </span><span style="font-family:Arial;font-size:10pt;"><span>$816.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> cash on hand plus net borrowings of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$1.22 billion</span></span><span style="font-family:Arial;font-size:10pt;">, after deducting lender fees of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$30.5 million</span></span><span style="font-family:Arial;font-size:10pt;">, under a term loan facility (see Note 8—Indebtedness). </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pursuant to the Merger Agreement, the Company replaced certain outstanding restricted stock units originally granted by WageWorks with the Company’s equivalent awards. The outstanding WageWorks vested and unvested stock options, and certain unvested restricted stock units, were settled in cash as specified in the Merger Agreement. The portion of the fair value of partially vested awards associated with pre-acquisition service of WageWorks award recipients represented a component of the total consideration, as presented below.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Acquisition was accounted for under the acquisition method of accounting for business combinations. Under this accounting method, the total consideration paid was:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Aggregate fair value of WageWorks stock acquired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,018.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of previously owned investment in WageWorks stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of equity awards exchanged for cash attributable to pre-Acquisition service</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of equity awards replaced attributable to pre-Acquisition service</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total consideration paid</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,122.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the Acquisition date. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants to value acquired intangible assets. The initial allocation of the consideration paid is based on a preliminary valuation and is subject to potential adjustment during the measurement period (up to one year from the Acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Preliminary allocation of consideration</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Estimated fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>406.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property, plant, and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>42.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>715.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,330.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Client-held funds obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(237.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(69.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(128.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total consideration paid</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,122.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Acquisition resulted in </span><span style="font-family:Arial;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:10pt;"> of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational and financial benefits expected from the Acquisition, including custodial and interchange revenue synergies based on current contractual relationships, as well as operational cost synergies resulting from increased scale in service delivery and elimination of duplicative management functions and other back-office operational efficiencies. The goodwill created in the Acquisition is not expected to be deductible for tax purposes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Weighted-average remaining amortization period (years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships </span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>598.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology </span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>96.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.5</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade names &amp; trademarks </span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.0</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Identified intangible assets subject to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.4</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In-process software development costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">n/a</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total acquired intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>711.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the transaction, for the three and nine months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company incurred approximately $</span><span style="font-family:Arial;font-size:10pt;"><span>32.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$40.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, of acquisition costs, which are recorded as other expense, net. For the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, WageWorks contributed revenue of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$72.1 million</span></span><span style="font-family:Arial;font-size:10pt;">.  For the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, operating expenses related to WageWorks were approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$39.9 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Pro forma information</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The unaudited pro forma results presented below include the effects of the Acquisition as if it had been consummated as of February 1, 2018, with adjustments to give effect to pro forma events that are directly attributable to the Acquisition, which include adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings that may result from the integration of WageWorks. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the Acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations. The estimated pro forma revenue and net income (loss) includes the alignment of accounting policies, the effect of fair value adjustments related to the Acquisition, associated tax effects and the impact of the borrowings to finance the Acquisition and related expenses.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>194,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>186,022</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>598,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>573,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(21,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 51.35 2000000000.0 816900000 1220000000 30500000 Under this accounting method, the total consideration paid was:<div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Aggregate fair value of WageWorks stock acquired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,018.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of previously owned investment in WageWorks stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>81.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of equity awards exchanged for cash attributable to pre-Acquisition service</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value of equity awards replaced attributable to pre-Acquisition service</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total consideration paid</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,122.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 2018800000 81400000 18100000 3800000 2122100000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Preliminary allocation of consideration</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Estimated fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>406.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>56.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property, plant, and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>42.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>715.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,330.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Client-held funds obligation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(237.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(69.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(26.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Deferred tax liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(128.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total consideration paid</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,122.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 406800000 56500000 26600000 42500000 715300000 1330500000 5900000 237500000 69100000 26700000 128700000 2122100000 1300000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:</span></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Weighted-average remaining amortization period (years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Customer relationships </span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>598.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>15.0</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Developed technology </span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>96.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.5</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Trade names &amp; trademarks </span><span style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.0</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Identified intangible assets subject to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>707.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>13.4</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In-process software development costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">n/a</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total acquired intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>711.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.</span></div> 598500000 P15Y 96900000 P4Y6M 12300000 P3Y 707700000 P13Y4M24D 3800000 711500000 32900000 40700000 72100000 39900000 The estimated pro forma revenue and net income (loss) includes the alignment of accounting policies, the effect of fair value adjustments related to the Acquisition, associated tax effects and the impact of the borrowings to finance the Acquisition and related expenses.<div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>194,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>186,022</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>598,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>573,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(21,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>34,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 194450000 186022000 598815000 573520000 -3286000 -21145000 34559000 9120000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Supplemental financial statement information</span><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consist of the following:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Property and equipment</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment consisted of the following as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,889</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,890</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,242</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>49,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(13,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Depreciation expense for the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the nine months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Other expense, net</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other expense, net, consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>919</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gain on marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisition costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(32,932</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(849</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(40,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,074</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(348</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(996</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(478</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(30,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(8,347</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,427</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment consisted of the following as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>19,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Furniture and fixtures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>6,889</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Computer equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>22,890</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9,242</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>49,183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>17,301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated depreciation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(13,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(9,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>35,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 19404000 3583000 6889000 4476000 22890000 9242000 49183000 17301000 13984000 9078000 35199000 8223000 3600000 900000 5400000 2600000 <div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other expense, net, consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,046</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>919</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Gain on marketable equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>27,570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquisition costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(32,932</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(849</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(40,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,074</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Other expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(348</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(996</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(478</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total other expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(30,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(8,347</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(1,427</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 2046000 358000 5273000 919000 285000 0 27570000 0 32932000 849000 40712000 1074000 348000 996000 478000 1272000 -30949000 -1487000 -8347000 -1427000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Leases</span><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of approximately less than </span><span style="font-family:Arial;font-size:10pt;"><span>1</span></span><span style="font-family:Arial;font-size:10pt;"> year to </span><span style="font-family:Arial;font-size:10pt;"><span>11</span></span><span style="font-family:Arial;font-size:10pt;"> years, often with one or more Company options to renew. These renewal terms can extend the lease term from </span><span style="font-family:Arial;font-size:10pt;"><span>3</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>10</span></span><span style="font-family:Arial;font-size:10pt;"> years and are included in the lease term when it is reasonably certain that the Company will exercise the option. </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization and interest expense related to finance leases were not material during the three and nine months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of operating lease costs, lease term and discount rate are as follows:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Nine months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except for term and percentages)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,515</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">As of October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.36 years</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of operating lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fiscal year ending January 31, (in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Remaining 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,595</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55,389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19,289</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,780</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>73,052</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company had additional operating leases for office space that have not yet commenced with aggregate undiscounted lease payments of </span><span style="font-family:Arial;font-size:10pt;"><span>$80.2 million</span></span><span style="font-family:Arial;font-size:10pt;">. These operating leases will commence in fiscal year 2021 with a lease term of approximately </span><span style="font-family:Arial;font-size:10pt;"><span>11 years</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental cash flow information related to the Company's operating leases was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Nine months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,746</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">ROU assets obtained in exchange for new operating lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> P1Y P11Y P3Y P10Y <div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The components of operating lease costs, lease term and discount rate are as follows:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Nine months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands, except for term and percentages)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,515</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Net operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>5,266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">As of October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>9.36 years</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4.37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Supplemental cash flow information related to the Company's operating leases was as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Three months ended </span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Nine months ended</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,746</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>4,575</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">ROU assets obtained in exchange for new operating lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>34,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 3354000 5515000 249000 249000 3105000 5266000 P9Y4M9D 0.0437 <div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Maturities of operating lease liabilities as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fiscal year ending January 31, (in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Remaining 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>14,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,595</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>55,389</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>103,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(19,289</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>10,780</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Non-current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>73,052</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>83,832</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 375000 14340000 14135000 10595000 8287000 55389000 103121000 19289000 83832000 10780000 73052000 83832000 80200000 P11Y 2746000 4575000 34196000 34394000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Intangible assets and goodwill</span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Intangible assets</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company recorded </span><span style="font-family:Arial;font-size:10pt;"><span>$711.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> of acquired identified intangible assets as a result of the Acquisition of WageWorks. For further information about these acquired identified intangible assets, see Note 3—Business Combination.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the nine months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company acquired the rights to act as a custodian of HSA portfolios for </span><span style="font-family:Arial;font-size:10pt;"><span>$7.7 million</span></span><span style="font-family:Arial;font-size:10pt;">. The Company has determined the acquired intangible HSA assets to have a useful life of </span><span style="font-family:Arial;font-size:10pt;"><span>15 years</span></span><span style="font-family:Arial;font-size:10pt;">. The assets are being amortized using the straight-line amortization method, which has been determined to be appropriate to reflect the pattern over which the economic benefits of existing assets are realized.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, the Company capitalized software development costs of </span><span style="font-family:Arial;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$14.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$6.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, for the nine months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, related to significant enhancements and upgrades to its technology-enabled services platforms.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software and software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>44,835</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired HSA portfolios</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>92,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85,110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>601,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired developed technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>96,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets, gross</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>870,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(77,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(53,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total amortizable intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>792,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>796,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, the Company expensed a total of </span><span style="font-family:Arial;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$13.8 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, respectively, in software development costs primarily related to the post-implementation and operation stages of its technology platforms. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortization expense for the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;"> was </span><span style="font-family:Arial;font-size:10pt;"><span>$15.7 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, and </span><span style="font-family:Arial;font-size:10pt;"><span>$23.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$10.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, for the </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">During the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company recorded </span><span style="font-family:Arial;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:10pt;"> of goodwill from the Acquisition of WageWorks. For further information about the resulting goodwill, see Note 3—Business Combination.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">There were </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> other changes to the goodwill carrying value during the </span><span style="font-family:Arial;font-size:10pt;">three and nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">.</span></div> 711500000 7700000 P15Y 7000000.0 2200000 14700000 6400000 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software and software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>44,835</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired HSA portfolios</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>92,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85,110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>601,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired developed technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>96,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets, gross</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>870,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(77,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(53,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total amortizable intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>792,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>796,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">January 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Software and software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>66,633</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>44,835</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired HSA portfolios</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>92,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>85,110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired customer relationships</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>601,382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>2,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired developed technology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>96,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired trade names</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>12,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Amortizable intangible assets, gross</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>870,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>132,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(77,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(53,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total amortizable intangible assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>792,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Acquired in-process software development costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>3,236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>796,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>79,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 66633000 44835000 92770000 85110000 601382000 2882000 96924000 0 12300000 0 870009000 132827000 77017000 53161000 792992000 79666000 3236000 0 796228000 79666000 6200000 3400000 13800000 10000000.0 15700000 3700000 23600000 10900000 1300000000 0 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Commitments and contingencies</span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Commitments</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition to the indebtedness described in Note 8 below, the Company’s principal commitments consist of operating lease obligations for office space</span><span style="font-family:Arial;font-size:10pt;background-color:#ffffff;">,</span><span style="font-family:Arial;font-size:10pt;"> </span><span style="font-family:Arial;font-size:10pt;">data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments. </span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Future minimum lease payments under non-cancelable operating leases, excluding the contractual sublease income of </span><span style="font-family:Arial;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is expected to be received through February 2023, and other agreements, are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year ending January 31, (in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other agreements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,692</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,793</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67,717</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,248</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146,485</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Rent expense was $</span><span style="font-family:Arial;font-size:10pt;"><span>3.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the three and </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, respectively. Sublease income was </span><span style="font-family:Arial;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:Arial;font-size:10pt;"> for the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Legal matters</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">WageWorks is pursuing affirmative claims against the Office of Personnel Management ("OPM") to obtain payment for services provided by WageWorks between March 1, 2016 and August 31, 2016 pursuant to its contract with OPM. In connection with WageWorks' claims against OPM, OPM has also claimed that an erroneous statement in a certificate signed by a former executive officer constituted a violation of the False Claims Act and moved to dismiss part of WageWorks' claim against OPM as a result. As with all legal proceedings, no assurance can be provided as to the outcome of these matters or if WageWorks or OPM will be successful.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks, its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleges claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On June 22, 2018 and September 6, 2018, </span><span style="font-family:Arial;font-size:10pt;"><span>two</span></span><span style="font-family:Arial;font-size:10pt;"> derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages and fees and costs. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">WageWorks voluntarily contacted the San Francisco office of the SEC Division of Enforcement regarding the restatement of WageWorks' financial statements and related independent investigation. WageWorks is providing information and documents to the SEC and continues to cooperate with the SEC’s investigation into these matters. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The U.S. Attorney’s Office for the Northern District of California also opened an investigation. WageWorks has provided documents and information to the U.S. Attorney’s Office and continues to cooperate with any inquiries by the U.S. Attorney’s Office regarding the matter.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Beginning on July 30, 2019, putative class action suits were filed in the U.S. District Court Courts for the Southern District of New York, the District of Delaware, and the Northern District of California asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, as amended, against WageWorks and the former members of its board of directors. The complaints generally allege disclosure violations in the proxy statement issued by WageWorks in connection with the stockholder vote on the proposed merger with the Company. After WageWorks issued certain supplemental disclosures, these actions were voluntarily dismissed, but WageWorks may still be required to pay attorneys fees to the plaintiffs' lawyers.</span></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense of its former directors and officers in the legal proceedings described above. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. While it is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, the Company believes, based on current knowledge, that such litigation, proceedings and claims will not have a material impact on the Company’s financial position, results of operations and cash flows for the period. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company maintains liability insurance coverage that is intended to cover the legal matters described above; however, it is possible that claims may be denied by our insurance carriers or could exceed the amount of our applicable insurance coverage, we may be required by our insurance carriers to contribute to the payment of claims, and our insurance coverage may not continue to be available to us on acceptable terms or in sufficient amounts.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on currently available information, the Company does not believe that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.</span></div> <div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Future minimum lease payments under non-cancelable operating leases, excluding the contractual sublease income of </span><span style="font-family:Arial;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is expected to be received through February 2023, and other agreements, are as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year ending January 31, (in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other agreements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,340</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,692</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,793</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>67,717</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>403</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68,120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,248</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146,485</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 6000000.0 375000 2524000 2899000 14340000 10325000 24665000 15692000 7182000 22874000 12191000 4602000 16793000 9922000 1212000 11134000 67717000 403000 68120000 120237000 26248000 146485000 3400000 5500000 200000 2 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Indebtedness</span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, long-term debt consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Term loan facility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: unamortized loan issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-term debt, net of issuance costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">On September 30, 2015, the Company entered into a credit facility that provided for a secured revolving credit facility in the aggregate principal amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:Arial;font-size:10pt;"> for a term of </span><span style="font-family:Arial;font-size:10pt;"><span>five years</span></span><span style="font-family:Arial;font-size:10pt;">. Upon closing of the Acquisition on August 30, 2019, the credit facility was terminated. At the time of termination, </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> amounts were drawn and the Company was in compliance with all covenants.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the closing of the Acquisition, on August 30, 2019, the Company entered into a credit facility (the "Credit Agreement”) that provided for:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:60px;text-indent:-36px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of </span><span style="font-family:Arial;font-size:10pt;"><span>$1.25 billion</span></span><span style="font-family:Arial;font-size:10pt;">, the proceeds of which were used to finance the Acquisition, to refinance substantially all outstanding indebtedness of HealthEquity and WageWorks and to pay related fees and expenses; and</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:60px;text-indent:-36px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">(ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to </span><span style="font-family:Arial;font-size:10pt;"><span>$350 million</span></span><span style="font-family:Arial;font-size:10pt;">, which may be used for working capital and general corporate purposes, including acquisitions and other investments. </span><span style="font-family:Arial;font-size:10pt;"><span>No</span></span><span style="font-family:Arial;font-size:10pt;"> amounts were drawn under the Revolving Credit Facility as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Borrowings under the Credit Facilities will bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from </span><span style="font-family:Arial;font-size:10pt;"><span>1.25%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>2.25%</span></span><span style="font-family:Arial;font-size:10pt;"> or (ii) an alternate base rate plus a margin ranging from </span><span style="font-family:Arial;font-size:10pt;"><span>0.25%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>1.25%</span></span><span style="font-family:Arial;font-size:10pt;">, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from </span><span style="font-family:Arial;font-size:10pt;"><span>0.20%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>0.40%</span></span><span style="font-family:Arial;font-size:10pt;">, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The loans made under the Term Loan Facility are required to be repaid as described in the following table:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fiscal year ending January 31, (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Principal payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Remaining 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>969</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total principal payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than </span><span style="font-family:Arial;font-size:10pt;"><span>5.25</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00, which steps down to (x) </span><span style="font-family:Arial;font-size:10pt;"><span>5.00</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) </span><span style="font-family:Arial;font-size:10pt;"><span>4.50</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to </span><span style="font-family:Arial;font-size:10pt;"><span>5.00</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of </span><span style="font-family:Arial;font-size:10pt;"><span>$100 million</span></span><span style="font-family:Arial;font-size:10pt;">), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than </span><span style="font-family:Arial;font-size:10pt;"><span>3.00</span></span><span style="font-family:Arial;font-size:10pt;"> to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of HealthEquity and the guarantors, in each case, subject to certain customary exceptions.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, long-term debt consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Term loan facility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Less: unamortized loan issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Long-term debt, net of issuance costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1250000000 23000000 1227000000 100000000.0 P5Y 0 1250000000 350000000 0 0.0125 0.0225 0.0025 0.0125 0.0020 0.0040 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The loans made under the Term Loan Facility are required to be repaid as described in the following table:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Fiscal year ending January 31, (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Principal payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Remaining 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>969</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total principal payments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 8000000 39000000 63000000 70000000 101000000 969000000 1250000000 5.25 5.00 4.50 5.00 100000000 3.00 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Income taxes</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company follows FASB Accounting Standards Codification 740-270, </span><span style="font-family:Arial;font-size:10pt;font-style:italic;">Income Taxes - Interim Reporting</span><span style="font-family:Arial;font-size:10pt;">, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the </span><span style="font-family:Arial;font-size:10pt;">three and nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company recorded an income tax benefit of </span><span style="font-family:Arial;font-size:10pt;"><span>$9.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> and income tax expense of </span><span style="font-family:Arial;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. This resulted in an effective income tax </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">benefit rate of </span><span style="font-family:Arial;font-size:10pt;"><span>31.7%</span></span><span style="font-family:Arial;font-size:10pt;"> and an income tax expense rate of </span><span style="font-family:Arial;font-size:10pt;"><span>8.9%</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">three and nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, respectively, compared with an effective income tax expense rate of </span><span style="font-family:Arial;font-size:10pt;"><span>10.0%</span></span><span style="font-family:Arial;font-size:10pt;"> and an effective income tax benefit rate of </span><span style="font-family:Arial;font-size:10pt;"><span>2.2%</span></span><span style="font-family:Arial;font-size:10pt;"> for the </span><span style="font-family:Arial;font-size:10pt;">three and nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, respectively. For the </span><span style="font-family:Arial;font-size:10pt;">three and nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">2018</span><span style="font-family:Arial;font-size:10pt;">, the net impact of discrete tax items caused a percentage point benefit of </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><span>1.1</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>8.7</span></span><span style="font-family:Arial;font-size:10pt;"> and a percentage point benefit of </span><span style="font-family:Arial;font-size:10pt;"><span>11.2</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>24.1</span></span><span style="font-family:Arial;font-size:10pt;">, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the Company’s total gross unrecognized tax benefit was </span><span style="font-family:Arial;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. Certain unrecognized tax benefits have been netted against their related tax assets. As of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, an unrecognized tax benefit of </span><span style="font-family:Arial;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> was recorded. As of </span><span style="font-family:Arial;font-size:10pt;">January 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, </span><span style="font-family:Arial;font-size:10pt;"><span>no</span></span><span style="font-family:Arial;font-size:10pt;"> unrecognized tax benefits had been recorded. If recognized, </span><span style="font-family:Arial;font-size:10pt;"><span>$7.4 million</span></span><span style="font-family:Arial;font-size:10pt;"> of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.</span></div> -9900000 3900000 0.317 0.089 0.100 -0.022 -0.011 -0.087 -0.112 -0.241 8100000 1700000 400000 0 7400000 <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Stock-based compensation</span><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sales and marketing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Technology and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">General and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Merger integration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,714</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,714</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows stock-based compensation by award type: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,631</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,956</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,467</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,843</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total non-cash stock-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,461</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Acquisition awards exchanged for cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Stock award plans</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Plan. </span><span style="font-family:Arial;font-size:10pt;">The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of </span><span style="font-family:Arial;font-size:10pt;"><span>2.6 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock. As described below, in connection with the Acquisition, the shares of common stock available for issuance under the Incentive Plan were increased by </span><span style="font-family:Arial;font-size:10pt;"><span>5.3 million</span></span><span style="font-family:Arial;font-size:10pt;"> shares. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by </span><span style="font-family:Arial;font-size:10pt;"><span>3%</span></span><span style="font-family:Arial;font-size:10pt;"> of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">WageWorks Incentive Plan. </span><span style="font-family:Arial;font-size:10pt;">At the closing of the Acquisition, and in accordance with the Merger Agreement, certain RSUs with respect to WageWorks common stock, granted under WageWorks, Inc. 2010 Equity Incentive Plan (the "WageWorks Incentive Plan"), were replaced by the Company and converted into RSUs with respect to </span><span style="font-family:Arial;font-size:10pt;"><span>523,318</span></span><span style="font-family:Arial;font-size:10pt;"> shares of common stock of the Company.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In connection with the Acquisition, an additional </span><span style="font-family:Arial;font-size:10pt;"><span>5,255,027</span></span><span style="font-family:Arial;font-size:10pt;"> shares of the Company, representing the remaining number of shares of common stock of WageWorks that were available for issuance under the WageWorks Incentive Plan immediately prior to the Acquisition, became available for issuance under the Incentive Plan. The additional shares may be utilized for equity-based awards to be granted under the Incentive Plan, provided that (i) the period during which such shares are available under the Incentive Plan may not be extended beyond the period during which they would have been available under the WageWorks Incentive Plan, absent the Acquisition, and (ii) such equity-based awards may not be granted to individuals who were employees, directors or consultants of HealthEquity or its affiliates at the time the Acquisition was consummated.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Stock options</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonqualified stock options. Incentive stock options may be granted only to Company team members. Nonqualified stock options may be granted to Company executive officers, other team members, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;"> from the date of issuance, or are forfeited </span><span style="font-family:Arial;font-size:10pt;"><span>90 days</span></span><span style="font-family:Arial;font-size:10pt;"> after termination of employment. Shares of common stock underlying stock options that are forfeited or that expire are returned to the Incentive Plan.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Valuation assumptions.</span><span style="font-family:Arial;font-size:10pt;"> The Company has adopted the provisions of Topic 718, which requires the measurement and recognition of compensation for all stock-based awards made to team members and directors, based on estimated fair values.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under Topic 718, the Company uses the Black-Scholes option pricing model as the method of valuation for stock options. The determination of the fair value of stock-based awards on the date of grant is affected by the fair value of the stock as well as assumptions regarding a number of complex and subjective variables. The variables include, but are not limited to, 1) the expected life of the option, 2) the expected volatility of the fair value of the Company's common stock over the term of the award estimated by averaging the Company's historical volatility in addition to published volatilities of a relative peer group, 3) risk-free interest rate, and 4) expected dividends.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected dividend yield</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected stock price volatility</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37.09</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">35.98% - 36.53%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">37.09% - 37.84%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.21% - 2.43%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.52% - 2.79%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected life of options</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.25 years</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.95 - 5.09 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.17 - 6.25 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">* </span><span style="font-family:Arial;font-size:7pt;"><span>No</span></span><span style="font-family:Arial;font-size:7pt;"> stock options were granted during the three months ended October 31, 2019.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company historically used the "simplified" method to estimate the expected life of an option as determined under Staff Accounting Bulletin No. 110 due to limited option exercise history as a public company. Commencing February 1, 2019, the Company began estimating the expected life of an option using its own historical option exercise and termination data. Expected volatility is determined using weighted average volatility of the Company's </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">historical common stock price in addition to published volatilities of publicly traded peer companies. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of </span><span style="font-family:Arial;font-size:10pt;"><span>zero</span></span><span style="font-family:Arial;font-size:10pt;"> is based on the fact that the Company expects to invest cash in operations. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of stock option activity is as follows:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding stock options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except for exercise prices and term)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of<br/>options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Range of<br/>exercise<br/>prices</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>exercise<br/>price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate<br/>intrinsic<br/>value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$63.64 - 73.61</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(314</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 44.53</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$24.36 - 44.53</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of October 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested and expected to vest as of October 31, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,202</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.13</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercisable as of October 31, 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The aggregate intrinsic value in the table above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">As of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the weighted-average vesting period of non-vested awards expected to vest is approximately </span><span style="font-family:Arial;font-size:10pt;"><span>1.5 years</span></span><span style="font-family:Arial;font-size:10pt;">; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods is approximately </span><span style="font-family:Arial;font-size:10pt;"><span>$8.8 million</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">Restricted stock units and restricted stock awards</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The Company grants RSUs and RSAs to certain team members, officers, and directors under the Incentive Plan. RSUs and RSAs vest upon service-based criteria and performance-based criteria. Generally, service-based RSUs and RSAs vest over a four-year period in equal annual installments commencing upon the first anniversary of the grant date. RSUs and RSAs are valued based on the current value of the Company's closing stock price on the date of grant less the present value of future expected dividends discounted at the risk-free interest rate. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of WageWorks. </span><span style="font-family:Arial;font-size:10pt;">As described above, at the closing of the Acquisition, and in accordance with the Merger Agreement, </span><span style="font-family:Arial;font-size:10pt;"><span>523,318</span></span><span style="font-family:Arial;font-size:10pt;"> service-based RSUs with respect to WageWorks common stock were replaced by the Company and converted into RSUs with respect to common stock of the Company. These replaced awards are included in the granted amounts in the summary of RSU and RSA activity below. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The awards replaced by the Company in the Acquisition were measured at the Acquisition date based on the estimated fair value of </span><span style="font-family:Arial;font-size:10pt;"><span>$29.7 million</span></span><span style="font-family:Arial;font-size:10pt;">. A portion of that fair value, </span><span style="font-family:Arial;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:Arial;font-size:10pt;">, which represented the pre-Acquisition service provided by team members to WageWorks, was included in the total consideration paid as part of the Acquisition. As of the closing of the Acquisition, the remaining portion of the fair value of those awards was </span><span style="font-family:Arial;font-size:10pt;"><span>$25.9 million</span></span><span style="font-family:Arial;font-size:10pt;">, representing post-Acquisition share-based compensation expense, </span><span style="font-family:Arial;font-size:10pt;"><span>$8.1 million</span></span><span style="font-family:Arial;font-size:10pt;"> of which was recognized during the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> as acquisition-related costs, and the remainder of which will be recognized in the ordinary course as these team members provide service over the remaining vesting periods. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Additionally, at the closing of the Acquisition, and in accordance with the Merger Agreement, the Company exchanged for cash certain WageWorks equity awards measured at the Acquisition date based on the estimated fair value of </span><span style="font-family:Arial;font-size:10pt;"><span>$23.6 million</span></span><span style="font-family:Arial;font-size:10pt;">. A portion of that fair value, </span><span style="font-family:Arial;font-size:10pt;"><span>$18.1 million</span></span><span style="font-family:Arial;font-size:10pt;">, which represented the pre-Acquisition service provided by team members to WageWorks, was included in the total consideration paid as part of the Acquisition. As of the closing of the Acquisition, the remaining portion of the fair value of the awards exchanged for cash </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">was </span><span style="font-family:Arial;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:Arial;font-size:10pt;">, representing post-Acquisition share-based compensation expense that was recognized during the three months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Performance restricted stock units and awards.</span><span style="font-family:Arial;font-size:10pt;"> In March 2017, the Company awarded </span><span style="font-family:Arial;font-size:10pt;"><span>146,964</span></span><span style="font-family:Arial;font-size:10pt;"> performance-based RSUs ("PRSUs"). Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2020. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>150%</span></span><span style="font-family:Arial;font-size:10pt;"> of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In March 2018, the Company awarded </span><span style="font-family:Arial;font-size:10pt;"><span>227,760</span></span><span style="font-family:Arial;font-size:10pt;"> performance-based RSAs ("PRSAs"). Vesting of the PRSAs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2021. The Company records stock-based compensation related to PRSAs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurred at the grant date. The Company believes it is probable that the PRSAs will vest at least in part. The vesting of the PRSAs will ultimately range from </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>200%</span></span><span style="font-family:Arial;font-size:10pt;"> based on the level of achievement of the performance goals. The PRSAs were issued at the </span><span style="font-family:Arial;font-size:10pt;"><span>200%</span></span><span style="font-family:Arial;font-size:10pt;"> level of achievement. As the underlying shares were issued at grant date, they are subject to clawback based on actual Company performance. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">In March 2019, the Company awarded </span><span style="font-family:Arial;font-size:10pt;"><span>129,963</span></span><span style="font-family:Arial;font-size:10pt;"> PRSUs. Vesting of the PRSUs is dependent upon the achievement of certain financial criteria and cliff vest on January 31, 2022. The Company records stock-based compensation related to PRSUs when it is considered probable that the performance conditions will be met. Issuance of the underlying shares occurs at vesting. The Company believes it is probable that the PRSUs will vest at least in part. The vesting of the PRSUs will ultimately range from </span><span style="font-family:Arial;font-size:10pt;"><span>0%</span></span><span style="font-family:Arial;font-size:10pt;"> to </span><span style="font-family:Arial;font-size:10pt;"><span>200%</span></span><span style="font-family:Arial;font-size:10pt;"> of the number of shares underlying the PRSU grant based on the level of achievement of the performance goals. As a result of the Acquisition, we expect the Compensation Committee of the Board of Directors to consider revisions to certain existing PRSU performance goals.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the RSU and RSA activity is as follows: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs and PRSUs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSAs and PRSAs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except weighted-average grant date fair value)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,368</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">For the </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;">, the aggregate intrinsic value of RSUs and RSAs released was </span><span style="font-family:Arial;font-size:10pt;"><span>$19.9 million</span></span><span style="font-family:Arial;font-size:10pt;"> and </span><span style="font-family:Arial;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:Arial;font-size:10pt;">, respectively. For the </span><span style="font-family:Arial;font-size:10pt;">nine</span><span style="font-family:Arial;font-size:10pt;"> months ended </span><span style="font-family:Arial;font-size:10pt;">October 31, 2018</span><span style="font-family:Arial;font-size:10pt;">, the aggregate intrinsic value of RSUs released was </span><span style="font-family:Arial;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:Arial;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Total unrecorded stock-based compensation expense as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> associated with RSUs and PRSUs was </span><span style="font-family:Arial;font-size:10pt;"><span>$67.1 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>2.6 years</span></span><span style="font-family:Arial;font-size:10pt;">. Total unrecorded stock-based compensation expense as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span><span style="font-family:Arial;font-size:10pt;"> associated with RSAs and PRSAs was </span><span style="font-family:Arial;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:Arial;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:Arial;font-size:10pt;"><span>1.6 years</span></span><span style="font-family:Arial;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sales and marketing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,469</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Technology and development</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">General and administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,570</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Merger integration</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,714</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,714</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1415000 788000 3285000 2008000 1304000 990000 3469000 2586000 2171000 1386000 5600000 3677000 3332000 2570000 9486000 7190000 1220000 0 1220000 0 13714000 0 13714000 0 23156000 5734000 36774000 15461000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table shows stock-based compensation by award type: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,631</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,917</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,664</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock units</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,956</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,718</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,543</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>793</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,467</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,843</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Performance restricted stock awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total non-cash stock-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,461</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Acquisition awards exchanged for cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,461</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 1631000 1917000 5140000 5664000 0 178000 0 503000 14099000 1956000 20718000 5543000 1422000 793000 3467000 1843000 164000 172000 491000 399000 260000 718000 1378000 1509000 17576000 5734000 31194000 15461000 5580000 0 5580000 0 23156000 5734000 36774000 15461000 2600000 5300000 0.03 523318 5255027 P10Y P90D <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine months ended October 31,</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected dividend yield</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected stock price volatility</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37.09</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">35.98% - 36.53%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">37.09% - 37.84%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.21% - 2.43%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.52% - 2.79%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected life of options</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.25 years</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.95 - 5.09 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">5.17 - 6.25 years</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div><span style="font-family:Arial;font-size:7pt;">* </span><span style="font-family:Arial;font-size:7pt;"><span>No</span></span> stock options were granted during the three months ended October 31, 2019 0 0 0 0.3709 0.0279 P6Y3M 0 0 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of stock option activity is as follows:</span></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">  </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Outstanding stock options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except for exercise prices and term)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of<br/>options</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Range of<br/>exercise<br/>prices</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>exercise<br/>price</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate<br/>intrinsic<br/>value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,444</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$63.64 - 73.61</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercised </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(314</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 44.53</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$24.36 - 44.53</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of October 31, 2019</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$0.10 - 82.39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vested and expected to vest as of October 31, 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,202</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6.13</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,562</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exercisable as of October 31, 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 2444000 27.37 P6Y8M26D 85971000 108000 73.27 314000 23.42 36000 30.15 2202000 30.14 P6Y1M17D 61562000 2202000 30.14 P6Y1M17D 61562000 1501000 22.91 P5Y6M 51131000 P1Y6M 8800000 523318 29700000 3800000 25900000 8100000 23600000 18100000 5600000 146964 0 1.50 227760 0 2 2 129963 0 2 <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">A summary of the RSU and RSA activity is as follows: </span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSUs and PRSUs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RSAs and PRSAs</span></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(in thousands, except weighted-average grant date fair value)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Weighted-average grant date fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of January 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58.01</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Outstanding as of October 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,368</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>62.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div> 647000 55.18 256000 61.93 1124000 64.61 0 0 320000 58.01 11000 62.75 83000 56.02 10000 61.72 1368000 62.22 235000 61.91 19900000 800000 5500000 67100000 P2Y7M6D 4300000 P1Y7M6D <span style="font-family:Arial;font-size:12pt;font-weight:bold;text-decoration:underline;">Fair value</span><span style="font-family:Arial;font-size:12pt;font-weight:bold;"> </span><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Fair value measurements are made at a specific point in time, based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div></td></tr></table><span style="font-family:Arial;font-size:10pt;">Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of </span><span style="font-family:Arial;font-size:10pt;">October 31, 2019</span> due to the short-term nature of these instruments. XML 36 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation (Stock-based compensation expense by award type) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 23,156 $ 5,734 $ 36,774 $ 15,461
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,631 1,917 5,140 5,664
Performance stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 0 178 0 503
Restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 14,099 1,956 20,718 5,543
Performance restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 1,422 793 3,467 1,843
Restricted stock awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 164 172 491 399
Performance restricted stock awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 260 718 1,378 1,509
Total non-cash stock-based compensation expense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 17,576 5,734 31,194 15,461
Acquisition awards exchanged for cash        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 5,580 $ 0 $ 5,580 $ 0
XML 37 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Intangible assets and goodwill (Schedule of intangible assets) (Details) - USD ($)
$ in Thousands
Oct. 31, 2019
Jan. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross $ 870,009 $ 132,827
Accumulated amortization (77,017) (53,161)
Total amortizable intangible assets, net 792,992 79,666
Intangible Assets, Net (Excluding Goodwill) [Abstract]    
Intangible assets, net 796,228 79,666
In-process software development costs    
Indefinite-lived Intangible Assets [Line Items]    
Acquired in-process software development costs 3,236 0
Software and software development costs    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 66,633 44,835
Acquired HSA portfolios    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 92,770 85,110
Acquired customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 601,382 2,882
Acquired developed technology    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 96,924 0
Acquired trade names    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross $ 12,300 $ 0
XML 38 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Indebtedness (Narrative) (Details)
Aug. 30, 2019
USD ($)
Sep. 30, 2015
USD ($)
Credit Agreement Prior To Acquisition | Line of Credit | Secured Revolving Credit Facility    
Debt Instrument [Line Items]    
Credit facility, amount   $ 100,000,000.0
Facility term   5 years
Long-term line of credit $ 0  
Credit Agreement | Secured Debt | Line of Credit    
Debt Instrument [Line Items]    
Facility term 5 years  
Credit Agreement | Line of Credit | Secured Revolving Credit Facility    
Debt Instrument [Line Items]    
Credit facility, amount $ 350,000,000  
Facility term 5 years  
Long-term line of credit $ 0  
Credit Agreement | Line of Credit | Secured Revolving Credit Facility | Minimum    
Debt Instrument [Line Items]    
Commitment fee percentage 0.20%  
Credit Agreement | Line of Credit | Secured Revolving Credit Facility | Maximum    
Debt Instrument [Line Items]    
Commitment fee percentage 0.40%  
Credit Agreement | Line of Credit | Term Loan Facility    
Debt Instrument [Line Items]    
Credit facility, amount $ 1,250,000,000  
Credit Agreement | Line of Credit | Line of Credit    
Debt Instrument [Line Items]    
Minimum interest coverage ratio 3.00  
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, beginning August 30, 2019    
Debt Instrument [Line Items]    
Maximum leverage ratio 5.25  
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, beginning July 31, 2020    
Debt Instrument [Line Items]    
Maximum leverage ratio 5.00  
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, beginning July 31, 2021    
Debt Instrument [Line Items]    
Maximum leverage ratio 4.50  
Credit Agreement | Line of Credit | Line of Credit | Debt covenant, acquisition holiday provision    
Debt Instrument [Line Items]    
Maximum leverage ratio 5.00  
Acquisition threshold for maximum total net leverage ratio $ 100,000,000  
Credit Agreement | Line of Credit | Line of Credit | London Interbank Offered Rate (LIBOR) | Minimum    
Debt Instrument [Line Items]    
Variable rate borrowing spread 1.25%  
Credit Agreement | Line of Credit | Line of Credit | London Interbank Offered Rate (LIBOR) | Maximum    
Debt Instrument [Line Items]    
Variable rate borrowing spread 2.25%  
Credit Agreement | Line of Credit | Line of Credit | Customary Base Rate | Minimum    
Debt Instrument [Line Items]    
Variable rate borrowing spread 0.25%  
Credit Agreement | Line of Credit | Line of Credit | Customary Base Rate | Maximum    
Debt Instrument [Line Items]    
Variable rate borrowing spread 1.25%  
XML 39 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed consolidated statements of cash flows (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Cash flows from operating activities:    
Net income (loss) $ 39,854 $ 60,780
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 28,791 13,498
(Gains) losses on marketable equity securities and other (25,303) 895
Deferred taxes 690 394
Stock-based compensation 31,194 15,461
Changes in operating assets and liabilities:    
Accounts receivable (2,817) (2,863)
Other assets (4,937) (4,568)
Operating lease right-of-use assets 3,340  
Accounts payable 524 (1,087)
Accrued compensation (8,012) (2,617)
Accrued liabilities and other current liabilities 13,655 451
Operating lease liabilities, non-current (2,859)  
Other long-term liabilities (50) 441
Net cash provided by operating activities 74,070 80,785
Cash flows from investing activities:    
Acquisitions, net of cash acquired (1,630,066) 0
Purchases of intangible member assets (9,070) (1,195)
Purchases of marketable equity securities and other (53,845) (574)
Purchases of property and equipment (5,180) (3,467)
Purchases of software and capitalized software development costs (17,232) (7,352)
Net cash used in investing activities (1,715,393) (12,588)
Cash flows from financing activities:    
Proceeds from long-term debt 1,250,000 0
Payment of debt issuance costs (30,504) 0
Settlement of client-held funds obligation (230,928) 0
Proceeds from follow-on equity offering, net of payment for offering costs 458,495 0
Proceeds from exercise of common stock options 7,342 21,338
Net cash provided by financing activities 1,454,405 21,338
Increase (decrease) in cash and cash equivalents (186,918) 89,535
Beginning cash and cash equivalents 361,475 199,472
Ending cash and cash equivalents 174,557 289,007
Supplemental cash flow data:    
Interest expense paid in cash 249 162
Income taxes paid in cash, net of refunds received 9,127 628
Supplemental disclosures of non-cash investing and financing activities:    
Equity-based acquisition consideration 3,776 0
Purchases of property and equipment included in accounts payable or accrued liabilities at period end 168 6
Exercise of common stock options receivable 21 28
Computer software intangible asset    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of intangible assets 316 156
Acquired HSA portfolios    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of intangible assets $ (151) $ 0
XML 40 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed consolidated balance sheets - USD ($)
$ in Thousands
Oct. 31, 2019
Jan. 31, 2019
Current assets    
Cash and cash equivalents $ 174,557 $ 361,475
Accounts receivable, net of allowance for doubtful accounts as of October 31, 2019 and January 31, 2019 of $1,021 and $125, respectively 66,647 25,668
Other current assets 29,119 7,534
Total current assets 270,323 394,677
Property and equipment, net 35,199 8,223
Operating lease right-of-use assets 88,515  
Intangible assets, net 796,228 79,666
Goodwill 1,335,187 4,651
Deferred tax asset 0 1,677
Other assets 34,469 21,122
Total assets 2,559,921 510,016
Current liabilities    
Accounts payable 7,966 3,520
Accrued compensation 37,559 16,981
Accrued liabilities 54,305 8,552
Current portion of long-term debt 31,250 0
Operating lease liabilities 10,780  
Total current liabilities 141,860 29,053
Long-term debt, net of issuance costs 1,196,016 0
Operating lease liabilities, non-current 73,052  
Deferred tax liability 128,642 916
Other long-term liabilities 2,590 2,968
Total liabilities 1,542,160 32,937
Commitments and contingencies (see note 7)
Stockholders’ equity    
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively 0 0
Common stock, $0.0001 par value, 900,000 shares authorized, 70,832 and 62,446 shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively 7 6
Additional paid-in capital 806,050 305,223
Accumulated earnings 211,704 171,850
Total stockholders’ equity 1,017,761 477,079
Total liabilities and stockholders’ equity $ 2,559,921 $ 510,016
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and contingencies Operating Lease Maturity (Tables)
9 Months Ended
Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Operating lease liability maturity schedule
Future minimum lease payments under non-cancelable operating leases, excluding the contractual sublease income of $6.0 million, which is expected to be received through February 2023, and other agreements, are as follows:
Year ending January 31, (in thousands)
 
Operating leases

 
Other agreements

 
Total

2020
 
$
375

 
$
2,524

 
$
2,899

2021
 
14,340

 
10,325

 
24,665

2022
 
15,692

 
7,182

 
22,874

2023
 
12,191

 
4,602

 
16,793

2024
 
9,922

 
1,212

 
11,134

Thereafter
 
67,717

 
403

 
68,120

Total
 
$
120,237

 
$
26,248

 
$
146,485


XML 42 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Business combination (Tables)
9 Months Ended
Oct. 31, 2019
Business Combinations [Abstract]  
Total Consideration Paid Under this accounting method, the total consideration paid was:
(in millions)
 
 
Aggregate fair value of WageWorks stock acquired
 
$
2,018.8

Fair value of previously owned investment in WageWorks stock
 
81.4

Fair value of equity awards exchanged for cash attributable to pre-Acquisition service
 
18.1

Fair value of equity awards replaced attributable to pre-Acquisition service
 
3.8

Total consideration paid
 
$
2,122.1


Preliminary Allocation of Consideration
Preliminary allocation of consideration
(in millions)
 
Estimated fair value

Cash and cash equivalents
 
$
406.8

Other current assets
 
56.5

Property, plant, and equipment
 
26.6

Operating lease right-of-use assets
 
42.5

Intangible assets
 
715.3

Goodwill
 
1,330.5

Other assets
 
5.9

Client-held funds obligation
 
(237.5
)
Other current liabilities
 
(69.1
)
Other long-term liabilities
 
(26.7
)
Deferred tax liability
 
(128.7
)
Total consideration paid
 
$
2,122.1


Preliminary Allocation of Consideration Paid to Acquired Identified Intangible Assets
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
(in millions)
 
Fair value

 
Weighted-average remaining amortization period (years)
Customer relationships (1)
 
$
598.5

 
15.0
Developed technology (1)
 
96.9

 
4.5
Trade names & trademarks (1)
 
12.3

 
3.0
Identified intangible assets subject to amortization
 
707.7

 
13.4
In-process software development costs
 
3.8

 
n/a
Total acquired intangible assets
 
$
711.5

 
 
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.
Pro Forma Information The estimated pro forma revenue and net income (loss) includes the alignment of accounting policies, the effect of fair value adjustments related to the Acquisition, associated tax effects and the impact of the borrowings to finance the Acquisition and related expenses.
(in thousands)
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
 
2019

 
2018

 
2019

 
2018

Revenue
 
$
194,450

 
$
186,022

 
$
598,815

 
$
573,520

Net income (loss)
 
$
(3,286
)
 
$
(21,145
)
 
$
34,559

 
$
9,120


XML 43 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Net income (loss) per share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Numerator (basic and diluted):        
Net income (loss) $ (21,334) $ 15,686 $ 39,854 $ 60,780
Denominator (basic):        
Weighted-average common shares outstanding (in shares) 70,524,000 62,088,000 65,727,000 61,718,000
Denominator (diluted):        
Weighted-average common shares outstanding (in shares) 70,524,000 62,088,000 65,727,000 61,718,000
Weighted-average dilutive effect of stock options and restricted stock units (in shares) 0 1,835,000 1,423,000 1,910,000
Diluted weighted-average common shares outstanding (in shares) 70,524,000 63,923,000 67,150,000 63,628,000
Net income (loss) per share:        
Basic (in usd per share) $ (0.30) $ 0.25 $ 0.61 $ 0.98
Diluted (in usd per share) $ (0.30) $ 0.25 $ 0.59 $ 0.96
Antidilutive securities excluded from computation of earnings per share (in shares) 3,200,000 36,000 300,000 100,000
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Business combination (Pro Forma Results) (Details) - WageWorks, Inc - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Business Acquisition [Line Items]        
Revenue $ 194,450 $ 186,022 $ 598,815 $ 573,520
Net income (loss) $ (3,286) $ (21,145) $ 34,559 $ 9,120
XML 45 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Lease Cost) (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
USD ($)
Oct. 31, 2019
USD ($)
Leases [Abstract]    
Operating lease cost $ 3,354 $ 5,515
Sublease income (249) (249)
Net operating lease cost $ 3,105 $ 5,266
Weighted average remaining lease term 9 years 4 months 9 days 9 years 4 months 9 days
Weighted average discount rate 4.37% 4.37%
XML 46 R9999.htm IDEA: XBRL DOCUMENT v3.19.3
Label Element Value
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 13,007,000
Accounting Standards Update 2016-01 [Member] | Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (356,000)
Accounting Standards Update 2016-01 [Member] | AOCI Attributable to Parent [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 269,000
XML 47 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of business and significant accounting policies (Policies)
9 Months Ended
Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of consolidation
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, HealthEquity Trust Company, HEQ Insurance Services, Inc., HealthEquity Advisors, LLC, HealthEquity Retirement Services, LLC, and, after the closing of the Acquisition on August 30, 2019, WageWorks, Inc. and its subsidiaries MyFlexMobile, Inc., WageWorks India, Inc. and WageWorks Services, LLP (collectively referred to as the "Company").
Prior to the closing of the Acquisition, the Company held a 4% ownership interest in WageWorks. The Company measured the investment at fair value, and all gains on the investment were recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). In connection with the closing of the Acquisition on August 30, 2019, the Company's investment in WageWorks was canceled, and WageWorks became a wholly owned subsidiary of the Company.
The Company has a 22% ownership interest in a limited partnership for investment in and the management of early stage companies in the healthcare industry; this partnership interest is accounted for using the equity method of accounting. The investment was approximately $0.2 million as of October 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
The Company has a 1% ownership interest in a limited partnership that engages in the development of technology-based financial healthcare products. The Company elected the measurement alternative for non-marketable equity investments to account for the investment. The investment was valued at $0.5 million as of October 31, 2019 and is included in investments on the accompanying condensed consolidated balance sheet.
Acquisitions of businesses, including the Acquisition of WageWorks, are accounted for as business combinations, and accordingly, the results of operations of acquired businesses are included in the condensed consolidated financial statements from the date of acquisition. All significant intercompany balances and transactions have been eliminated.
Basis of presentation
Basis of presentation
The accompanying condensed consolidated financial statements as of October 31, 2019 and for the three and nine months ended October 31, 2019 and 2018 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended January 31, 2019. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Leases
Leases. The Company determines if a contract contains a lease at inception or any modification of the contract. A contract contains a lease if the contract conveys the right to control the use of an identified asset for a specified period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset.
The Company has entered into various operating leases consisting of office space, data storage facilities, and other leases with remaining lease terms of approximately less than 1 year to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option. Leases with an expected term of 12 months or less at commencement are not accounted for on the balance sheet. All operating lease expense is recognized on a straight-line basis over the expected lease term. Certain leases also include obligations to pay for non-lease services, such as utilities and common area maintenance. The services are accounted for separately from lease components, and the Company allocates payments to the lease and other services components based on estimated stand-alone prices.
Operating lease right-of-use ("ROU") assets and liabilities are recognized based on the present value of future minimum lease payments over the expected lease term at commencement date. As the rate implicit in each lease is not readily determinable, management uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The Company used its incremental borrowing rate on February 1, 2019 for all leases that commenced prior to that date.
Operating leases are included in operating lease right-of-use assets, operating lease liabilities and operating lease liabilities, non-current on the condensed consolidated balance sheets beginning February 1, 2019.
Investments in equity securities
Investments in equity securities. Marketable equity securities are strategic equity investments with readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for at fair value and were classified as investments on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net in the condensed consolidated statements of operations and comprehensive income (loss). As a result of the Acquisition on August 30, 2019, the Company's marketable equity security investment in WageWorks was canceled.
Non-marketable equity securities are strategic equity investments without readily determinable fair values and for which the Company does not have the ability to exercise significant influence are accounted for using the measurement alternative and are classified as other assets on the condensed consolidated balance sheets. All gains and losses on these investments, realized and unrealized, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).
Equity method investments are equity securities in investees the Company does not control but over which the Company has the ability to exercise significant influence. Equity-method investments are included in other assets on the condensed consolidated balance sheets. The Company's share of the earnings or losses as reported by equity-method investees, amortization of basis differences, and related gains or losses, if any, are recognized in other expense, net on the condensed consolidated statements of operations and comprehensive income (loss).
The Company assesses whether an other-than-temporary impairment loss on equity method investments and an impairment loss on non-marketable equity securities has occurred due to declines in fair value or other market conditions. If any impairment is considered other than temporary for equity method investments or impairment is identified for non-marketable equity securities, the Company will write down the investment to its fair value and record the corresponding
charge through other expense, net in the condensed consolidated statements of operations and comprehensive income (loss).
Client-held funds
Client-held funds. Many of the Company's client services agreements with employers (referred to as "Clients") provide that Clients remit funds to the Company to pre-fund Client and employee participant contributions related to flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”, respectively) and commuter accounts. These Client-held funds remitted to the Company do not represent cash assets of the Company to the extent that they are not combined with corporate cash, and accordingly are not included in cash and cash equivalents on the Company's condensed consolidated balance sheets.
Recent adopted and issued accounting pronouncements
Recent adopted accounting pronouncements
In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (codified as "ASC 842"), which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. ASC 842 requires that a lessee recognize a liability to make lease payments (the lease liability) and a ROU asset representing its right to use the underlying asset for the lease term on the balance sheet.
The Company adopted ASC 842 on February 1, 2019 using the modified retrospective transition method with the adoption date as the date of initial application. Consequently, prior period balances and disclosures have not been restated. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The adoption of ASC 842 on February 1, 2019 resulted in the recognition on the Company's condensed consolidated balance sheet of both operating lease liabilities of $40.6 million and ROU assets of $38.0 million, which equals the lease liabilities net of accrued rent previously recorded on its consolidated balance sheet under previous guidance. The adoption of ASC 842 did not have an impact on the Company's condensed consolidated statement of operations, stockholders’ equity and cash flows for the three and nine-month period ended October 31, 2019.
In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This ASU permits the capitalization of implementation costs incurred in a software hosting arrangement. This ASU is effective for fiscal years beginning after December 15, 2019. The Company elected to early adopt the new standard as of October 31, 2019 using the prospective transition method. The adoption of this standard did not have a material effect on the Company’s condensed consolidated financial statements.
Recent issued accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires financial assets measured at amortized cost be presented at the net amount expected to be collected. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The Company does not plan to early adopt this ASU. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, which removes step two from the goodwill impairment test. As a result, an entity should perform its annual goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting units' fair value. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the timing of adoption; however, it does not believe this ASU will have a material impact on the Company's consolidated financial statements.
In August 2018, FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends ASC 820, "Fair Value Measurement." ASU 2018-13 modifies the disclosure requirements for fair value measurements by removing, modifying and adding certain disclosures. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential effect of this ASU on the consolidated financial statements.
XML 48 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Indebtedness
9 Months Ended
Oct. 31, 2019
Debt Disclosure [Abstract]  
Indebtedness Indebtedness
As of October 31, 2019, long-term debt consisted of the following:
(in millions)
 
October 31, 2019

Term loan facility
 
$
1,250

Less: unamortized loan issuance costs
 
(23
)
Long-term debt, net of issuance costs
 
$
1,227


On September 30, 2015, the Company entered into a credit facility that provided for a secured revolving credit facility in the aggregate principal amount of $100.0 million for a term of five years. Upon closing of the Acquisition on August 30, 2019, the credit facility was terminated. At the time of termination, no amounts were drawn and the Company was in compliance with all covenants.
In connection with the closing of the Acquisition, on August 30, 2019, the Company entered into a credit facility (the "Credit Agreement”) that provided for:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion, the proceeds of which were used to finance the Acquisition, to refinance substantially all outstanding indebtedness of HealthEquity and WageWorks and to pay related fees and expenses; and
(ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of October 31, 2019.
Borrowings under the Credit Facilities will bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The loans made under the Term Loan Facility are required to be repaid as described in the following table:
Fiscal year ending January 31, (in millions)
 
Principal payments

Remaining 2020
 
$
8

2021
 
39

2022
 
63

2023
 
70

2024
 
101

Thereafter
 
969

Total principal payments
 
$
1,250


The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 5.25 to 1.00, which steps down to (x) 5.00 to 1.00 beginning with the fiscal quarter ending July 31, 2020 and (y) 4.50 to 1.00 beginning with the fiscal quarter ending July 31, 2021 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of October 31, 2019.
The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and each of the Company's subsequently acquired or organized direct and indirect domestic subsidiaries and are secured by security interests in substantially all assets of HealthEquity and the guarantors, in each case, subject to certain customary exceptions.
XML 49 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental financial statement information
9 Months Ended
Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental financial statement information Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consist of the following:
Property and equipment
Property and equipment consisted of the following as of October 31, 2019 and January 31, 2019:
(in thousands)
 
October 31, 2019

 
January 31, 2019

Leasehold improvements
 
$
19,404

 
$
3,583

Furniture and fixtures
 
6,889

 
4,476

Computer equipment
 
22,890

 
9,242

Property and equipment, gross
 
49,183

 
17,301

Accumulated depreciation
 
(13,984
)
 
(9,078
)
Property and equipment, net
 
$
35,199

 
$
8,223


Depreciation expense for the three months ended October 31, 2019 and 2018 was $3.6 million and $0.9 million, respectively, and $5.4 million and $2.6 million for the nine months ended October 31, 2019 and 2018, respectively.
Other expense, net
Other expense, net, consisted of the following:
 
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)
 
2019

 
2018

 
2019

 
2018

Interest income
 
$
2,046

 
$
358

 
$
5,273

 
$
919

Gain on marketable equity securities
 
285

 

 
27,570

 

Acquisition costs
 
(32,932
)
 
(849
)
 
(40,712
)
 
(1,074
)
Other expense
 
(348
)
 
(996
)
 
(478
)
 
(1,272
)
Total other expense, net
 
$
(30,949
)
 
$
(1,487
)
 
$
(8,347
)
 
$
(1,427
)

XML 50 R52.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation (Stock option activity) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2019
Oct. 31, 2019
Jan. 31, 2019
Number of options (shares)      
Opening balance (shares)   2,444,000  
Granted (shares) 0 108,000  
Exercised (shares)   (314,000)  
Forfeited (shares)   (36,000)  
Ending balance (shares) 2,202,000 2,202,000 2,444,000
Vested and expected to vest as of year end (in shares) 2,202,000 2,202,000  
Exercisable as of year end (in shares) 1,501,000 1,501,000  
Range of exercise prices (usd per share)      
Beginning balance, minimum (usd per share)   $ 0.10  
Beginning balance, maximum (usd per share)   82.39  
Granted, minimum (usd per share)   63.64  
Granted, maximum (usd per share)   73.61  
Exercised, minimum (usd per share)   0.10  
Exercised, maximum (usd per share)   44.53  
Forfeited, minimum (usd per share)   24.36  
Forfeited, maximum (usd per share)   44.53  
Ending balance, minimum (usd per share) $ 0.10 0.10 $ 0.10
Ending balance, maximum (usd per share) 82.39 82.39 82.39
Weighted- average exercise price (usd per share)      
Opening balance (usd per share)   27.37  
Granted (usd per share)   73.27  
Exercised (usd per share)   23.42  
Forfeited (usd per share)   30.15  
Ending balance (usd per share) 30.14 30.14 $ 27.37
Vested and expected to vest as of year end, weighted average exercise price (usd per share) 30.14 30.14  
Exercisable as of year end, weighted-average exercise price (usd per share) $ 22.91 $ 22.91  
Weighted- average contractual term (in years)   6 years 1 month 17 days 6 years 8 months 26 days
Vested and expected to vest as of year end, weighted average contractual term (in years)   6 years 1 month 17 days  
Exercisable as of year end, weighted-average contractual term (in years)   5 years 6 months  
Aggregate intrinsic value $ 61,562 $ 61,562 $ 85,971
Vested and expected to vest as of year end, aggregate intrinsic value (usd per share) 61,562 61,562  
Exercisable as of year end, aggregate intrinsic value $ 51,131 $ 51,131  
XML 51 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and contingencies (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 06, 2018
lawsuit
Jun. 22, 2018
lawsuit
Oct. 31, 2019
USD ($)
Oct. 31, 2019
USD ($)
Jan. 31, 2019
USD ($)
Commitments and Contingencies Disclosure [Abstract]          
Sublease income         $ 6,000
Rent expense     $ 3,354 $ 5,515  
Sublease income     $ 249 $ 249  
Number of derivative lawsuits | lawsuit 2 2      
XML 52 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Income taxes (Details) - USD ($)
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Jan. 31, 2019
Income Tax Disclosure [Abstract]          
Income tax provision (benefit) $ (9,918,000) $ 1,745,000 $ 3,908,000 $ (1,322,000)  
Effective tax rate 31.70% 10.00% 8.90% (2.20%)  
Decrease in effective tax rate, primarily due to excess tax benefit on stock-based compensation expense 1.10% 11.20% 8.70% 24.10%  
Gross unrecognized tax benefits $ 8,100,000   $ 8,100,000   $ 1,700,000
Unrecognized tax benefit 400,000   400,000   $ 0
Unrecognized tax benefits that would impact the effective tax rate $ 7,400,000   $ 7,400,000    
XML 53 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation (Tables)
9 Months Ended
Oct. 31, 2019
Share-based Payment Arrangement [Abstract]  
Summary of share based compensation recognized
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:


Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Cost of revenue

$
1,415

 
$
788

 
$
3,285

 
$
2,008

Sales and marketing

1,304

 
990

 
3,469

 
2,586

Technology and development

2,171

 
1,386

 
5,600

 
3,677

General and administrative

3,332

 
2,570

 
9,486

 
7,190

Merger integration
 
1,220

 

 
1,220

 

Other expense, net
 
13,714

 

 
13,714

 

Total stock-based compensation expense

$
23,156

 
$
5,734

 
$
36,774

 
$
15,461


Summary of stock-based compensation expense by award type
The following table shows stock-based compensation by award type:


Three months ended October 31,
 
 
Nine months ended October 31,
 
(in thousands)

2019


2018

 
2019

 
2018

Stock options

$
1,631

 
$
1,917

 
$
5,140

 
$
5,664

Performance stock options


 
178

 

 
503

Restricted stock units

14,099

 
1,956

 
20,718

 
5,543

Performance restricted stock units

1,422

 
793

 
3,467

 
1,843

Restricted stock awards

164

 
172

 
491

 
399

Performance restricted stock awards

260

 
718

 
1,378

 
1,509

Total non-cash stock-based compensation expense
 
17,576

 
5,734

 
31,194

 
15,461

Acquisition awards exchanged for cash
 
5,580

 

 
5,580

 

Total stock-based compensation expense

$
23,156

 
$
5,734

 
$
36,774

 
$
15,461


Summary of assumptions
The key input assumptions that were utilized in the valuation of the stock options granted during the periods presented:
  

Three months ended October 31,
 
 
Nine months ended October 31,
 
  

2019
 
2018

 
2019

 
2018

Expected dividend yield

*

%
 
%
 
%
Expected stock price volatility

*

37.09
%
 
35.98% - 36.53%

 
37.09% - 37.84%

Risk-free interest rate

*

2.79
%
 
2.21% - 2.43%

 
2.52% - 2.79%

Expected life of options

*

6.25 years

 
4.95 - 5.09 years

 
5.17 - 6.25 years


* No stock options were granted during the three months ended October 31, 2019
Summary of stock option activity
A summary of stock option activity is as follows:
  

Outstanding stock options
 
(in thousands, except for exercise prices and term)

Number of
options


Range of
exercise
prices

Weighted-
average
exercise
price


Weighted-
average
contractual
term
(in years)

Aggregate
intrinsic
value

Outstanding as of January 31, 2019

2,444


$0.10 - 82.39

$
27.37


6.74

$
85,971

Granted

108


$63.64 - 73.61

$
73.27





Exercised

(314
)

$0.10 - 44.53

$
23.42





Forfeited

(36
)

$24.36 - 44.53

$
30.15





Outstanding as of October 31, 2019

2,202


$0.10 - 82.39

$
30.14


6.13

$
61,562

Vested and expected to vest as of October 31, 2019

2,202




$
30.14


6.13

$
61,562

Exercisable as of October 31, 2019

1,501




$
22.91


5.50

$
51,131


Summary of restricted stock unit activity
A summary of the RSU and RSA activity is as follows:


RSUs and PRSUs
 

RSAs and PRSAs
 
(in thousands, except weighted-average grant date fair value)

Shares


Weighted-average grant date fair value


Shares


Weighted-average grant date fair value

Outstanding as of January 31, 2019

647


$
55.18


256


$
61.93

Granted

1,124


64.61





Released

(320
)

58.01


(11
)

62.75

Forfeited

(83
)

56.02


(10
)

61.72

Outstanding as of October 31, 2019

1,368


$
62.22


235


$
61.91


XML 54 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Tables)
9 Months Ended
Oct. 31, 2019
Leases [Abstract]  
Lease cost
The components of operating lease costs, lease term and discount rate are as follows:
 
 
Three months ended

 
Nine months ended

(in thousands, except for term and percentages)
 
October 31, 2019

 
October 31, 2019

Operating lease cost
 
$
3,354

 
$
5,515

Sublease income
 
(249
)
 
(249
)
Net operating lease cost
 
$
3,105

 
$
5,266

 
 
 
 
 
 
 
 
 
As of October 31, 2019

Weighted average remaining lease term
 
9.36 years

Weighted average discount rate
 
4.37
%

Supplemental cash flow information related to the Company's operating leases was as follows:
 
 
Three months ended

 
Nine months ended

(in thousands)
 
October 31, 2019

 
October 31, 2019

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
Operating cash flows from operating leases
 
$
2,746

 
$
4,575

ROU assets obtained in exchange for new operating lease obligations
 
$
34,196

 
$
34,394


Operating lease liability maturity schedule
Maturities of operating lease liabilities as of October 31, 2019 were as follows:
Fiscal year ending January 31, (in thousands)
 
Operating leases

Remaining 2020
 
$
375

2021
 
14,340

2022
 
14,135

2023
 
10,595

2024
 
8,287

Thereafter
 
55,389

Total lease payments
 
103,121

Less imputed interest
 
(19,289
)
Present value of lease liabilities
 
$
83,832

 
 
 
Current
 
$
10,780

Non-current
 
73,052

Total lease liabilities
 
$
83,832


XML 55 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Net income (loss) per share
9 Months Ended
Oct. 31, 2019
Earnings Per Share [Abstract]  
Net income (loss) per share Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
(in thousands, except per share data)
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
 
2019

 
2018

 
2019

 
2018

Numerator (basic and diluted):
 
 
 
 
 
 
 
 
Net income (loss)
 
$
(21,334
)
 
$
15,686

 
$
39,854

 
$
60,780

Denominator (basic):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
70,524

 
62,088

 
65,727

 
61,718

Denominator (diluted):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
70,524

 
62,088

 
65,727

 
61,718

Weighted-average dilutive effect of stock options and restricted stock units
 

 
1,835

 
1,423

 
1,910

Diluted weighted-average common shares outstanding
 
70,524

 
63,923

 
67,150

 
63,628

Net income (loss) per share:
 
 
 
 
 
 
 
 
Basic
 
$
(0.30
)
 
$
0.25

 
$
0.61

 
$
0.98

Diluted
 
$
(0.30
)
 
$
0.25

 
$
0.59

 
$
0.96


For the three months ended October 31, 2019 and 2018, approximately 3.2 million and 36,000 shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.
For the nine months ended October 31, 2019 and 2018, approximately 0.3 million and 0.1 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.
XML 56 R4.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Oct. 31, 2018
Revenue:        
Total revenue $ 157,118 $ 70,495 $ 330,793 $ 211,466
Cost of revenue:        
Total cost of revenue 61,083 24,678 118,565 74,718
Gross profit 96,035 45,817 212,228 136,748
Operating expenses:        
Sales and marketing 12,654 7,502 30,015 21,605
Technology and development 23,511 8,678 46,061 25,055
General and administrative 19,222 9,161 37,193 24,561
Amortization of acquired intangible assets 13,051 1,490 16,036 4,438
Merger integration 17,675 0 20,459 0
Total operating expenses 86,113 26,831 149,764 75,659
Income from operations 9,922 18,986 62,464 61,089
Interest expense (10,225) (68) (10,355) (204)
Other expense, net (30,949) (1,487) (8,347) (1,427)
Income (loss) before income taxes (31,252) 17,431 43,762 59,458
Income tax provision (benefit) (9,918) 1,745 3,908 (1,322)
Net income (loss) (21,334) 15,686 39,854 60,780
Comprehensive income $ (21,334) $ 15,686 $ 39,854 $ 60,780
Net income (loss) per share:        
Basic (in usd per share) $ (0.30) $ 0.25 $ 0.61 $ 0.98
Diluted (in usd per share) $ (0.30) $ 0.25 $ 0.59 $ 0.96
Weighted-average number of shares used in computing net income (loss) per share:        
Basic (in shares) 70,524 62,088 65,727 61,718
Diluted (in shares) 70,524 63,923 67,150 63,628
Service revenue        
Revenue:        
Total revenue $ 87,620 $ 25,041 $ 140,710 $ 74,797
Cost of revenue:        
Total cost of revenue 52,278 17,562 92,672 52,808
Custodial revenue        
Revenue:        
Total revenue 46,972 31,564 132,538 90,713
Cost of revenue:        
Total cost of revenue 4,384 3,551 12,716 10,492
Interchange revenue        
Revenue:        
Total revenue 22,526 13,890 57,545 45,956
Cost of revenue:        
Total cost of revenue $ 4,421 $ 3,565 $ 13,177 $ 11,418
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and contingencies Operating Lease Maturity (Details)
$ in Thousands
Jan. 31, 2019
USD ($)
Operating Leased Assets [Line Items]  
2020 $ 2,899
2021 24,665
2022 22,874
2023 16,793
2024 11,134
Thereafter 68,120
Total 146,485
Office Lease  
Operating Leased Assets [Line Items]  
2020 375
2021 14,340
2022 15,692
2023 12,191
2024 9,922
Thereafter 67,717
Total 120,237
Other Agreements  
Operating Leased Assets [Line Items]  
2020 2,524
2021 10,325
2022 7,182
2023 4,602
2024 1,212
Thereafter 403
Total $ 26,248
XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Indebtedness Schedule of Maturities of Long-term Debt (Details)
$ in Millions
Oct. 31, 2019
USD ($)
Debt Disclosure [Abstract]  
Remaining 2020 $ 8
2021 39
2022 63
2023 70
2024 101
Thereafter 969
Total $ 1,250
XML 60 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of business and significant accounting policies (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Aug. 30, 2019
Oct. 31, 2019
Oct. 31, 2018
Aug. 29, 2019
Feb. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Non-marketable equity securities   $ 500      
Client held funds, included in corporate cash   7,000      
Segregated client-held funds   230,928 $ 0    
Operating lease liabilities   83,832      
Operating lease right of use asset   $ 88,515      
Minimum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Remaining operating lease terms   1 year      
Lease renewal terms extension   3 years      
Maximum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Remaining operating lease terms   11 years      
Lease renewal terms extension   10 years      
Accounting Standards Update 2016-02          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Operating lease liabilities         $ 40,600
Operating lease right of use asset         $ 38,000
WageWorks, Inc          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Merger related costs, price per share $ 51.35        
Aggregate fair value of WageWorks stock acquired $ 2,122,100        
Client held funds, included in corporate cash 238,000        
Client-held funds, non-assets 444,000        
WageWorks, Inc          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Investment ownership percentage       4.00%  
Limited partnership          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Investment ownership percentage   1.00%      
WageWorks, Inc          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Client-held funds, total 682,000        
Client held funds, included in corporate cash $ 238,000        
Limited partnership          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Equity method investment ownership percentage   22.00%      
Equity method investments   $ 200      
XML 61 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Intangible assets and goodwill (Tables)
9 Months Ended
Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of finite-lived intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2019 and January 31, 2019:
(in thousands)
 
October 31, 2019

 
January 31, 2019

Amortizable intangible assets:
 
 
 
 
Software and software development costs
 
$
66,633

 
$
44,835

Acquired HSA portfolios
 
92,770

 
85,110

Acquired customer relationships
 
601,382

 
2,882

Acquired developed technology
 
96,924

 

Acquired trade names
 
12,300

 

Amortizable intangible assets, gross
 
870,009

 
132,827

Accumulated amortization
 
(77,017
)
 
(53,161
)
Total amortizable intangible assets, net
 
792,992

 
79,666

Acquired in-process software development costs
 
3,236

 

Total intangible assets, net
 
$
796,228

 
$
79,666


Schedule of indefinite-lived intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of October 31, 2019 and January 31, 2019:
(in thousands)
 
October 31, 2019

 
January 31, 2019

Amortizable intangible assets:
 
 
 
 
Software and software development costs
 
$
66,633

 
$
44,835

Acquired HSA portfolios
 
92,770

 
85,110

Acquired customer relationships
 
601,382

 
2,882

Acquired developed technology
 
96,924

 

Acquired trade names
 
12,300

 

Amortizable intangible assets, gross
 
870,009

 
132,827

Accumulated amortization
 
(77,017
)
 
(53,161
)
Total amortizable intangible assets, net
 
792,992

 
79,666

Acquired in-process software development costs
 
3,236

 

Total intangible assets, net
 
$
796,228

 
$
79,666


XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed consolidated statements of stockholders' equity (unaudited) - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated comprehensive loss
Accumulated earnings
Beginning balance at Jan. 31, 2018 $ 346,274 $ 6 $ 261,237 $ (269) $ 85,300
Issuance of common stock upon exercise of stock options, and for restricted stock   0 21,366    
Issuance of common stock   0      
Other issuance of common stock     0    
Stock-based compensation     15,461    
Net income (loss) 60,780       60,780
Ending balance at Oct. 31, 2018 456,801 6 298,064 0 158,731
Beginning balance at Jul. 31, 2018 432,619 6 289,568 0 143,045
Issuance of common stock upon exercise of stock options, and for restricted stock   0 2,762    
Issuance of common stock   0      
Other issuance of common stock     0    
Stock-based compensation     5,734    
Net income (loss) 15,686       15,686
Ending balance at Oct. 31, 2018 456,801 6 298,064 0 158,731
Beginning balance at Jan. 31, 2019 477,079 6 305,223 0 171,850
Issuance of common stock upon exercise of stock options, and for restricted stock   0 7,363    
Issuance of common stock   1      
Other issuance of common stock     462,270    
Stock-based compensation     31,194    
Net income (loss) 39,854       39,854
Ending balance at Oct. 31, 2019 1,017,761 7 806,050 0 211,704
Beginning balance at Jul. 31, 2019 1,017,031 7 783,986 0 233,038
Issuance of common stock upon exercise of stock options, and for restricted stock   0 712    
Issuance of common stock   0      
Other issuance of common stock     3,776    
Stock-based compensation     17,576    
Net income (loss) (21,334)       (21,334)
Ending balance at Oct. 31, 2019 $ 1,017,761 $ 7 $ 806,050 $ 0 $ 211,704
XML 64 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover Page - shares
9 Months Ended
Oct. 31, 2019
Dec. 02, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Oct. 31, 2019  
Document Transition Report false  
Entity File Number 001-36568  
Entity Registrant Name HEALTHEQUITY, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 52-2383166  
Entity Address, Address Line One 15 West Scenic Pointe Drive  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Draper,  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84020  
City Area Code 801  
Local Phone Number 727-1000  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol HQY  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   70,879,268
Entity Central Index Key 0001428336  
Current Fiscal Year End Date --01-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 65 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Business combination
9 Months Ended
Oct. 31, 2019
Business Combinations [Abstract]  
Business combination Business combination
Acquisition of WageWorks
Overview and total consideration paid
On August 30, 2019, the Company closed the Acquisition of WageWorks for $51.35 per share in cash, or approximately $2.0 billion to WageWorks stockholders. The Company financed the transaction through a combination of $816.9 million cash on hand plus net borrowings of approximately $1.22 billion, after deducting lender fees of approximately $30.5 million, under a term loan facility (see Note 8—Indebtedness).
Pursuant to the Merger Agreement, the Company replaced certain outstanding restricted stock units originally granted by WageWorks with the Company’s equivalent awards. The outstanding WageWorks vested and unvested stock options, and certain unvested restricted stock units, were settled in cash as specified in the Merger Agreement. The portion of the fair value of partially vested awards associated with pre-acquisition service of WageWorks award recipients represented a component of the total consideration, as presented below.
The Acquisition was accounted for under the acquisition method of accounting for business combinations. Under this accounting method, the total consideration paid was:
(in millions)
 
 
Aggregate fair value of WageWorks stock acquired
 
$
2,018.8

Fair value of previously owned investment in WageWorks stock
 
81.4

Fair value of equity awards exchanged for cash attributable to pre-Acquisition service
 
18.1

Fair value of equity awards replaced attributable to pre-Acquisition service
 
3.8

Total consideration paid
 
$
2,122.1


Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the Acquisition date. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants to value acquired intangible assets. The initial allocation of the consideration paid is based on a preliminary valuation and is subject to potential adjustment during the measurement period (up to one year from the Acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
Preliminary allocation of consideration
(in millions)
 
Estimated fair value

Cash and cash equivalents
 
$
406.8

Other current assets
 
56.5

Property, plant, and equipment
 
26.6

Operating lease right-of-use assets
 
42.5

Intangible assets
 
715.3

Goodwill
 
1,330.5

Other assets
 
5.9

Client-held funds obligation
 
(237.5
)
Other current liabilities
 
(69.1
)
Other long-term liabilities
 
(26.7
)
Deferred tax liability
 
(128.7
)
Total consideration paid
 
$
2,122.1


The Acquisition resulted in $1.3 billion of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational and financial benefits expected from the Acquisition, including custodial and interchange revenue synergies based on current contractual relationships, as well as operational cost synergies resulting from increased scale in service delivery and elimination of duplicative management functions and other back-office operational efficiencies. The goodwill created in the Acquisition is not expected to be deductible for tax purposes.
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
(in millions)
 
Fair value

 
Weighted-average remaining amortization period (years)
Customer relationships (1)
 
$
598.5

 
15.0
Developed technology (1)
 
96.9

 
4.5
Trade names & trademarks (1)
 
12.3

 
3.0
Identified intangible assets subject to amortization
 
707.7

 
13.4
In-process software development costs
 
3.8

 
n/a
Total acquired intangible assets
 
$
711.5

 
 
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.
In connection with the transaction, for the three and nine months ended October 31, 2019, the Company incurred approximately $32.9 million and $40.7 million, respectively, of acquisition costs, which are recorded as other expense, net. For the three months ended October 31, 2019, WageWorks contributed revenue of approximately $72.1 million.  For the three months ended October 31, 2019, operating expenses related to WageWorks were approximately $39.9 million.
Pro forma information
The unaudited pro forma results presented below include the effects of the Acquisition as if it had been consummated as of February 1, 2018, with adjustments to give effect to pro forma events that are directly attributable to the Acquisition, which include adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation.
The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings that may result from the integration of WageWorks. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the Acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations. The estimated pro forma revenue and net income (loss) includes the alignment of accounting policies, the effect of fair value adjustments related to the Acquisition, associated tax effects and the impact of the borrowings to finance the Acquisition and related expenses.
(in thousands)
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
 
2019

 
2018

 
2019

 
2018

Revenue
 
$
194,450

 
$
186,022

 
$
598,815

 
$
573,520

Net income (loss)
 
$
(3,286
)
 
$
(21,145
)
 
$
34,559

 
$
9,120


XML 66 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Business combination (Acquired Intangible Assets) (Details) - WageWorks, Inc - USD ($)
$ in Millions
3 Months Ended
Aug. 30, 2019
Oct. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]    
Fair value $ 707.7  
Total acquired intangible assets 711.5 $ 711.5
In-process software development costs    
Acquired Finite-Lived Intangible Assets [Line Items]    
In-process software development costs 3.8  
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Fair value $ 598.5  
Weighted-average remaining amortization period (years) 15 years  
Acquired developed technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Fair value $ 96.9  
Weighted-average remaining amortization period (years) 4 years 6 months  
Trade names & trademarks    
Acquired Finite-Lived Intangible Assets [Line Items]    
Fair value $ 12.3  
Weighted-average remaining amortization period (years) 3 years  
Identified intangible assets subject to amortization    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted-average remaining amortization period (years) 13 years 4 months 24 days  
XML 67 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Narrative) (Details)
$ in Millions
9 Months Ended
Oct. 31, 2019
USD ($)
Lessee, Lease, Description [Line Items]  
Operating lease not yet commenced undiscounted amount $ 80.2
Operating lease not yet commenced term of contract 11 years
Minimum  
Lessee, Lease, Description [Line Items]  
Remaining operating lease terms 1 year
Lease renewal terms extension 3 years
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining operating lease terms 11 years
Lease renewal terms extension 10 years
XML 68 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Income taxes
9 Months Ended
Oct. 31, 2019
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three and nine months ended October 31, 2019, the Company recorded an income tax benefit of $9.9 million and income tax expense of $3.9 million, respectively. This resulted in an effective income tax
benefit rate of 31.7% and an income tax expense rate of 8.9% for the three and nine months ended October 31, 2019, respectively, compared with an effective income tax expense rate of 10.0% and an effective income tax benefit rate of 2.2% for the three and nine months ended October 31, 2018, respectively. For the three and nine months ended October 31, 2019 and 2018, the net impact of discrete tax items caused a percentage point benefit of
1.1 and 8.7 and a percentage point benefit of 11.2 and 24.1, respectively, to the effective income tax rate primarily due to the excess tax benefit on stock-based compensation expense recognized in the provision for income taxes in the condensed consolidated statements of operations and comprehensive income (loss).
As of October 31, 2019 and January 31, 2019, the Company’s total gross unrecognized tax benefit was $8.1 million and $1.7 million, respectively. Certain unrecognized tax benefits have been netted against their related tax assets. As of October 31, 2019, an unrecognized tax benefit of $0.4 million was recorded. As of January 31, 2019, no unrecognized tax benefits had been recorded. If recognized, $7.4 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of October 31, 2019.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.
XML 69 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Leases
9 Months Ended
Oct. 31, 2019
Leases [Abstract]  
Leases Leases
The Company has entered into various non-cancelable operating lease agreements for office space, data storage facilities, and other leases with remaining lease terms of approximately less than 1 year to 11 years, often with one or more Company options to renew. These renewal terms can extend the lease term from 3 to 10 years and are included in the lease term when it is reasonably certain that the Company will exercise the option.
Amortization and interest expense related to finance leases were not material during the three and nine months ended October 31, 2019.
The components of operating lease costs, lease term and discount rate are as follows:
 
 
Three months ended

 
Nine months ended

(in thousands, except for term and percentages)
 
October 31, 2019

 
October 31, 2019

Operating lease cost
 
$
3,354

 
$
5,515

Sublease income
 
(249
)
 
(249
)
Net operating lease cost
 
$
3,105

 
$
5,266

 
 
 
 
 
 
 
 
 
As of October 31, 2019

Weighted average remaining lease term
 
9.36 years

Weighted average discount rate
 
4.37
%

Maturities of operating lease liabilities as of October 31, 2019 were as follows:
Fiscal year ending January 31, (in thousands)
 
Operating leases

Remaining 2020
 
$
375

2021
 
14,340

2022
 
14,135

2023
 
10,595

2024
 
8,287

Thereafter
 
55,389

Total lease payments
 
103,121

Less imputed interest
 
(19,289
)
Present value of lease liabilities
 
$
83,832

 
 
 
Current
 
$
10,780

Non-current
 
73,052

Total lease liabilities
 
$
83,832


As of October 31, 2019, the Company had additional operating leases for office space that have not yet commenced with aggregate undiscounted lease payments of $80.2 million. These operating leases will commence in fiscal year 2021 with a lease term of approximately 11 years.
Supplemental cash flow information related to the Company's operating leases was as follows:
 
 
Three months ended

 
Nine months ended

(in thousands)
 
October 31, 2019

 
October 31, 2019

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
 
Operating cash flows from operating leases
 
$
2,746

 
$
4,575

ROU assets obtained in exchange for new operating lease obligations
 
$
34,196

 
$
34,394


XML 70 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Net income (loss) per share (Tables)
9 Months Ended
Oct. 31, 2019
Earnings Per Share [Abstract]  
Schedule of earnings (loss) per share, basic and diluted
The following table sets forth the computation of basic and diluted net income (loss) per share:
(in thousands, except per share data)
 
Three months ended October 31,
 
 
Nine months ended October 31,
 
 
2019

 
2018

 
2019

 
2018

Numerator (basic and diluted):
 
 
 
 
 
 
 
 
Net income (loss)
 
$
(21,334
)
 
$
15,686

 
$
39,854

 
$
60,780

Denominator (basic):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
70,524

 
62,088

 
65,727

 
61,718

Denominator (diluted):
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
70,524

 
62,088

 
65,727

 
61,718

Weighted-average dilutive effect of stock options and restricted stock units
 

 
1,835

 
1,423

 
1,910

Diluted weighted-average common shares outstanding
 
70,524

 
63,923

 
67,150

 
63,628

Net income (loss) per share:
 
 
 
 
 
 
 
 
Basic
 
$
(0.30
)
 
$
0.25

 
$
0.61

 
$
0.98

Diluted
 
$
(0.30
)
 
$
0.25

 
$
0.59

 
$
0.96


EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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end XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 211 389 1 false 67 0 false 5 false false R1.htm 0001000 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed consolidated balance sheets Sheet http://healthequity.com/role/CondensedConsolidatedBalanceSheets Condensed consolidated balance sheets Statements 2 false false R3.htm 1001001 - Statement - Condensed consolidated balance sheets (Parenthetical) Sheet http://healthequity.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed consolidated balance sheets (Parenthetical) Statements 3 false false R4.htm 1003000 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Sheet http://healthequity.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Statements 4 false false R5.htm 1004000 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) Sheet http://healthequity.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed consolidated statements of stockholders' equity (unaudited) Statements 5 false false R6.htm 1006000 - Statement - Condensed consolidated statements of cash flows (unaudited) Sheet http://healthequity.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed consolidated statements of cash flows (unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Summary of business and significant accounting policies Sheet http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPolicies Summary of business and significant accounting policies Notes 7 false false R8.htm 2106100 - Disclosure - Net income (loss) per share Sheet http://healthequity.com/role/NetIncomeLossPerShare Net income (loss) per share Notes 8 false false R9.htm 2107100 - Disclosure - Business combination Sheet http://healthequity.com/role/BusinessCombination Business combination Notes 9 false false R10.htm 2110100 - Disclosure - Supplemental financial statement information Sheet http://healthequity.com/role/SupplementalFinancialStatementInformation Supplemental financial statement information Notes 10 false false R11.htm 2122100 - Disclosure - Leases Sheet http://healthequity.com/role/Leases Leases Notes 11 false false R12.htm 2128100 - Disclosure - Intangible assets and goodwill Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwill Intangible assets and goodwill Notes 12 false false R13.htm 2134100 - Disclosure - Commitments and contingencies Sheet http://healthequity.com/role/CommitmentsAndContingencies Commitments and contingencies Notes 13 false false R14.htm 2135100 - Disclosure - Indebtedness Sheet http://healthequity.com/role/Indebtedness Indebtedness Notes 14 false false R15.htm 2136100 - Disclosure - Income taxes Sheet http://healthequity.com/role/IncomeTaxes Income taxes Notes 15 false false R16.htm 2139100 - Disclosure - Stock-based compensation Sheet http://healthequity.com/role/StockBasedCompensation Stock-based compensation Notes 16 false false R17.htm 2140100 - Disclosure - Fair value Sheet http://healthequity.com/role/FairValue Fair value Notes 17 false false R18.htm 2201201 - Disclosure - Summary of business and significant accounting policies (Policies) Sheet http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies Summary of business and significant accounting policies (Policies) Policies 18 false false R19.htm 2306301 - Disclosure - Net income (loss) per share (Tables) Sheet http://healthequity.com/role/NetIncomeLossPerShareTables Net income (loss) per share (Tables) Tables http://healthequity.com/role/NetIncomeLossPerShare 19 false false R20.htm 2307301 - Disclosure - Business combination (Tables) Sheet http://healthequity.com/role/BusinessCombinationTables Business combination (Tables) Tables http://healthequity.com/role/BusinessCombination 20 false false R21.htm 2310301 - Disclosure - Supplemental financial statement information (Tables) Sheet http://healthequity.com/role/SupplementalFinancialStatementInformationTables Supplemental financial statement information (Tables) Tables http://healthequity.com/role/SupplementalFinancialStatementInformation 21 false false R22.htm 2322301 - Disclosure - Leases (Tables) Sheet http://healthequity.com/role/LeasesTables Leases (Tables) Tables http://healthequity.com/role/Leases 22 false false R23.htm 2328301 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwillTables Intangible assets and goodwill (Tables) Tables http://healthequity.com/role/IntangibleAssetsAndGoodwill 23 false false R24.htm 2334301 - Disclosure - Commitments and contingencies Operating Lease Maturity (Tables) Sheet http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityTables Commitments and contingencies Operating Lease Maturity (Tables) Tables 24 false false R25.htm 2335301 - Disclosure - Indebtedness (Tables) Sheet http://healthequity.com/role/IndebtednessTables Indebtedness (Tables) Tables http://healthequity.com/role/Indebtedness 25 false false R26.htm 2339301 - Disclosure - Stock-based compensation (Tables) Sheet http://healthequity.com/role/StockBasedCompensationTables Stock-based compensation (Tables) Tables http://healthequity.com/role/StockBasedCompensation 26 false false R27.htm 2401402 - Disclosure - Summary of business and significant accounting policies (Narrative) (Details) Sheet http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails Summary of business and significant accounting policies (Narrative) (Details) Details http://healthequity.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicies 27 false false R28.htm 2406402 - Disclosure - Net income (loss) per share (Details) Sheet http://healthequity.com/role/NetIncomeLossPerShareDetails Net income (loss) per share (Details) Details http://healthequity.com/role/NetIncomeLossPerShareTables 28 false false R29.htm 2407402 - Disclosure - Business combination (Narrative) (Details) Sheet http://healthequity.com/role/BusinessCombinationNarrativeDetails Business combination (Narrative) (Details) Details http://healthequity.com/role/BusinessCombinationTables 29 false false R30.htm 2407403 - Disclosure - Business combination (Consideration Transferred) (Details) Sheet http://healthequity.com/role/BusinessCombinationConsiderationTransferredDetails Business combination (Consideration Transferred) (Details) Details http://healthequity.com/role/BusinessCombinationTables 30 false false R31.htm 2407404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) Sheet http://healthequity.com/role/BusinessCombinationPreliminaryAllocationOfConsiderationDetails Business combination (Preliminary Allocation of Consideration) (Details) Details http://healthequity.com/role/BusinessCombinationTables 31 false false R32.htm 2407405 - Disclosure - Business combination (Acquired Intangible Assets) (Details) Sheet http://healthequity.com/role/BusinessCombinationAcquiredIntangibleAssetsDetails Business combination (Acquired Intangible Assets) (Details) Details http://healthequity.com/role/BusinessCombinationTables 32 false false R33.htm 2407406 - Disclosure - Business combination (Pro Forma Results) (Details) Sheet http://healthequity.com/role/BusinessCombinationProFormaResultsDetails Business combination (Pro Forma Results) (Details) Details http://healthequity.com/role/BusinessCombinationTables 33 false false R34.htm 2410402 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) Sheet http://healthequity.com/role/SupplementalFinancialStatementInformationPropertyAndEquipmentDetails Supplemental financial statement information (Property and equipment) (Details) Details http://healthequity.com/role/SupplementalFinancialStatementInformationTables 34 false false R35.htm 2410403 - Disclosure - Supplemental financial statement information (Other expense, net) (Details) Sheet http://healthequity.com/role/SupplementalFinancialStatementInformationOtherExpenseNetDetails Supplemental financial statement information (Other expense, net) (Details) Details http://healthequity.com/role/SupplementalFinancialStatementInformationTables 35 false false R36.htm 2422402 - Disclosure - Leases (Narrative) (Details) Sheet http://healthequity.com/role/LeasesNarrativeDetails Leases (Narrative) (Details) Details http://healthequity.com/role/LeasesTables 36 false false R37.htm 2422403 - Disclosure - Leases (Lease Cost) (Details) Sheet http://healthequity.com/role/LeasesLeaseCostDetails Leases (Lease Cost) (Details) Details http://healthequity.com/role/LeasesTables 37 false false R38.htm 2422404 - Disclosure - Leases (Maturities of Operating Lease Liabilities) (Details) Sheet http://healthequity.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails Leases (Maturities of Operating Lease Liabilities) (Details) Details http://healthequity.com/role/LeasesTables 38 false false R39.htm 2422405 - Disclosure - Leases (Supplemental Cash Flow Information) (Details) Sheet http://healthequity.com/role/LeasesSupplementalCashFlowInformationDetails Leases (Supplemental Cash Flow Information) (Details) Details http://healthequity.com/role/LeasesTables 39 false false R40.htm 2428402 - Disclosure - Intangible assets and goodwill (Narrative) (Details) Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwillNarrativeDetails Intangible assets and goodwill (Narrative) (Details) Details http://healthequity.com/role/IntangibleAssetsAndGoodwillTables 40 false false R41.htm 2428403 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) Sheet http://healthequity.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetails Intangible assets and goodwill (Schedule of intangible assets) (Details) Details http://healthequity.com/role/IntangibleAssetsAndGoodwillTables 41 false false R42.htm 2434402 - Disclosure - Commitments and contingencies Operating Lease Maturity (Details) Sheet http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails Commitments and contingencies Operating Lease Maturity (Details) Details http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityTables 42 false false R43.htm 2434403 - Disclosure - Commitments and contingencies (Details) Sheet http://healthequity.com/role/CommitmentsAndContingenciesDetails Commitments and contingencies (Details) Details http://healthequity.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityTables 43 false false R44.htm 2435402 - Disclosure - Indebtedness Schedule of Long-term Debt (Details) Sheet http://healthequity.com/role/IndebtednessScheduleOfLongTermDebtDetails Indebtedness Schedule of Long-term Debt (Details) Details 44 false false R45.htm 2435403 - Disclosure - Indebtedness (Narrative) (Details) Sheet http://healthequity.com/role/IndebtednessNarrativeDetails Indebtedness (Narrative) (Details) Details http://healthequity.com/role/IndebtednessTables 45 false false R46.htm 2435404 - Disclosure - Indebtedness Schedule of Maturities of Long-term Debt (Details) Sheet http://healthequity.com/role/IndebtednessScheduleOfMaturitiesOfLongTermDebtDetails Indebtedness Schedule of Maturities of Long-term Debt (Details) Details 46 false false R47.htm 2436401 - Disclosure - Income taxes (Details) Sheet http://healthequity.com/role/IncomeTaxesDetails Income taxes (Details) Details http://healthequity.com/role/IncomeTaxes 47 false false R48.htm 2439402 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) Sheet http://healthequity.com/role/StockBasedCompensationSummaryOfShareBasedCompensationRecognizedDetails Stock-based compensation (Summary of share based compensation recognized) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 48 false false R49.htm 2439403 - Disclosure - Stock-based compensation (Stock-based compensation expense by award type) (Details) Sheet http://healthequity.com/role/StockBasedCompensationStockBasedCompensationExpenseByAwardTypeDetails Stock-based compensation (Stock-based compensation expense by award type) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 49 false false R50.htm 2439404 - Disclosure - Stock-based compensation (Narrative) (Details) Sheet http://healthequity.com/role/StockBasedCompensationNarrativeDetails Stock-based compensation (Narrative) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 50 false false R51.htm 2439405 - Disclosure - Stock-based compensation (Assumptions) (Details) Sheet http://healthequity.com/role/StockBasedCompensationAssumptionsDetails Stock-based compensation (Assumptions) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 51 false false R52.htm 2439406 - Disclosure - Stock-based compensation (Stock option activity) (Details) Sheet http://healthequity.com/role/StockBasedCompensationStockOptionActivityDetails Stock-based compensation (Stock option activity) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 52 false false R53.htm 2439407 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) Sheet http://healthequity.com/role/StockBasedCompensationRestrictedStockUnityActivityDetails Stock-based compensation (Restricted stock unity activity) (Details) Details http://healthequity.com/role/StockBasedCompensationTables 53 false false R9999.htm Uncategorized Items - hqy-2019x10x3110q.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - hqy-2019x10x3110q.htm Cover 54 false false All Reports Book All Reports hqy-2019x10x3110q.htm exhibit311-ceo302x2019.htm exhibit312-cfo302x2019.htm exhibit321-ceo906x2019.htm exhibit322-cfo906x2019.htm hqy-20191031.xsd hqy-20191031_cal.xml hqy-20191031_def.xml hqy-20191031_lab.xml hqy-20191031_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 73 R53.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-based compensation (Restricted stock unity activity) (Details)
shares in Thousands
9 Months Ended
Oct. 31, 2019
$ / shares
shares
RSUs and PRSUs  
Shares  
Unvested, beginning balance (in shares) | shares 647
Granted (in shares) | shares 1,124
Released (in shares) | shares (320)
Forfeited (in shares) | shares (83)
Unvested, ending balance (in shares) | shares 1,368
Weighted-average grant date fair value  
Unvested, beginning balance (usd per share) | $ / shares $ 55.18
Granted (usd per share) | $ / shares 64.61
Released (usd per share) | $ / shares 58.01
Forfeited (usd per share) | $ / shares 56.02
Unvested, ending balance (usd per share) | $ / shares $ 62.22
RSAs and PRSAs  
Shares  
Unvested, beginning balance (in shares) | shares 256
Granted (in shares) | shares 0
Released (in shares) | shares (11)
Forfeited (in shares) | shares (10)
Unvested, ending balance (in shares) | shares 235
Weighted-average grant date fair value  
Unvested, beginning balance (usd per share) | $ / shares $ 61.93
Granted (usd per share) | $ / shares 0
Released (usd per share) | $ / shares 62.75
Forfeited (usd per share) | $ / shares 61.72
Unvested, ending balance (usd per share) | $ / shares $ 61.91